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CHAPTERl 
INTRODUCTION 
The purpose of this research was to improve the haemocompatibility of blood-
contacting biomaterials by modifying the surface of the material in such a way that it 
utilizes naturally occurring compounds and mechanisms in the body to maintain 
biocompatibility. The Merriam-Webster definition of biocompatibility is the 
compatibility with living tissue or a living system by not being toxic or injurious and not 
causing immunological rejection. The term haemocompatibility has been used to 
describe the biocompatibility of materials in direct contact with blood, or haem. The 
Clemson University Advisory Board for Biomaterials has formally defined a biomaterial 
. ~ 
to be "a systemically and pharmacologically inert substance designed for implantation 
within or incorporation with living systems." Biomaterials play a central role in 
extra.corporeal devices, from blood oxygenators to kidney dialyzers, and are important 
components of implants, from vascular grafts to heart valve prostheses. The first 
biomaterials used clinically were not originally designed as such, hut were off-the-shelf 
materials that clinicians used to improvise until something better was developed. Since 
limited information was available about how a material interacted with living tissue or 
fluids, usually a material was chosen solely based on its availability and physical 
properties. Therefore, dialysis tubing was originally made of cellulose acetate, a 
commodity plastic, vascular grafts were originally made with polymers derived from 
1 
textiles, such as Dacron, and the parts used for artificial hearts were based on 
commercial-grade polyurethanes. There was some success in using these materials as 
treatments; however, their use also introduced serious complications. In some cases, the 
dialysis tubing activated platelets and the complement system. Vascular grafts made 
from Dacron could only be used if their diameter exceeded about 6 mm, otherwise 
occlusion occurred due to biological reactions at the blood-material interfaces. Blood-
material interactions can also lead to clot formation in an artificial heart, leading to the 
, 
possibility of stroke or other complications. 
As the haemocompatibility of blood-contacting materials continues to improve, 
their clinical use continues to increase. The following statistics, provided by the 
American Heart Association, indicate the car~iovascular procedures and implants that 
involve the use ofbiomatenals (Association, 2003) .. Unless otherwise stated, the 
statistics describe procedures performed in the United States in 2000. From 1979 to 
2000, the number of cardiac catherizations increased 34 lt percent. An estimated 
1,318,000 in-patient cardiac catheterizations were performed. It is estimated that 519,000 
coronary artery bypass surgery procedures and 686,000 open-heart surgery procedures, 
both using an excorporeal blood oxygenator device, were performed. An estimated 
1,025,000 angioplasty procedures were performed, with percutaneous transluminal 
coronary angioplasty procedures accounting for 561,000 of the angioplasty procedures 
and stenting accounting for the rest. The number of implantable defibrillators, 
pacemakers, and heart valves included 34,000; 152,000; and 87,000; respectfully. These 
statistics of procedures and implants only show one area in which blood-contacting 
materials are in use. The statistics would be even higher when considering the entire 
2 
field that utilizes blood-contacting materials. As a result, it is evident how important it is 
to continue to improve and develop more haemocompatible biomaterials. 
To improve the haemocompatibility of blood-contacting surfaces, two strategies 
are available. The first strategy is to design new materials so that their surfaces are 
completely biocompatible. In general, it is very difficult to develop a material with the 
required mechanical properties that also has the desired surface biocompatibility. The 
second strategy is to modify the blood-contacting surface of existing materials in order to 
improve the haemocompatibility. Surface modification is a more generally applied 
technique to obtain heamocompatible surfaces than the development of new materials. 
There are three general approaches used to modify the surface of a biomaterial in 
order to make it more haemocompatible. The first i~ to increase the surface 
hydrophilicity by grafting hydrophilic chains onto the surface. Most commonly used 
modifications are long chains of poly( ethylene oxide) grafted onto other polymer 
surfaces, such as polyurethane (PU) or poly(vinyl chloride) (PVC) (Brinkman et al., 
1989; Golander and Kiss, 1988; Nojiri et al., 1990). A problem with this approach is that 
if the surface must interact with the surroundings, these long chains can create a great 
steric hindrance that can affect the biological properties of the biomaterial. The second 
approach is to disguise the surface in such a way that it will not be recognized by blood 
as a foreign surface, by such methods as endothelialization, albumin passivation, and 
phospholipid mimicking surfaces (Durrani et al., 1986; Herring et al., 1984; Kottke-
Marchant et al., 1989). A problem with this approach is that covering the surface with 
such factors changes the surface properties and can also affect the biological properties of 
the biomaterial. The last approach is to provide the surface with a biologically active 
3 
compound, which inhibits blood foreign material interactions. This is often done by 
grafting the biologically active compound into the material, and then the compound is 
released from the material over time, making the material haemocompatible. Some 
common biologically active compounds used in such applications include heparin, 
enzymes, and nitric oxide (NO) (Heyman et al., 1985; Kitamoto et al., 1991; Tullett and 
Rees, 1999). The major problem with this approach is that the release rates of the 
biologically active compounds from the biomaterials can be difficult to control and can 
lead to dangerously high levels released into the body. Also, once the entire compound is 
released, the material loses its haemocompatibility. 
The approach taken by this research was to modify the surface of a biomaterial in 
such a way that it utilizes naturally occurring components ~d mechanisms that are 
readily available and that will not expire. One of the naturally occurring components 
utilized by this design is endogenous NO bound to serum albumin in human plasma 
(Stamler et al., 1992a). By attaching L-cysteine to the surface of a biomaterial one of the · 
naturally occurring mechanisms used by this design is the transfer of NO from the serum 
albumin to the L-cysteine through transnitrosation (Meyer et al., 1994; Scharfstein et al., . 
1994). The nitrosated L-cysteine is very unstable due to the presence of naturally present 
metal ions in blood (Beloso and Williams, 1997; Singh et al., 1996); therefore, NO is 
released from the surface and is available to inhibit platelet attachment. The benefits of 
this design include: 
• The design utilizes naturally occurring components and mechanisms. 
• The design is self-replenishing so that it may continue to inhibit platelet 
attachment to the surface of the biomaterial for long periods of time. 
4 
• The design has a localized effect that only prevents platelet attachment at the 
biomaterial surface. 
The objectives for this project include surface characterization of the modified 
material in order to depict changes to the surface and to accurately measure these 
changes, optimization of the process to modify the biomaterial in order to maximize its 
effectiveness, and to utilize the material in a system with platelets in order to measure the 
effectiveness of the material to prevent platelet attachment. These objectives are outlined 
in more detail below. 
1.1 Objective #1: Surface characterization of the modified polymer 
Measuring the amount cifL-cysteine that is attached to the solid surface has been 
difficult with current techniques due to such limitations as, steric hindrance, reactions 
with other species, and concentrations below detectable limits. Techniques used for 
surface characterization and measurement in this research included fluorescence 
microscopy, x-ray photoelectron spectroscopy (XPS), and several chemiluminescence-
based assays that were used to measure thiols on surfaces .and solutions. 
The advantage of fluorescence microscopy is the ability to visualize the surface 
coverage of a fluorescent probe. Some disadvantages with fluorescence microscopy 
include lack of specificity of the fluorescence probe and the analysis is more qualitative 
and does not directly measure surface molar concentrations. 
The advantage of XPS is that it is a highly precise and detailed analysis of only 
the surface of a material. The disadvantage of XPS is that it only shows atomic 
percentages on a surface, which makes it difficult to determine a molar surface 
concentration. 
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The chemiluminescence-based assays were the most successful in measuring 
surface molar concentrations ofL-cysteine. The advantage of this method is that it can 
accurately measure (within 1 % error) molar concentrations of L-cysteine in solution with 
a detection limit in the pmol range. The one disadvantage to this method is that L-
cysteine must first be broken off of the surface and into solution prior to measurement, 
therefore leaving the sample unable to be reused. 
Currently, ther~ are few methods to accurately measure thiols in solution at low 
concentrations (~ 1 µM) and no available methods to measure molar surface 
concentrations of thiols attached to a surface. Therefore, this research is significant in 
furthering the ability to measure thiols both in solution and on surfaces at low 
concentrations. Some of the surface measurement techniques could also be easily 
adapted to measure various other small molecules on surfaces. 
1.2 Objective #2: Optimization of the polymer modification process 
The hypothesis was that the addition of more L-cysteine sites or different L-
cysteine-containing moieties on the polymer will increase the NO-release rate per unit 
area and will increase the inhibition of platelet deposition. The following systems were· 
used in the optimization of the polymer modification process: 1. L-cysteine residues, 2. a 
L-cysteine containing moiety, 2-Iminothiolane, and 3. a polypeptide containing multiple 
cysteine residues, Each system was attached to PET by using lin:ker groups. 
Optimization of each was performed by using full factorial and Plackett-Burman factorial 
designs that vary the. reaction times and molar concentrations of each group involved in 
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the modification process. The optimal design was determined by measuring the relative 
amount of the thiol groups on the surface by techniques described in Objective #1. 
Few studies have shown the attachment ofL-cysteine and 2-iminothiolane to a 
solid surface, and although there are many examples of polypeptide chains attached to a 
solid support, little has been studied about a polypeptide containing multiple cysteine 
residues attached to a surface. Therefore, the optimization and characterization studies 
using these systems have greatly increased the present state of knowledge about the 
degree of attachment to a solid surface and the behavior of the attached system. 
1.3 Objective #3: Utilization of the optimized polymers in an in vitro system with 
platelets 
The hypothesis was that the optimized polymers will significantly decrease 
platelet attachment to the polymer surface compared to control samples. As described 
previously, the modified polymer inhibits platelet attachment by utilizing naturally 
occurring nitrosothiols in the plasma that can transfer NO to the attached thiol on the 
modified polymer. There are other plasma components, such as metal ions, that promote 
the release of NO from nitrosothiols (Beloso and Williams, 1997; Singh et al., 1996). 
Therefore, the plasma containing the nitrosothiols must be present with the platelets in 
order for the modified polymer to inhibit platelet attachment. Studies were performed 
using solutions containing platelets in a buffer solution only, in a solution of nitrosated 
serum albumin, and in a solution of plasma. Hemoglobin found in red blood cells in 
whole blood has also been shown to react readily with NO in solution and take part in 
transnitrosation between circulating nitrosothiols (Winterbourn, 1990). In order to study 
the effect of whole blood on platelet inhibition, platelets in a solution of whole blood was 
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also tested. Control samples included both blank PET and PET modified with an 
unreactive, non thiol-containing residue. 
There are many studies that investigate the mechanisms involved when platelets 
come into contact with foreign surfaces or modified surfaces and the degree of reaction to 
the surface. However, this system was unique because it investigated how platelets react 
to thiol containing groups on a surface releasing small fluxes of NO, These studies also 
gave further insight into the role of nitrosothiols along with the possible role of other 
blood constituents in the mechanisms involved to inhibit platelet attachment. 
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CHAPTER2 
REVIEW OF LITERATURE 
To fully understand how the modified material increases the haemocompatibility 
of blood-contacting biomaterials by utilizing naturally occurring mechanisms and 
components, one must first understand all of the biological processes involved. This 
chapter will review the important mechanisms and components involved in the 
interactions of various blood components with biomaterials. In practice, a material must 
not cause certain events, such as adhesion, platelet aggregation, blood coagulation, or 
obstruction of blood flow. Also in this chapter will be discussed some of the important 
components and mechanisms that can prevent the interaction of blood components with 
biomaterials and how these are utilized in the design of the modified biomaterial. 
Finally, a briefreview of the past research leading up to this project will be discussed at 
the end of the chapter. 
2.1 Blood Components 
Blood is the vehicle of transportation that makes possible the cellular interactions 
and mechanisms that occur within the human body. Blood, which makes up about 6% of 
body weight, is a suspension of various types of cells in a complex aqueous medium, the 
plasma (Beutler and Williams, 1995). Table 2.1 summarizes the physical properties of 
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TABLE 2.1 
Physical Properties of Adult Human Blood 
Property Value 
Whol¢B1ood 
pH 7.35 - 7.40 
Viscosity (37 °C) 3. 0 cP ( at high shear rates) 
Specific Gravity (25/4 °C) 1.056 
Venous Hematocrit 
Male 0.47 
Female 0.42 
Whole Blood Volume ~ 78 ml/kg body weight 
f Plasma or Serm:n 
Colloid Osmotic Pressure 
pH 7.3 - 7.5 
Viscosity (37 °C) 1.2 cP 
Specific Gravity (25/4 °C) 1.0239 
Erythrocytes (Red Blood Cells) 
pH 7.396 
Specific Gravity (25/4 °C) 1.098 
Count 
Male 5.4 x 109/ml whole blood 
Female 4.8 x 109/ml whole blood 
Average Life Span 120 days 
Production Rate 4.5 x 107/ml whole blood/day 
Hemoglobin Concentration 0.335 g/ml of erythrocyte 
Platelets 
Count ~2.8 x 108/ml whole blood 
Diameter ~2 - 5 µm 
Leukocytes 
Count ~7.4 x 106/ml whole blood 
Diameter 7 - 20 µm 
Data from (Cooney, 1976) 
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blood. The elements of blood serve multiple functions essential for respiration, 
metabolism, and the defense of the body against injury. 
2.1.1 Plasma 
To study plasma and its constituents, venous or arterial blood must be mixed with 
an anticoagulant to inhibit coagulation, or clot formation. Plasma is separated from the 
blood cells by centrifugation. If blood is drawn without adding an anticoagulant, then it 
will clot and the cell-depleted fluid phase of blood, devoid of fibrinogen, is called serum. 
The normal adult has an average of 25 to 45 ml of plasma per kg of body weight 
(Berne and Levy, 1993). Many substances are dissolved in plasma, including 
electrolytes, proteins, lipids, carbohydrates, amino acids, vitamins, hormones, 
nitrogenous breakdown products of metabolism, and gaseous oxygen, carbon dioxide, 
and nitrogen. The concentrations of these constituents are influenced by diet, metabolic 
demand, and the levels of hormones and vitamins. Normally, the composition of blood is 
maintained at biologically safe and useful levels by a variety of homeostatic mechanisms. 
The balance may be upset by impaired function in a multitude of disorders, particularly 
those involving the lungs, the cardiovascular system, kidneys, liver, and endocrine 
organs. 
There are hundreds of different proteins that are dissolved in plasma. The normal 
protein concentration in plasma is about 7 g/dl (Berne and Levy, 1993). The bulk of 
protein belongs to two groups; albumin and the various immunoglobulins. Albumin is a 
protein that is synthesized by hepatic parenchymal cells. It has a molecular weight of 
69,000 and is normally present at an average concentration of 4 g/dl (Fournier, 1999). 
Because albumin diffuses poorly through intact vascular endothelium, it provides the 
11 
critical colloid osmotic or oncotic pressure that regulates the passage of water and 
diffusible solutes through the capillaries. Albumin is also the carrier for substances that 
are adsorbed to it. Such substances include normal components of blood, such as 
bilirubin and fatty acids, and certain exogenous agents, such as drugs. Albumin also 
supplies some of the anions needed to balance the cations of plasma. 
Among the proteins, the antibodies (immunoglobulins) are normally second to 
albumin in concentration. Antibodies become active after the stimulation of lymphocytes 
in response to exposure to antigens, which are agents usually foreign to the normal body 
that evoke formation of specific antibodies, Immunoglobulins are synthesized by plasma 
cells in the lymphoid organs and are critical as a defense against infection. The gamma 
globulins constitute the bulk of immunoglobulins in plasma. Other plasma proteins 
include: (1) the clotting factors needed for blood coagulation; (2) the components of 
complement, a group of proteins that mediate the biological effects of immune reactions; 
(3) many enzymes or their precursors; ( 4) enzyme inhibitors; (5) specific carriers of such 
constituents as iron, copper, hormones, and vitamins; ( 6) scavengers of agents 
inadvertently released into plasma (Berne and Levy, 1993). 
2.1.2 Erythrocytes (Red Blood Cells) 
The most abundant cells found in blood are the red blood cells or erythrocytes 
comprising about 95% of the cellular components of blood (Fournier, 1999). The mature 
erythrocyte is an anuclear cell surrounded by a deformable membrane well adapted to the 
need to traverse narrow capillaries. The erythrocytes are biconcave disks, each with a 
diameter of about 8 µm, a thickness of2 µmat its edge, and a volume of about 94 µm3 
(Beutler and Williams, 1995). In normal adults, the red cells make up approximately 
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47% of the volume of blood in males and about 42% in females (Berne and Levy, 1993) . 
. The percentage of the volume of blood made up by erythrocytes is defined as the 
hematocrit. The red blood cell count (the concentration ofred cells in blood) normally 
averages about 5.4 million/µl in adult men and 4.8 million/µl in women (Berne and Levy, 
1993). The average life span of the normal erythrocyte in the circulation is 120 days 
(Berne and Levy, 1993). The major role of red blood cells is the transport of oxygen by 
hemoglobin contained within the red blood cells. 
The principal protein constituent of the cytoplasm of the mature erythrocyte is 
hemoglobin. Normal blood has about 15 g/dl of hemoglobin in adult men and about 13.5 
g/dl in adult women (Berne and Levy, 1993). Hemoglobin is a complex protein 
synthesized in the marrow by the nucleated precursors of erythrocytes and has a 
molecular weight of68,000 (Berne and Levy, 1993). It is composed of two dissimilar 
pairs of polypeptide "globin" subunits, two alpha chains and two nonalpha chains; the 
latter are either 13, y, or 8 chains (Beutler and Williams, 1995). Each globin subunit is 
. attached covalently to a prosthetic group consisting of a tetrapyrrole, heme. Heme is 
synthesized from glycine and succinyl-coenzyme A by a sequence of steps that lead to 
the formation of a pyrrole, porphobilinogen, and then to a tetrapyrrole ring compound, 
protoporphyrin IX. A mitochondrial enzyme, ferrochelatase, inserts an atom of ferrous 
iron into protoporphyrin IX to form heme. Oxygen binds reversibly to the iron 
incorporated into the heme unit. The combination of oxygen with hemoglobin in 
pulmonary capillaries and release of oxygen from hemoglobin in the capillaries of other 
tissues are all part of the respiratory system. 
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2.1.3 Platelets 
The platelets are the next most abundant cell type found in blood, comprising 
about 4.9% of the cell volume (Beutler and Williams, 1995). Normal human blood 
contains approximately 1000 billion (1012) platelets, (150 - 350) x 106 J ml (Berne and 
Levy, 1993). They circulate as anucleate disks, 2 -5 µmin diameter, and have an 
expected life span of IO days within the human circulation (Schror et al., 1994). Their 
job is to survey the lining of blood vessels, the endothelium. In acute damage and 
extravasation, platelets are activated by contact with exposed collagen and aggregate 
together at the wound site to initiate clotting and stop bleeding (Authi etal., 1993). Their 
small size and high number reflect their fundamental role in the process ofhemostatic 
repair, to form mechanical plugs during the normal hemostatic response to vascular 
injury. However, in certain situations, overactive platelets can prematurely adhere to the 
internal walls of normal arteries and capillaries, perhaps a result of high blood pressure 
(Jobin, 1970), raised plasma cholesterol (Gupta, 1969), or smoking (Hawkins, 1972). 
The abnormal behavior has pathological consequences by impeding blood flow and 
contributing to the constriction of arteries, it promotes a variety of vascular 
complications, including thrombosis, premature heart disease, myocardial infarcts, and 
strokes (Harrison, 1997). It is essential that during normal vascular hemostasis, platelet 
activation is tightly controlled. 
2.1.4 Leukocytes (White Blood Cells) 
The remaining 0.1 % of the cellular components of blood consists of the white 
blood cells or leukocytes, which form the basis of the cellular components of the immune 
system (Fournier, 1999). Normal blood contains between 4000 and 10,000 leukocytes/µl 
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(Berne and Levy, 1993). Of these cells, about 40% to 75% are neutrophils, 20% to 45% 
are lymphocytes, 2% to 10% are monocytes, 1 % to 6% are eosinophils, and less than 1 % 
are basophils (Berne and Levy, 1993). Further description of these cell types goes 
beyond the scope of this thesis. This research investigates the increased 
haemocompatibility of the modified biomaterial and not the immunogenecity of the 
material, or its reaction with the immune system. 
2.2 Platelet Activation 
Platelets can become_activated due to a variety of reasons, including the 
following: (1) when platelets are removed from the circulation, (2) when platelets contact 
· an abnormal blood vessel or extravascular tissue, (3) when platelets are exposed to a 
physiological activator (platelet agonist), or (4) when platelets contact a foreign material 
(Authi et al., 1993). Four general platelet activation responses resulting from contact 
with a foreign material have been identified: (Holmsen, 1994) 
1. Adhesion: Platelets form a carpetlike monolayer on a blood vessel wall at the 
site of injury and exposed subendothelium, or on the surface of a foreign 
material. 
2. Shape Change: Disk-shaped resting cells are rapidly converted to spiculated 
spheres, resembling lumps of tissue with spikes or points on the surface. 
3. Aggregation: Platelet surface receptors for fibrinogen (GPIIb-Ila complex) 
become activated, allowing platelet-platelet interactions to occur. 
4. Granule Secretion: Due to a series of intracellular signalling events that cause 
platelet granule membranes to fuse with invaginations in the plasma 
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membrane, called the open canalicular system, leading to discharge of the 
granule content into the extracellular space. 
Figure 2.1 shows the steps of platelet activation due to contact with a surface. Of 
all of the steps, aggregation is the most notable, since during this step platelet activation 
becomes irreversible and leads to problems related to thrombosis and embolism. 
2.2.1 Physical Changes of Platelet Aggregation 
In response to stimuli, platelets adhere to each other and form aggregates of 
various sizes. Aggregation is the result of numerous interlinked reactions at the surface 
of the platelet membrane and in the cytoplasm. Initially, platelets are activated by 
binding of agonists, including adenosine diphosphate (ADP), serotonin, thrombin, or 
collagen, to their respective receptors in the platelet surface membrane (Kroll and 
Schafer, 1989; Siess, 1989). Aggregation then occurs within one minute of activation 
(Savi and Herbert, 1996). Platelet-plat~let interactions develop when the GPilb-IIIa 
complex is activated to bind fibrinogen. Each molecule of fibrinogen recognizes two 
GPilb-IIIa complexes, which allows molecular bridges to form between two adjacent 
platelets (Perutelli and Mori, 1992). When the stimulation of platelets is minor, the 
aggregated platelets dissociate from each other and freely resuspend; this is called, 
"primary aggregation" and is a reversible process (Kroll and Schafer, 1989). A strong 
stimulus results in what is called, "secondary aggregation" which is irreversible due to 
the secretion of platelet granular constituents such as ADP (Meyers et al., 1979). This 
degranulation and release of ADP promotes further aggregation (autocrine stimulation) 
and leads to the formation of a plug over the damaged area (Holmsen, 1994). Examples 
of reversible and irreversible aggregation are shown in Figure 2.2. As shown, the higher 
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Figure 2.1 The four steps of platelet activation due to contact with a surface. 
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Figure 2.2 Platelet aggregation. (A) Scanning electron micrographs of resting and 
agonist-stimulated platelets. The appearance of many pseudopodia on 
activation/stimulation that increases the membrane area, thereby enhancing 
platelet-platelet interactions. (B) Typical platelet aggregometer tracings of 
ADP-induced aggregation in citrated platelet-rich plasma at 37°C. The optical 
density of the suspension decreases progressively as aggregation begins and 
reaches a plateau when aggregation is maximal (Riddell et al., 1997). 
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concentration ofADP leads to irreversible aggregation and noticeable shape changes of 
the platelets. 
2.2.2 Biochemistry of Platelet Aggregation 
Calcium signaling is central to the process of platelet aggregation and has been 
reviewed by Sage, et al. (Sage et al., 1993). Most aggregating agents act via the G 
protein-coupled receptors to activate phospholipase C (PLC), with the released 
diacylglycerol (DAG) and inositol 1,4,5-triphosphate (IP3) stimulating protein kinase C 
(PKC) and mobilizing intracellular Caz+, respectively (Brass, 1991; Puri and Colman, 
1997; Savi and Herbert, 1996). Aggregating agents also cause an influx of extracellular 
· Caz+, which is thought to be triggered by the discharge of intracellular Ca2+ stores 
(Haynes, 1993). Intraplatelet Ca2+ levels, in both the cytoplasm and releasable store (the 
dense tubular system) are tightly regulated by a system of pumps, leaks, and receptor-
operated channels (ROC), which are modulated by othe;r second messengers. These 
include cyclic adenosine 3 ',5 '-monophosphate ( cAMP), cyclic guanosine 3 ',5 ' -
monophosphate ( cGMP), and DAG, which stimulate their respective protein kinases. 
Therefore, Ca2+ homeostasis at rest and Ca2+ mobilization during aggregation are 
controlled by these protein kinases, which modulate the activities of pumps, ROCs, or 
other regulatory proteins by phosphorylation (Haynes, 1993). In addition, cytoplasmic 
Ca2+ is self-regulated, mediated by its calmodulin complex (Ca-CAM), which activates 
numerous regulatory enzymes. 
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2.3 Platelet Inhibition 
The activation of human platelets is inhibited by numerous agents, examples 
include inhibitors ofthrombin (e.g. hirudin) (Glusa, 1991), scavengers of ADP (e.g. 
apyrase) (Walsh et al., 1977), inhibitors ofthromboxane A2 generation (e.g. aspirin) 
(Vane, 1994), and physiological and pharmacological agents which raise intraplatelet 
cyclic nucleotides (Haynes, 1993). Under basal conditions and in response to numerous 
vasoactive agents, vascular endothelial cells synthesize and secrete two of the most 
important physiological inhibitors of platelet activation: prostacyclin and the 
endothelium-derived relaxing factor (EDRF), which increase levels of the intracellular 
messenger molecules, cAMP and cGMP, respectively, in human platelets (Haynes, 1993; 
Vane, 1994). 
EDRF was first described in 1980 when it was recognized that an endothelium-
derived labile humoral substance was responsible for mediating the vascular relaxations 
induced by acetylcholine (Furchgott and Zawadzki, 1980). Later it was shown that 
EDRF was also a potent inhibitor of platelet aggregation (Azuma et al., 1986; Radomski 
et al., 1987a) and that it caused an increase of cGMP in platelets or other target cells 
(Furchgott and Zawadzki, 1980; Radomski et al., 1987b). However, the biochemical 
pathways regulating the production and downstream physiological effects of EDRF were 
only revealed following the discovery that the biological and chemical properties of 
EDRF were identical to those of nitric oxide (NO) (Ignarro et al., 1987a; lgnarro et al., 
1987b; Palmer et al., 1987). 
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2.3.1 Synthesis of Nitric Oxide 
As a free radical gas, NO is a diffusible and reactive molecular messenger with 
diverse biological actions throughout the body including in the vascular, immune, and 
nervous systems (Anggard, 1994; Butler and Williams, 1993; Christopherson and Bredt, 
1997; Harrison, 1997; Mayer and Hemmens, 1997; Michel and Feron, 1997; Moncada et 
al., 1991; Nathan, 1997; Sase and Michel, 1997; Schmidt and Walter, 1994). In the brain, 
NO modulates synaptic plasticity and influences brain development, memory formation, 
and behavior. In the peripheral nervous system, it resembles a classical neurotransmitter 
to regulate gut motility, regional blood flow, and neuroendocrine function 
(Christopherson and Bredt, 1997; Michel and Feron, 1997). NO release is an important 
means for controlling infection, by the expression of an inducible NO synthase isoform 
by macrophages in response to immunological or inflammatory stimuli (Nathan, 1997). 
The continuous generation of NO by the vascular endothelium is crucial for the 
regulation of blood pressure and blood flow (Michel and Feron, 1997; Sase and Michel, 
1997; Schmidt and Walter, 1994). The endothelium-derived NO has a critical role in · 
preventing premature platelet adhesion and aggregation (Moncada et al., 1991). 
NO is generated by the five-electron oxidation of the terminal guanidinium 
nitrogen of the amino acid L-arginine, yielding L-citrulline as the coproduct (Knowles 
and Moncada, 1994). The mechanism is a complex two-stage stereospecific reaction 
involving molecular oxygen and reduced nicotinamide adenine dinucleotide phosphate 
(NADPH) as cosubstrates, with numerous other redox cofactors. This formation of NO 
from L-arginine is catalyzed by NO synthase (NOS) (Knowles and Moncada, 1994; 
Mayer and Hemmens, 1997). Earlier studies, based on cellular location, regulation of 
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activity, and substrate/inhibitor profiles indicated that there were three distinct NOS 
isoforms: 
• NOS-I or nNOS: a calcium and calmodulin (Ca-CAM) -requiring constitutive 
enzyme present in neurons and skeletal muscle (Christopherson and Bredt, 
1997; Mayer and Hemmens, 1997; Schmidt and Walter, 1994). 
• NOS-II or iNOS: a calcium-independent isoform isolated from macrophages, 
vascular smooth muscle cells, and hepatocytes following induction by specific 
cytokines (Anggard, 1994; Mayer and Hemmens, 1997; Nathan, 1997). 
• NOS-III or eNOS: a constitutive form found in vascular endothelial cells and 
regulated by Ca-CAM (Michel and Feron, 1997; Sase and Michel, 1997). 
Due to the numerous roles of NO in cell biology, the distribution of the three isoforms 
overlaps in many tissues and cell types, the subcelluar location of the three isoforms is 
variable, the same isoform in different cells may evoke different biological effects, and 
the eNOS and nNOS are also inducible (Michel and Feron, 1997). 
2.3.2 Actions ofNitric Oxide 
Usually, molecules acting as inter- or intracellular messengers interact with 
defined receptors on target cells to induce a specific response. However, NO does not 
comply with this typical signaling process, due to its lipophilic and free radical 
properties. Instead, it diffuses three-dimensionally away from its point of synthesis to 
interact with numerous metal- and thiol-containing molecules (Moncada et al., 1991). 
Although this process may appear random, these properties of NO are crucial to mediate 
many of its biological effects. However, the best characterized target site for NO is the 
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iron bound within the heme moiety of soluble guanylate cyclase (SGC) (Buechler et al., 
1994). 
In contrast to adenylate cyclase, which is exclusively membrane-bound, guanylate 
cyclase exists in both cytosolic and particulate fractions of cells (Brass, 1991; Buechler et 
al., 1994). Particulate guanylate cyclase is found in the plasma membrane of many cells 
and at least five isoforms have been cloned and characterized. The exact physiological 
roles of particulate guanylate cyclase isoforms remain unresolved, although their primary 
function may be as receptors for atrial natriuretic peptides (Garbers, 1992). It is the 
soluble isoform of guanylate cyclase that plays a central role in the NO-cGMP signal 
transduction pathway (Buechler et al., 1994). SGC is a Mn2+-dependent enzyme found in 
the cytosolic fraction of most mammalian cells and is very abundant in platelets 
(Buechler et al., 1994; Chhajlani et al., 1989). 
Platelet SGC has been purified to a homogeneity and consists of an 83 kDa a-
subunit and a 71 kDa ~-subunit (Chhajlani et al., 1989); Although each monomer 
contains a near-identical catalytic domain, with a high degree of homology to particulate 
guanylate cyclase, both a- and ~-subunits are required for catalytic activity (Buechler et 
al., 1994). A key characteristic of SGCis the presence of heme as a prosthetic group. 
Recent studies have shown that both subunits of SGC are required to form a functional 
heme-binding site within the enzyme (Foerster et al., 1996). NO interacts with SGC 
through this heme group to induce a conformational change that stimulates the 
conversion ofGTP to cGMP (Anggard, 1994; Radomski and Moncada, 1993). 
Cumulative evidence suggests that the major mechanism by which NO inhibits 
platelet activation is through activation of platelet SGC to increase levels of cGMP 
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(Radomski and Moncada, 1993). As a result, the inhibitory effects of NO can be 
reproduced by addition of cGMP analogues, and the anti platelet action of NO donors can 
be blocked by treating platelets with lH-[1,2,4 ]oxadiazolo[ 4,3-a ]quinoxalin-1-one 
(ODQ), a specific and potent inhibitor of SGC (Moro et al., 1996; Nguyen et al., 1991; 
Riddell et al., 1997). However, other mechanisms of NO action that are independent of 
cGMP production have also been described (Gordge et al., 1998). These include NO-
mediated ADP ribosylation, inhibition of glyceraldehyde-3-phosphate dehydrogenase and 
inhibition of intracellular calcium mobilization (Brune and Lapetina, 1989; Dimmeler 
and Brune, 1992; Dimmeler et aL, 1992; Menshikov et al., 1993). The relative functional 
importance of such non-SGC-non-cGMP-mediated actions of NO has not yet been 
determined: 
The effects of NO.on platelet function differ significantly from those of many· 
other antiplatelet agents. These include the cyclooxygenase inhibitor acetylsalicylic acid 
(aspirin), which irreversibly inhibits platelet activation by preventing the formation of the 
proaggregatory thromboxane A2 (Vane, 1994). By contrast, NO inhibits platelet 
activation at an earlier stage and its effects are quickly and completely reversible 
(Buechler et al., 1994; Radomski and Moncada, 1993). · Thus, in addition to inhibiting 
platelet adhesion to the vessel wall, NO also interferes with the initial thrombus 
formation by inhibiting aggregation and the autocrine stimulation and recruitment of 
· adjacent platelets (Freedman et al., 1997; Radomski and Moncada, 1993). 
2.4 Nitric Oxide and Thiol Groups 
lgnarro et al. demonstrated that reactions with cellular thiols contributed to the 
bioactivities of certain pharmacological nitrogen oxide (NOx) donors in 1981, several 
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years before making the observation that NO is synthesized endogenously in mammalian 
cells (Ignarro et al., 1987b; lgnarro et al., 1981). Kowaluk and Fung later showed that S-
nitrosothiols (RSNOs) exerted bioactivities independent of breaking down to NO 
(Kowaluk and Fung, 1990). There was little information about thiol-NO interactions 
until Stamler et al. perceived RSNOs as nitrosonium (NO+) and nitroxyl (NO] donors 
with chemical reactivities distinct from those of NO, which were: (1) capable of forming 
in and modifying proteins, and (2) present in mammalian tissue (Gaston et al., 1993; 
Stamler et al., 1992a). S-nitrosothiols have also been shown to have similar biological 
actions as of NO and play an important role in many processes, including platelet 
inhibition, signal transduction, DNA repair, host defense, blood pressure control, ion 
channel regulation, and neurotransmission (Brune et al., 1998; Campbell et al., 1996; 
delaTorre et al., 1998; Gow and Stamler, 1998;Lander et al., 1996; Persichini et al., 
1998; Radomski et al., 1992). 
2.4.1 Synthesis of S-Nitrosothiols 
The reactivity of NO with sulfhydryl (RSH) groups depends on the electron 
configuration of its 2p-Il antibonding orbital (Stamler et al., 1992c ). The presence of one 
(radical) electron in this orbital does not ordinarily promote reactivity with R-SH groups, 
although it allows reaction with thiyl radical species. On the other hand, loss of this 
electron to form NO+ promotes strong electrophilicity and reactivity towards most 
biological RSH species (Arnelle and Stamler, 1995; Stamler et al., 1992c). A second 
electron in the 2p-TI orbital, forming NO-, may under certain circumstances promote the 
reactivity with relatively electropositive R-SH species, particularly in the presence of 
ferrous ion or other transition metals (Arnelle and Stamler, 1995; Stamler et al., 1992c; 
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Vanin et al., 1997). A summary of the chemistry of the redox-interrelated forms ofNO 
of potential biological significance is illustrated in Figure 2.3. 
The third order reactivity of NO with oxygen under physiological conditions (rate 
constant in aqueous phase - 6.6 x 106 M-2s-1) predicts relatively slow production of 
dinitrogen trioxide (N203) as a nitrosating agent in the form of (No+· .. N02) (Wink et al., 
1993). This reaction is accelerated 300-fold in the hydrophilic core of biological 
membranes (Liu et al., 1998). On the other hand, reactions of NO with superoxide are so 
rapid as to be diffusion limited (k- 7 x 109 M-1s-1) (Haddad et al., 1994). Both amines 
and sulfhydryl groups are highly susceptible to reactions with N20 3 and ONOO- (Gow et 
al., 1997; Liu et al., 1998; Schmidt et al., 1996; Wink et al., 1991). Thiol nitrosation 
{RSNO) is preferred under physiological conditions, both because of the tendency of 
amines to be more basic and because, unlike deamination of primary amines after NO+ -
induced diazotization, loss of the RSNO group thiolate does not generally occur rapidly 
(Stamler et al., 1992c; Wink et al., 1991). Reactivity of these nitrosating species toward 
carbon groups is less than toward amino groups and sulfhydryl groups. Therefore, S-
nitrosation of proteins has been demonstrated to be preferred over N- and C-nitrosation 
under physiological conditions and that large, stable reservoirs of S-NO, but not N-NO or 
C-NO, species have been identified in tissues (Gaston et al., 1993; Giovannoni et al., 
1997; Jia et al., 1996; Kluge et al., 1997; Simon et al., 1996; Stamler et al., 1992a). 
2.4.2 S-Nitrosothiol Reservoirs 
Titration of free -SH groups by radioactive SH-modifying reagents, ultraviolet-
visible sprectrophotometry, and electrospray ionization-mass spectrometry can be used to 
monitor the binding of NO to peptides (on precise amino acids) (Catani et al., 1998; 
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Figure 2.3 Summary of the chemistry of the redox-interrelated forms of NO ofpotential 
biological significance. The primary reactions of NO involve oxygen, 
superoxide, and redox metals (M). NO- is reactive with metals.and with 
sulfhydryls. Spontaneous dimerization of NO- results in the formation of 
-N20. Nitrosation reactions involve sulfhydryl (RSH) and addition to bases 
(B), including peroxide (Stamler et aL, 1992). 
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delaTorre et al., 1998; Mirza et al., 1995). These techniques have demonstrated that 
cysteine residues are rapidly nitrosated, while reactions with other amino acids occur at 
much slower rates. Cysteine residues are therefore the main targets of S-nitrosation. It 
should be noted that the RS-NO bond is labile and therefore difficult to study and 
quantify (Mirza et al., 1995). 
Numerous studies have concentrated on the chemistry and pharmacology of 
RSNOs, including their synthesis, properties, reactions that lead to NO (NO+) formation, 
and reactions where the NO group can be transferred to other thiol groups, but the main 
issue that remained was the possibility of such chemical reactions (S-nitrosation) 
occurring in vivo and not only at acidic pH (Pryor et al., 1982; Pryor and Lightsey, 1981 ). 
This issue had been controversial until new methods were developed to :measure the free 
redox-modulated forms of NO, such as NO\ in vivo. Gow et al. have recently proposed a 
mechanism for the formation ofRSNOs in vivo (under physiological conditions) (Gow et 
al., 1997). They proposed a mechanism whereby NO reacts directly with reduced thiol to 
produce a radical intermediate, R-S-N:-0-H. This intermediate then reduces an available 
electron acceptor to produce a RSNO. Under aerobic conditions, 0 2 acts as the electron 
acceptor and is reduced to produce superoxide (02). 
The formation of a RSNO has now been shown to occur in vivo for an array of 
proteins (Butler et al., 1995; Lander, 1997). RSNOs like S-nitrosoalbumin (AlbSNO), S-
nitrosoglutathione (GSNO), or S-nitroso-L-cysteine (CySNO) have been detected and 
quantified in vivo and they may be responsible for some of the well-documented 
physiological processes that have been previously attributed to NO itself (Kluge et al., 
1997). The single free cysteine of serum albumin, Cys-34, has been shown to be 
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particularly reactive toward NO under physiological conditions, primarily because of its 
anomalously low pK (Stamler et al., 1992a). Studies have reported a range ofRSNO 
concentrations measured in human plasma. One study shows that human plasma contains 
-7 µM RSNOs, of which 96% are S-nitrosoproteins, 82% of which is accounted for by 
AlbSNO (Stamler et al., 1992a). Another study measured the concentration ofRSNOs in 
human plasma to be in the 20 nM range (Marley et al., 2000). By contrast, plasma levels 
of free nitric oxide are only in the 3 ± 0.58 nM range (Stamler et al., 1992a). It has been 
hypothesized that naturally produced NO circulates in plasma primarily complexed in 
RSNO species, mainly as AlbSNO. This abundant, relatively long-lived adduct likely 
serves as a reservoir with which plasma levels of highly reactive, short-lived free NO can 
be regulated. The chemical half-life ofreleased NO is very short and is inactivated 
within-02 s (Kelm and Schrader, 1990). In comparison with NO, RSNOs are often 
very stable compounds with half-lives up to 40 min, as in the case of AlbSNO (Stamler et 
al., 1992b ). 
The high-affinity of NO binding to hemoglobin (Hb) has given further insight into 
· the relationship of heme proteins and of small diffusible signaling molecules. 
Specifically, NO binds rapidly to the heme iron in Hb (kon -107 M-1s-1) and once bound, 
the NO activity is larg~ly irretrievable (Ki - I 0-5 s-1) (Stamler et al., 1997). The binding 
is so strong, that it is unaffected by 0 2 or CO. However, these general principles do not 
consider the allosteric state ofHb or the nature of the allosteric effector, and they mostly 
are derived from the functional behavior of fully nitrosated Hb, whereas Hb is only 
partially nitrosated in vivo. Stamler et al. who studied blood flow regulation by Hb in the 
· physiological oxygen gradient found that the binding of oxygen to heme irons in Hb 
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promotes the binding of NO to a particular cysteine residue (Cysp93), forming S-
nitrosohemoglobin (HbSNO) (Stamler et al., 1997). Deoxygenation is accompanied by 
an allosteric transition in HbSNO [ from the R ( oxygenated) to the T ( deoxygenated) 
structure] that releases the NO group. HbSNO contracts blood vessels and decreases 
cerebral perfusion in the R structure and relaxes vessels to improve blood flow in the T 
structure. Thus, by sensing the physiological oxygen gradient in tissues, Hb exploits 
conformation-associated changes in the position of Cysp93 ofHbSNO to bring local 
blood flow into line with oxygen requirements. HbSNO can therefore release NO on 
deoxygenation in the microcirculation. Pawloski et al. have additionally shown that 
HbSNO inhibits platelet aggregation and that this mechanism is cGMP independent 
(Pawloski et al., 1998). 
2.4.3 Transnitrosation: Transfer of Nitric Oxide Between S-Nitrosothiols 
Plasma albumin reacts with NO to form the bioactive adduct AlbSNO; however, 
the limited intracellular access of AlbSNO suggests the need for a vascular transfer 
mechanism of NO from a large plasma AlbSNO pool to affect biological function. NO 
exchange among thiols has been documented by several investigators under non-
physiologic conditions (Bennett et al., 1986; Keaney et al., 1993; Keen et al., 1976; Oae 
et al., 1978). Scharfstein et al. have reported that the transfer of NO between AlbSNO 
and low molecular weight (LMW) thiol (transnitrosation), such as L-cysteine, occurs 
rapidly and completely, in vitro under physiologic conditions (Scharfstein et al., 1994). 
In addition, NO appears to shift transiently from high molecular weight (HMW) to LMW 
S-nitrosothiol pools in vivo, as shown in Equation 2.1 (Scharfstein et al., 1994). 
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AlbSNO + CySH ~ AlbSH + CySNO Eq. 2.1 
Once transnitrosation has occurred and S-nitrosothiols have been formed, these smaller, 
less diffusion-limited NO adducts can transport NO more efficiently to the vascular 
smooth muscle cell or platelet surface. Once at the cell surface, the specific metabolic 
steps that lead to the activation of intracellular guanylyl cyclase and other target effector 
sites remain unclear. Possible mechanisms include the direct transport ofRSNOs into the 
cytosol or alternatively, cell surface interactions with membrane bound species bearing 
thiols or heme-containing prosthetic groups (Mordvintsev et al., 1986). Studies 
performed by Malinski and Taha support these possible mechanisms by showing that a 
significant NO gradient exists across the vascular smooth muscle cell and platelet 
membrane, suggesting that transmembrane NO transport is not a diffusion-limited 
process (Malinski and Taha, 1992). 
Hemoglobin may serve as a catalyst for RSNO formation under conditions of high 
oxygen affinity, in whichS;..nitrosation of the single J3-chain reduced cysteine (93) is 
favored (Gow et al., 1997; Jia et al., 1996). The resulting SNO-hemoglobin synthesis in 
the lung allows for LMW RSNO formation through transnitrosation reactions (Jia et al., 
1996). The circulatory system may provide end organs with a steady supply ofLMW 
RSNOs which can diffuse out of the erythrocyte and into tissues (Jia et al., 1996). 
Furthermore, NOS activation itself may form RSNOs, perhaps through intermediate 
ONOO- in the presence ofthiol (Gow et al., 1997; Schmidt et al., 1996). Additional 
RSNO synthetic reactions may occur in vivo, such as protein nitrosation by nitrous acid 
(HN02) in acidic organelles, but these remain to be shown. 
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2.4.4 S-Nitrosothiol Breakdown in Biological Systems 
RSNOs breakdown to yield the corresponding disulfide and NO shown in 
Equation 2.2. 
RSNO ~NO+ Y2 RSSR Eq. 2.2 
Both photochemical and thermal pathways for this reaction have been established and 
more recently a metal ion-catalyzed route, dominant for decomposition in solution (Field 
et al., 1977; Pou et al., 1994; Sexton et al., 1994). In the absence of copper ions, RSNOs 
are stable in solution (Williams, 1996). However, even concentrations of copper ions as 
low as 10-6 M are sufficient to affect decomposition with production of NO. Initially it . 
was believed that the form of copper responsible was the abundant Cu(II), but a more 
detailed study has shown that it is Cu(I) which is the active catalyst (Askew et al., 1995). 
Cu(I) is readily formed from Cu(II) through reduction by a thiol, present either as an 
impurity or formed on hydrolysis of the RSNO. Whether this indicates a biological role 
for Cu(I) in the release of NO from RSNO stores in the body is still questionable; 
however, Gordge et al. have observed that the antiplatelet aggregation effect of an RSNO 
is lessened in the presence of a selective complexing agent for Cu(I) (Gordge et al., 
1995). Even when copper ions are complexed to a protein, there is still evidence of 
metal-catalyzed NO release (Dicks and Williams, 1996). Studies performed by Arnelle 
and Stamler have shown the stability ofRSNOs decrease in the order of AlbSNO > 
GSNO > S-nitroso-N-acetylpenicillamine (SNAP) > CySNO in the same environment 
whether it contains metal ion chelators or not (Arnelle and Stamler, 1995). Further, S-
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nitrosoproteins are often more stable than the s:..nitroso derivatives of amino acids and 
small peptides (Stamler et al., 1992b ). 
In many tissues, RSNO concentrations, sites of action, and bioactivities may be 
regulated more by catabolic processes than by synthesis. Several enzymes have been 
described to break down LMW RSNOs in vitro, as shown in Table 2.2 (Askew et al., 
1995; Freedman et al., 1995; Hou et al., 1996; Jensen et al., 1998; Trujillo et al., 1998). 
The relative distribution of these enzymes in different tissues could dramatically alter 
RSNO bioactivities. In the lung, for example, y-glutamyl transpeptidase, which converts 
GSNO to S-nitrosocystdnyl glycine, may give greater membrane permeability for 
submucosal/smooth muscle bioactivity (Hogg et al., J 997). Furthermore, glutathione 
peroxidase theoretically may produce NO with the net effect of inactivating GSNO and 
eliminating NOx through NO expiration and/or reaction of NO with heme iron(II) 
(Freedman et al., 1995; Hou et al., 1996). Additional catabolic enzymes have been 
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proposed to exist in platelets, airway epithelial cells, neutrophils, and Escherichia coli 
(Fang et al., 2000; Gordge et al., 1996; Hausladen et al;, 1996). ·Gordge et al. showed 
that release of NO from GSNO was catalyzed enzymatically by ultrasonicated platelet 
suspensions (Gordge et al., 1996). 
Inorganic reactions also cause RSNO breakdown. Intermediate Fe(S)NO 
formulation involving LMW thiol groups may contribute to RSNO catabolism (V anin et 
al., 1997). Inorganic reactions with copper are highly relevant to S-nitrosocysteine 
breakdown in vitro (Singh et al., 1996). These may theoretically be less relevant in vivo, 
where free copper(!) concentrations are low. However, Cu(I) chelation results in 
inhibition of bioactivities, which are thought to be related in GSNO catabolism in 
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TABLE 2.2 
Enzyme Systems that Break Down GSNO In Vitro 
Enzyme 
(Thioredoxin) Thioredoxin Reductase 
(Scharfstein et al., 1994) 
Glutathione Peroxidase (Hou et al., 1996) 
y-Glutamyl Transpeptidase 
(Askew et al., 1995; Hogg et al., 1997) 
(Xanthine) Xanthine Oxidase (Trujillo et al., 1998) 
Glutathione-Dependent Formaldehyde Dehydrogenase 
(Jensen et al., 1998) 
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Nitrogen Oxide Product 
Nitric Oxide 
Nitric Oxide 
S-Nitroso-Cysteinyl Glycine 
Peroxynitrite 
H ydroxylamine 
platelets and cardiac myocytes (Gordge et al., 1996; Mayer et al., 1998). The RSNO 
catabolic effects of other biological transition metals are minimal compared with those of 
Cu and Fe (McAninly et al., 1993). 02" has been shown to cause CySNO and GSNO 
breakdown with second order (in RSNO) rate constants (Aleryani et al., 1998; Jourd'heuil 
et al., 1998). These reactions are apparently first-order in 0 2• (overall k- 3-6 x 108 M·2s· 
1 ). Therefore, micromolar RSNO concentrations would be degraded only very slowly 
(pMmin·1 range) by these reactions in the presence ofnanomolar 0 2• concentrations. 
2.5 A Novel Design to Improve the Haemocompatibility of Blood-Contacting Materials 
. by Utilizing Endogenous Nitric Oxide and Naturally-Occurring Mechanisms 
2.5.1 Description of the Novel Design 
The design exploits endogenous Nb and naturally-occurring mechanisms to 
increase the haemocompatibility of blood-contacting surfaces by mechanisms illustrated 
in Figure 2.4. First, L-cysteine residues are covalently attached to the surface of a blood-
contacting material in such a way that their thiol groups are exposed to the surroundings. 
When blood flows over the surface of the modified material, the exposed thiol groups are 
able to extract NO from free nitrosated thiols in the blood, specifically AlbSNO, via 
transnitrosation. The nitrosated L-cysteine residues on the surface formed following 
transnitrosation quickly release NO from the surface by catalysis of ascorbate and/or 
· copper, or other reducing thiols. Finally, the NO released into the surrounding area 
inhibits platelet adhesion, aggregation, and thrombus formation by mechanisms discussed 
previously. After the decomposition of the CySNOs on the surface of the modified 
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Figure 2.4 Illustration of the concept for the design that exploits endogenous NO and 
naturally-occurring mechanisms to increase the haemocompatibility ofblood-
contacting surfaces. 
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material, the L-cysteine residues are in their reduced form and are available to continue to 
participate in the transfer and release of NO. 
2.5.2 The Rationale for the Design 
As discussed in Section 2.3, NO was shown to be a potent inhibitor of platelet 
activation and aggregation (Azuma et al., 1986; Haynes, 1993; Radomski et al., 1987a) 
by causing an increase of cGMP in platelets (Furchgott and Zawadzki, 1980; Radomski et 
al., 1987b ). As discussed in Section 2.4.2, there is a large supply of endogenous NO in 
human blood plasma as NO bound to proteins (S-Nitrosoproteins), mostly as S-
nitrosoalbumin (AlbSNO). Stamler et al. have reported that human plasma contains - 7 
µM RSNOs, of which 96% are S-nitrosoproteins, 82% of which is accounted for by 
AlbSNO (Stamler et al., 1992a). It has been hypothesized that naturally produced NO 
circulates in plasma primarily complexed in RSNO species, mainly as AlbSNO. This 
abundant, relatively long-lived adduct likely serves as areservoir with which plasma 
levels of highly reactive, short-lived free NO can be regulated. The chemical half-life of 
released NO is very short and is inactivated within- 0.2 s (Kelm and Schrader, 1990). In 
comparison with NO, RSNOs are often very stable compounds with half-lives up to 40 
min, as in the case of AlbSNO (Stamler et al., 1992b ). 
A fast and spontaneous transnitrosation reaction (Equation 2.1) exists between 
AlbSNO and low molecular weight thiols (L-cysteine and glutathione) as shown in 
Section 2.4.3. Scharfstein et al. have reported that the transfer of NO (called 
transnitrosation) between AlbSNO and low molecular weight (LMW) thiols, such as L-
cysteine, occurs rapidly and completely, in vitro under physiologic conditions 
(Scharfstein et al., 1994). In addition, NO appears to shift transiently from high 
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molecular weight (HMW) to LMW S-nitrosothiol pools in vivo, as shown in Equation 2.1 
(Scharfstein et al., 1994). Since L-cysteine is the lowest molecular weight thiol in vivo, it 
is believed that the NO transfer from AlbSNO and CySH is faster than NO transfer to 
other low molecular weight thiols, such as glutathione. It has also been demonstrated that 
free L-cysteine, by transnitrosation, can catalyze NO release from AlbSNO (Gordge et. 
al., 1996; Meyer et al., 1994). 
NO is quickly released from CySNO due to the instability of CySNO in vivo. As 
discussed in Section 2.4.4, nitrosated high molecular weight thiols such as AlbSNO are 
much more stable than nitrosated low molecular weight thiols such as CySNO, which is 
the most unstable RSNO (Arnelle and Stamler, 1995). However, the stability ofRSNOs 
strongly depends on factors such as metal ions, pH, and temperature. As shown in 
Equation 2.2, nitrosated thiols decompose to yield the corresponding disulfide and the 
release of NO if no other reducing agents exist, as also discussed in Section 2.4.4. 
However; the decomposition ofCySNO may form NO and reduced L-cysteine if other 
reducing agents such as thiols and ascorbate are present to reduce Cu2+ to Cu+, as shown 
in Equation 2.3 (Hogg, 2000; Stubauer et al., 1999; Williams, 1996). 
CySNO + H+ cu 2• ~cu• > CySH + NO t 
2.6 Past Research 
1 2.6.1 Design of a Novel Apparatus to Study Nitric Oxide Inhibition of Platelet 
Attachment to a Surface 
Eq. 2.3 
The first work in this ar~a for our research group was to establish valid guidelines 
for the local delivery of NO to reduce platelet deposition on biomaterials. This included 
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the development of a suitable NO delivery device to study NO inhibition of platelet-
biomaterial interactions in vitro, and the development of a mathematical model to predict 
aqueous NO concentration and flux profiles required to inhibit platelet attachment to 
biomaterials (Ramamurthi and Lewis, 1997; Ramamurthi and Lewis, 1998). 
Figure 2.5 shows the thin-slit flow chamber device that was designed to 
investigate the inhibition of platelet deposition on a biomaterial surface under flow 
conditions via the local delivery of gaseous NO. A protein-coated polymer was exposed 
to a flowing platelet suspension, while NO gas permeated through the polymer and into 
the solution. fu one study, the platelets were labeled with a fluorescence dye in order to 
qualitatively study platelet attachment to the polymer surface. fu another study, the 
platelets were radio labeled with chromium-51 (Cr-51) in order to quantitatively study· 
platelet attachment to the polymer surface. Perfusion rates were based on wall shear rate 
requirements. Platelet-surface interactions are highly dependent on wall shear rates 
(Ramamurthi and Lewis, 2000): Physiologically relevant shear rates range between 40 
and 5000 s-1 {Turitto, 1982). Shear rates were restricted between 125 and 500 s-1, in order 
to minimize surface platelet aggregation and thrombus formation, which are substantially 
enhanced at higher shear rates. The wall shear rate (yin s-1) was determined from 
laminar flow analysis in a slit flow chamber, shown in Equation 2.4. 
3 Q 
y= 2 60Wb2 Eq.2.4 
Where Q is the volumetric flow rate ( cm3 /min), W is the slit width ( cm), and b is the half-
thickness of the flow slit (cm). Based on the geometry of the flow slit, a flow rate of 1 
ml/min corresponds to a shear rate of 250 s-1 and a Reynolds number (based on slit 
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A 
Figure 2.5 Thin-slit flow chamber device used to investigate the inhibition of platelet 
deposition on a biomaterial surface under flow conditions via the local 
delivery of gaseous nitric oxide (Ramamurthi and Lewis, 1998). 
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height) of 2. The NO exposure levels were varied in order to measure the effect of NO 
inhibition of platelet adhesion to the polymer. 
To predict aqueous NO spatial concentrations and fluxes within the flow slit 
beginning at the porous block, a steady-state dimensionless continuity equation for NO 
was derived and solved. For a full description of this model, please refer to (Ramamurthi 
and Lewis, 1997). This study has shown that NO concentrations near the surface on the 
order of 0.1 nM and surface fluxes on the order of 1 :finol cm-2 s-1, completely inhibit 
platelet deposition. Since the concentration of RSNOs in plasma have been shown to be 
in the micromolar range, there is a sufficient supply of NO that can be transferred to the 
surface of the L-cysteine-modified polymer by transnitrosation in order to inhibit platelet 
deposition on the surface. However, the amount of NO released from the surface of the 
modified material will depend on the concentration of free thiol groups on the surface and 
the transnitrosation and NO release rates, which were also studied. 
2.6.2 The Design and Characterization ofL-Cysteine Attached to a Surface 
To test the hypothesis that there is sufficient NO in the blood that can be 
transferred to a modified surface and released in order to prevent platelet attachment to 
the surface, a preliminary design of L-cysteine attached to a surface was first 
characterized and then used in studies involving platelets and plasma (Duan, 2001; Duan 
and Lewis, 2002). 
Two popular polymers used in blood~contacting applications, polyurethane (PU) 
and polyethylene terephthalate (PET), were selected as the substrates to attach L-
cysteine. There are two reactive groups on L-cysteine that can be used for 
immobilization: the primary amine (-NH2) and the thiol (-SH). A free thiol group is 
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desired following immobilization ofL-cysteine so that NO can be transferred from 
RSNOs in the blood to the free thiol group and then released into the surroundings to 
prevent platelet attachment. Therefore, the amino group of L-cysteine was chosen as the 
reaction group for L-cysteine immobilization. PU and PET have inert surfaces and have 
to be chemically modified to provide reactive groups for immobilization. This was done 
by adding an amine group to the surface of the polymer with ethylenediamine for PET 
and 3-aminopropyltriethoxysilane (APTES) for PU. Glutaraldehyde was chosen as a 
linker between the amino group ofL-cysteine and the aminated polymer surface. The 
complete reaction scheme used to attach L-cysteine to PET and PU is shown in Figure 
· 2.6. 
A chemiluminescence-based assay was developed in order to quantify the amount 
ofL-cysteine on the surface of PET and PU. The first step in this assay is to nitrosate the 
thiol group on L-cysteine attached to the surface in the presence of equal or excess nitrite 
under acidic conditions. This step also breaks off the L-cysteine residues due to the 
acidic conditions. It was believed that the amine bond is the one that actually breaks off, 
since it is the most susceptible to acidic conditions. Following nitrosation, the nitrosated 
L-cysteine, now in the solution surrounding the sample, and any remaining nitrite was 
converted to NO by the use of reducing agents and measured by the use of a NO 
chemiluminescence analyzer. The reducing solutions are made up of acetic acid with 
potassium iodide. An excess of free iodine is added in order to convert the nitrosated L-
cysteine and the excess nitrite into NO that can be measured. An excess of L-cysteine is 
added to the reducing solution in order to suppress the conversion of nitrosated L-
cysteine to NO and to only measure the amount of excess nitrite converted into NO. The 
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I 50% Ethylenediamine 
40°c, 24hrs 
(PET) 
24 hrs, under nitrogen I 2% APTES in toluene 
(PU) 
I% Glutaraldehyde I 
N=CH-(CH2)J-CHO 
pH 7, I hr, under nitrogen 
(GA-modified Polymer) 
0.2% L-Cysteine 
pH 7,3 hrs 
IN=CH-(CH2)3-C=N-Cys 
(L-cysteine-modified Polymer) 
Figure 2.6 Reaction schemes of immobilizing L-cysteine onto the surface of polyethylene 
terephthalate {PET) and polyurethane (PU) by first adding an amine group by 
the use of ethylenediamine and 3-aminopropyltriethoxysilane (APTES), 
respectively and then using glutaraldehyde as a crosslinker. 
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final concentration of the nitrosated L-cysteine can be determined by calculating the 
difference between the responses from the two reducing solutions. The detection limit 
for nitrite using this method was as low as 0.02 nmol per injection. The intra-assay 
variability was less than 2% and the inter-assay variability was less than 5%. The 
calculated value of L-cysteine immobilized on the PET surface and polyurethane were 
consistently 8.1 ± 1.1 nmol/cm2 (n=5) and 5.2 ± 0.9 nmol/cm2 (n=3), respectively. 
2.6.3 Testing the Ability of the Design to Inhibit Platelet Attachment to the Surface 
For this study, both stagnant and flow conditions were used to study the 
haemocompatiblity of the modified polymers with platelets. The platelets used in this 
study were first radio-labeled with isotope Cr-51, so that the amount of platelets could be 
quantified by measuring the radioactivity of the labeled platelets. Control samples for 
this study were glycine-modified PET and PU samples under the same experimental 
conditions. According to the results of the stagnant test the L-cysteine modified PET 
and PU samples had almost the same number of platelets attached to the samples as the 
control, when no plasma was present in the platelet suspension. However, when 50% 
plasma was present in the platelet suspension, the number of platelets attached to the 
samples was reduced - 60% and - 50%, respectively, as compared to the control. As 
indicated by the results from the flow test the number of platelets attached to the surface 
of the L-cysteine modified PET and PU was about 80% of the number of platelets 
attached to the surface of the control sample in the absence of plasma. The presence of 
plasma significantly reduced the number of platelets attached to the L-cysteine modified 
PET and PU samples to - 55% and - 25%, respectively, as compared to the control. The 
results of this study indicate that in order for the L-cysteine modified polymers to inhibit 
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platelet deposition, they must also be exposed to a source of plasma (containing RSNOs) 
that likely transfers NO from the plasma to the polymer, in order to inhibit platelet 
adhesion. 
The past studies laid the groundwork for the development of the design. First, the 
concentration of NO needed to prevent platelets from attaching to a surface was 
determined. Next, a design to attach L-cysteine to the surface of a polymer was 
developed and steps were taken to characterize the modified surface. Lastly, the 
modified material was tested in vitro with platelets in both at both stagnant and flow 
conditions. 
The research described in this thesis continues the work from past studies and 
attempts to solve any open problems from the past studies. There were some problems 
when attempting to characterize the surface of the modified material in the past research 
studies. There were not any methods readily available that could measure L-cysteine 
attached to a surface at low concentrations(< 10 nmols/~m2) and the chemiluminescence 
method developed by past studies showed some inconsistencies. It was also desired to 
have alternative methods that could be used to validate the chemiluminescence method. 
Therefore, Chapter 3 discusses various methods that were used to characterize the surface 
of the modified polymer. 
In past research studies, L-cysteine modified polymer was tested in vitro with 
platelets in both stagnant and flow conditions in order to measure the amount of platelet 
attachment to the surface. Although the studies showed a significant reduction in platelet 
attachment to the modified material, the modified materials were unable to completely 
inhibit platelet attachment to the surface. It was hypothesized that the addition of more 
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L-cysteine sites or different L-cysteine-containing moieties on the polymer will increase 
the NO-release rate per unit area and will increase the inhibition of platelet deposition. 
Chapter 4 describes the optimization of the polymer modification process that was 
performed in order to maximize the amount of thiol groups on the surface of the modified 
polymer. The following groups were used in the modification process: 1. L-cysteine 
residues, 2. a L-cysteine containing moiety, 2-hninothiolane, and 3 .. a polypeptide 
containing multiple cysteine residues. 
In past studies, only the L-cysteine modified polymer was tested in a perfusion 
chamber with platelet solutions, and the only platelet solutions that were studied were 
platelets in a buffer solution and platelets in a plasma solution. In Chapter 5, the 
optimized modified polymers were tested in vitro with platelets under various conditions 
. in order to investigate if the optimized polymers were able to further decrease the amount 
of platelet attachment to the surface as compared to past studies. These studies 
investigated not only polymer samples modified with L-cysteine, but also with 2-
iminothiolane and a cysteine polypeptide. Also, other platelet solutions were 
investigated, in addition to the platelets in a buffer solution and platelets in a plasma 
solution, including platelets in a 7 µM BSANO solution and platelets in a whole blood 
solution. 
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CHAPTER3 
SURFACE CHARACTERIZATION OF L-CYSTEINE MODIFIED POLYMERS 
3.1 Introduction 
An important step in the development of new biomaterials is the ability to 
accurately characterize the new material. This is especially important whenever surface 
modifications are made to the material, since the properties of a surface greatly affect its 
bioconipatibility. 
Immobilized L-cysteineon solid substrates (e.g., gel beads) is normally used for 
affinity chromatography and enzyme immobilization (Tyllianakis et al., 1994). Bui and 
Thompson reported that L-cysteine was successfully immobilized onto the surface of a 
biomedical polymer via silane, which was intended to improve the biocompatibility (Bui 
and Thompson, 1993). After S-nitrosothiols such as nitroso-L-cysteine (CySNO), S-
nitroso-glutathione (GSNO), and S-nitroso-bovine serum albumin (BSANO) were shown 
to have similar biological functions ( e.g., vasodilator and inhibitor of platelet 
aggregation) as free radical nitric oxide, (NO) (Myers et al., 1990; Stamler et al., 1992b) 
nitrosated L-cysteine immobilized on biomaterials was demonstrated to be able to inhibit 
platelet adhesion and reduce smooth muscle cell proliferation (Bohl and West, 2000). 
Furthermore, we reported that L-cysteine attached on polymeric biomaterials, without 
. prior nitrosation, could enhance the haemocompatibility ofbiomaterials via exploiting 
endogenous nitric oxide (S-transnitrosation and decomposition ofCySNO) (Duan and 
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Lewis, 2002). This latter method may overcome the disadvantages of NO-releasing 
polymers, including limited life span and toxicity. Thus, the quantification of 
immobilized L-cysteine would be necessary for characterizing the attachment of L-
cysteine and paving the way for its further applications. 
Using available thiol-measuring techniques, it was difficult to characterize the 
surface of the biomaterial modified with L-cysteine, a common thiol, since many of the 
techniques were developed for measuring thiols in solution and not thiols attached to a 
solid surface. Another difficulty was that the low molar concentration of L-cysteine 
expected on the surface (in the nanomolar range) was below the lowest detectable limits 
of many of the measurement techniques. This chapter reviews some of the more 
common surface characterization and thiol measurement methods and describes the 
problems encountered when using some of the methods to measure immobilized L-
cysteine and how some of the methods were adapted to characterize L-cysteine 
immobilized on a surface. 
L-cysteine and other thiol-containing compounds have often been quantified 
using Ellman's reagent, 5,5-dithiobis (2-nitrosbenzoic acid) (DTNB) (Jocelyn, 1987; 
Riddles et al., 1979). The disadvantages of this assay include thiol autoxication, 
sensitivity to pH, inability to accurately detect concentrations in the nanomolar range, and 
interference from oxygen, nucleophiles, and nitric oxide donors (Gergel and Cederbaum, 
1997; Riddles et al., 1979). Additionally, Tyllianakis et al. found that this method is not 
suitable for the assay of certain immobilized L-cysteine, which may be contributed to 
steric hindrance effects ofEllman's reagent (Tyllianakis et al., 1994). 
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The method reported by Tyllianakis et al. is more accurate to determine 
immobilized L-cysteine, since it utilizes bicinchoninic acid (BCA) to form a color 
complex with Cu+ after Cu2+ is reduced by a thiol group. However, color contribution 
may result from other reducing groups with a redox potential lower than Cu2+ ( e.g., 
aldehydo and hydrazido ). Another problem with this method is that it is unable to 
accurately detect concentrations ofL-cysteine in the range that is expected on the surface 
of the modified L-cysteine polymer. 
Other methods, such as fluorescence microscopy, (Cook et al., 1996; Swartz, 
1996) which utilizes a fluorescent probe specific for thiols that can be visualized on the 
surface of a modified material, and X-ray photoelectron spectroscopy, (Girardeaux et al., 
1996; Kim et al., 2000) which measures the atomic percentages of elements present on a 
modified surface by measuring the photoelectrons emitted from a surface excited with x-
rays, have been more successful methods for detecting immobilized L-cysteine at lower 
concentrations. However, these qualitative assays cannot determine molar surface 
concentrations of immobilized L-cysteine. 
One focus of this work involves modifying chemiluminescence-based assays 
developed for aqueous analysis of nitrosothiols for quantitatively determining surface 
concentrations of immobilized L-cysteine. These assays work via detecting nitrosothiols 
and/or nitrite changes in surrounding solution following the nitrosation of immobilized L-
cysteine with acidified nitrite. These assays are based on the following findings: (i) free 
and immobilized L-cysteine can be completely nitrosated to form CySNO with acidified 
· nitrite (Byler et al., 1983; Stamler et al., 1992b); (ii) both nitrosothiols and nitrite in the 
same solution can be measured by using a reducing agent of potassium iodide in glacial 
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acetic acid that is supplemented with iodine (Samouilov and Zweier, 1998); (iii) adding 
ammonia sulfamate or sulfanilamide to the reducing solutions abolishes the production of 
NO from the nitrite in the reducing solution (Marley et al., 2000; Samouilov and Zweier, 
1998); (iv) the release of NO from nitrosothiols can be blocked and the NO contribution 
from nitrite can be measured by using a reducing solution of potassium iodide in glacial 
acetic acid supplemented with free L-cysteine (Samouilov and Zweier, 1998); and (v) 
nitrosothiols can be detected by using a neutral pH reducing solution of copper chloride 
(CuCl) and L-cysteine (Fang et al., 1998). In this work, the immobilized L-cysteine is 
hydrolyzed by the strong acid during nitrosation and CySNO is detached from the. 
surface. The amount of CySNO that is broken off from the surface is measured by using · 
the methods described above. 
3 .2 Materials and Methods 
3.2.1 Reagents 
Glacial acetic acid, potassium iodide, and sodium nitrite were purchased from 
Fisher Scientific (Fairlawn, NJ). Phosphate buffered saline (PBS, pH 7.4) was obtained 
from Life Technologies (Gaithersburg, MD). Polyethylene terephthalate (PET) 
(thickness= 0.2 mm) was supplied by DuPont (Hopewell, VA). 5-
Iodoacetamidofluorescein (5-IAF) was purchased from Molecular Probes (Eugene, OR). 
Ammonia sulfamate, copper chloride, ethylenediamine, glutaraldehyde (GA), glycine, 
iodine, L-cysteine, sulfanilamide, and all the other reagents were purchased from Sigma 
Chemical Co. (St. Louis, MO). All water used was of HP LC-grade quality and was 
deoxygenated by bubbling nitrogen in the water prior to use. 
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3.2.2 Immobilization ofL-Cysteine onto PET Surface 
Primary amine groups were first attached onto the PET film surface as previously 
described (Desai and Hubbell, 1991). As described in the previous chapter, Figure 2.5 
· depicts the immobilization process that was initially used prior to optimization of the 
process, which is described later in Chapter 4. Briefly, PET sheets (1 cm x 3 cm) washed 
by acetone were incubated in 50% aqueous ethylenediamine for 24 hours at 40 °C to 
. incorporate a primary amine at the PET ester linkage. The aminated PET films were then 
washed with water and cured for at least 24 hours at ambient temperature. The PET films 
were then incubated with 1 % glutaraldehyde in 10 mM PBS with nitrogen bubbling 
through the solution for one hour to attach glutaraldehyde to the primary amine. 
Following glutaraldehyde addition, the PET films were rinsed and then immersed in a 
0.2% L-cysteine solution and gently shaken overnight to immobilize the L-cysteine to the 
PET. Prior to each assay, the PET films immobilized with L-cysteine were rinsed 
thoroughly to remove any absorbed L-cysteine. All steps of the modification process 
were performed in. a glove box under a dry nitrogen atmosphere to avoid oxidizing the 
thiol groups and oxygen was removed from all solutions by bubbling nitrogen through 
each solution. Also, all L-cysteine solutions and L-cysteine modified polymer samples 
were kept covered to prevent damaging light from oxidizing the thiol groups. 
3.2.3 Fluorescence Labeling ofL-Cysteine Modified PET Samples 
Fluorescent labeling is widely used in histochemistry, cell sorting, molecular 
structure and function studies, and many other experimental techniques for attaching 
highly sensitive visual and spectrophotometric markers to substances for identification 
and observation. When fluorescent molecules are irradiated with energy (light) of an 
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appropriate wavelength, a portion of this energy is absorbed and electrons are excited to a 
higher energy state. As these electrons return to their ground (unexcited) state, they do so 
in a series of steps or cascades. The energy associated with these electronic transitions is 
released and may be emitted as visible light. These releases take place in less than 104 
seconds. 
The most desirable characteristics in a fluorescent dye are strong light absorption, 
excitation stability, the nature of the wavelength shift, and high fluorescence efficiency. 
One of the most common fluorescent probes for the detection ofthiols, such as L-
cysteine, is 5-Iodoacetamidofluorescein (5-IAF). Reactions with iodoacetamides are 
generally carried out in the physiological pH range and usually are rapid at room 
temperature or below. The iodoacetamide derivative of fluorescein is also the most 
intensely fluorescent low molecular weight reagent available for detecting thiols. 
Possible problems associated with fluorescent staining are fading, 
autofluorescence, and nonspecific fluorescence. Exposure of the sample to blue light for 
only three minutes can cause a 50% loss of the intensity. Therefore, steps are taken 
during the experiments to prevent exposure of the samples to light, such as turning off all 
artificial lights, preventing natural light from entering the room, covering all samples 
with aluminum foil during the experiments, and storing all samples in a black film box. 
Some polymers may naturally autofluoresce without exposure to any fluorescent dyes. 
Therefore, a blank sample of PET should be checked for any autofluorescence prior to 
analyzing the L-cysteine modified PET samples. Nonspecific fluorescence may occur 
. when the fluorescent probe reacts with other chemical species on the sample other than 
the targeted thiol groups. To check for nonspecific fluorescence, the fluorescent probe 
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should be tested with each of the linker groups attached to the surface of the PET sample, 
the ethylenediamine and the glutaraldehyde. 
A 2 mM 5-IAF stock solution was prepared in a 50 mM phosphate buffer solution 
(pH 7). The 5-IAF solution was kept completely covered at all times to keep out 
damaging light that could cause fading. Each of the following PET samples, 1 cm x 1 
cm, were incubated with 4 ml of the stock solution for at least 1 hour: 1) blank PET, 2) 
ethylenediamine attached to PET, 3) ethylenediamine and glutaraldehyde attached to 
PET, 4) ethylenediamine, glutaraldehyde, and L-cysteine attached to PET, and 5) 
ethylenediamine, glutaraldehyde, and glycine attached to PET. All of the samples were 
continuously shaken during the incubation time to ensure complete reaction of the 
fluorescent probe with the L-cysteine on the sample. The samples were rinsed with water 
and kept in the dark until further analysis. The surface of each sample was examined by 
using an argon laser-scanning microscope (Leica TCS SP2, Exton, PA) in confocal mode 
with a 10.0 x 8.0 oil immersion objective lens. The filter set was set at 488 nm excitation 
and 515 nm emission. 
3.2.4 X-ray Photoelectron Spectroscopy (XPS) Analysis of L-Cysteine Modified PET 
Samples 
XPS provides a non-destructive trace elemental analysis of the outer few atomic 
layers on a variety of materials and can provide chemical bonding and/or oxidation state 
information. Photoelectron spectroscopy is based upon a single photon in I electron out 
process. In XPS, the photon is absorbed by an atom in a molecule or solid, leading to 
ionization and the emission of a core (inner shell) electron. The kinetic energy 
distribution of the emitted photoelectrons can be measured using an electron energy 
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analyzer in order to construct a photoelectron spectrum. For each and every element, 
there is a characteristic binding energy associated with each core atomic orbital, i.e. each 
element gives rise to a characteristic set of peaks in the photoelectron spectrum at kinetic 
energies determined by the photon energy and respective binding energies. The presence 
of peaks at particular energies therefore indicates the presence of a specific element in the 
sample under study. Furthermore, the intensity of the peaks is related to the 
concentration of the element within the sample region. Energy analysis of the 
photoelectrons emitted from the surface excited with x-rays can be used to characterize a 
variety of inorganic and organic materials including semiconductors, thin films, 
electropolished stainless steel, and insulating samples like ceramics, glasses, catalysts, 
paper, plastics, and biomedical devices. Typical data may include a low resolution 
survey scan for elemental composition and a high resolution energy scan for chemical 
bonding information. Detection limits are typically 0.01 - l atom% at a depth resolution 
oflO-lOOA. 
XPS analysis of samples was performed at the Chemical Engineering and 
Material Science Department at the University of Oklahoma (Norman, OK) and at the 
Chemistry Department at Lehigh University (Bethlehem, PA). Each of the following 
PET samples, 1 cm x 1 cm, was prepared for XPS analysis: 1) blank PET, 2) 
ethylenediamine and glutaraldehyde attached to PET, and 3) ethylenediamine, 
glutaraldehyde, and L-cysteine attached to PET. 
XPS was also used to ensure that L-cysteine is completely removed from the 
surface of PET after nitrosation with acidic nitrite. A modified PET sample, 1 cm x 1 
cm, was initially placed in 4 ml of a 0.5 M HCl solution containing 40 µM of excess 
54 
nitrite. The solution was gently shaken for the same time period used for nitrosation, one 
hour. The PET sample was removed from the acidic nitrite solution and rinsed prior to 
analysis. Two control samples were used for comparison in the analysis. One was a 
blank PET sample subjected to the same experimental conditions described above, and 
the other was a modified PET sample that was not subjected to the experimental 
conditions. 
3.2.5 Nitrosation of Free and Immobilized L-Cysteine 
The chemiluminescence method used for quantifying L-cysteine attached to the 
polymer surface required nitrosation ofL-cysteine (CySNO) on the surface and 
subsequent removal of CySNO from the polymer. The nitrosation reaction is equimolar 
between L-cysteine and nitrite (N02), according to Equation 3.1. 
CySH + N02- + H+ ~ CySNO + H20 Eq. 3.1 
Free L-cysteine and L-cysteine-modified PET (PET-Cys) were nitrosated via an 
acidified N02- solution, which is a typical method for nitrosating thiols (Byler et al., 
1983; Stamler et al., 1992b). During nitrosation, the solutions were gently shaken for one 
hour. All nitrosation procedures were carried out in capped, amber-colored tubes to 
prevent NO from escaping from the system and to keep light from entering the system 
and oxidizing the thiol groups. 
For nitrosation of immobilized L-cysteine, PET-Cys was freshly prepared and cut · 
into small pieces (1 cm x 3 cm). Each piece was added to a 4 ml 0.5 M HCl solution 
initially containing 40 µM N02-. A higher concentration ofN02- was used in the 
nitrosation of PET-Cys in order to ensure that there would be an excess of N02- for 
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complete nitrosation. For nitrosating free L-cysteine, various ratios of nitrite to L-
cysteine were added to a 0.5 M HCl solution. Equimolar concentrations ofN02- and L-
cysteine, as well as N02- concentrations less than L-cysteine concentrations were used in 
some cases to consume all of the N02-. 
3.2.6 Chemiluminescence Analysis ofL-Cysteine Modified PET Samples 
Chemiluminescence analysis of samples involved the formation of NO from 
CySNO and/or N02- and the subsequent reaction of NO with ozone. The reaction 
between NO and ozone leads to the formation of an excited form of N02 (N02 *) with 
subsequent release of electromagnetic radiation of characteristic frequency, as shown in 
the reaction steps below: 
. Eq. 3.2 
Eq. 3.3 
Emission from electronically excited nitrogen dioxide is in the red and near-
infrared region of the spectrum and is detected by a thermoelectrically cooled, red-
sensitive photomultiplier tube (PMT). NO from the sample and ozone produced in the 
electrical discharge of the detector are. mixed in the chemiluminescence reaction cell. A 
red cut-off filter between the reaction cell and the PMT selectively transmits the light 
emitted by the N0/03 reaction to be detected by a recorder. 
Following nitrosation, a Sievers 270B chemiluminescence NO analyzer (Sievers 
Corporation, Boulder, CO) was used to measure the amount ofnitrosated thiols and/or 
N02- in each sample, by measuring the equivalent amount of NO released upon exposure 
to a reducing solution. Several methods utilizing one or more of the research methods 
56 
described previously were used in order to determine the most accurate procedure to 
measure the CySNO detached from the surface of modified PET. 
Method 1 
This method uses two reducing solutions to measure the amount of L-cysteine on 
the modified PET surface. Reducing solution A is composed of0.2 M potassium iodide 
in glacial acetic acid saturated with iodine. This reducing solution instantaneously 
converts No2 • and nitrosothiols (such as CySNO) to NO; whereupon, the NO is rapidly 
purged from solution and detected. Thus, the NO purged represents the combined No2• 
and nitrosothiols concentration. Reducing solution B is composed of 0.2 M potassium 
iodide in glacial acetic acid supplemented with 25 mM free L-cysteine. Additional L-
cysteine has been shown to minimize NO release from GSNO, (Samouilov and Zweier, 
1998) such that similar effects were expected for CySNO. The excess L-cysteine in the 
reducing solution is believed to suppress the release of NO from CySNO, without 
affecting the excess No2• in solution from being converted to NO. Thus, the NO rapidly 
purged from this reducing solution represents only the No2 • concentration. The reaction 
between excess N02- and the reducing solution to produce NO is believed to occur at a 
much faster rate than the nitrosation reaction between excess N02- and L-cysteine. Thus, 
the NO rapidly purged from this reducing solution represents the No2· concentration. 
The nitrosothiol concentration was obtained by finding the difference between the 
concentration of the CySNO plus excess No2· determined by using reducing solution A 
and the concentration of excess No2 · determined by using reducing solution B. 
This method was validated by using standard solutions of free L-cysteine. For 
one test, a 10 µM nitrite solution, a 10 µM CySNO solution, and a solution containing 
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both 5 µM CySNO and 5 µM nitrite were each measured by using both reducing 
solutions. The 10 µM CySNO solution was made by adding an equimolar amount of L-
cysteine and nitrite to a 0.5 M HCl solution and assuming complete nitrosation. The 5 
µM CySNO and 5 µM nitrite solution was made by adding twice the molar concentration 
of nitrite to L-cysteine to a 0.5 M HCl solution and assuming complete nitrosation with 
an equimolar amount of excess nitrite remaining in the solution. For another test, 2.5, 5, 
and 10 µM L-cysteine solutions were nitrosated using 5 µM N02- solutions and then 
measured. 
To measure the amount ofL-cysteine on the surface of modified PET samples, 
· samples were obtained during nitrosation of the L-cysteine modified polymer. An acidic 
N02- solution composed of 40 µM N02- in 0.5M HCl was used to nitrosate the L-cysteine 
residues on the polymer: The acidic solution breaks the aldehyde bond between 
glutaraldehyde and L-cysteine (see Results section), thus the nitrosated cysteine breaks 
off during nitrosation and can be detected. The concentration of CySNO in the solution 
was then measured by using both reducing solutions A and B. 
Method 2 
This method measures the amount.ofL-cysteine on the surface of modified PET 
by using ammonium sulfamate or sulfanilamide, which are nitrite scavengers. Both 
ammonium sulfamate and sulfanilamide have been shown to react with nitrite in solution; 
however, sulfanilamide has been shown to be more effective (Marley et al., 2000). 
Solutions of 0.5% ammonium sulfamate or sulfanilamide were added to 5, 10, and 100 
µM nitrite standard solutions in a 1 :5 volume ratio. Any NO release from the standard 
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solutions was measured by injecting samples into reducing solution A. Thus, since N02-
was scavenged, the measurement is representative of only nitrosothiols. 
To validate the ability of this method to measure CySNO in solution, 
sulfanilamide was also used with free L-cysteine in solution nitrosated using either a 1: 1 
or a 1 :2 molar ratio of L-cysteine to nitrite. After the L-cysteine solutions were allowed 
to nitrosate for 1 hour while shaking gently, a 1 :5 volume ratio of 0.5 wt% sulfanilamide 
to sample was added to react with any excess nitrite. The concentration of CySNO in the 
solution was measured by using reducing solution A. Since both ammonium sulfamate 
and sulfanilamide were both shown to do equally well in scavenging excess nitrite in 
solution, only sulfanilamide was selected to be used to measure CySNO. L-cysteine 
concentrations of 1 µM and 10 µM were used because this is the range of the solution 
concentrations expected after CySNO is removed from the modified PET samples. 
To measure the amount ofL-cysteine on the surface of modified PET samples, 
samples were obtained by the nitrosation of the L-cysteine modified polymer, as 
described previously. A 0.5 wt% sulfanilamide solution was added to the sample (1:5 
volume ratio of sulfanilamide to sample) containing nitrite and the nitrosated L-cysteine 
· that had been broken off of the PET surface. The concentration of CySNO in the solution 
was measured by using reducing solution A. 
Method 3 
This method measures the amount ofL-cysteine on the surface of modified PET 
by measuring the concentration of CySNO directly by using a reducing solution at 50 ° C 
containing 100 µM saturated CuCl in a phosphate buffer (pH 7.4) with 1 mM free L-
cysteine. The neutral buffer does not promote the release of NO from any excess N02- in 
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the solution. Thus, the NO released into solution, then purged and detected, is indicative 
of only the nitrosothiol (i.e. CySNO). 
To validate this method, free L-cysteine in solution was nitrosated using either a 
1: 1 or a 1 :2 molar ratio of L-cysteine to N02-. The following L-cysteine concentrations 
were measured: 1, 5, 10, and 20 µM. To measure the amount of L-cysteine on the 
surface of modified PET samples, samples were obtained by the nitrosation of the L-
cysteine modified polymer, as described previously. The concentration of CySNO in the 
solution surrounding the sample after nitrosation was measured directly by using the 
CuCl reducing solution. 
For all three methods, the concentrations were determined by using a calibration 
curve determined by measuring the NO release via the reducing solutions from standard 
solutions of either N02- and/or nitrosated glutathione. 
The experimental set-up for chemiluminescence detection included a purging vial 
containing the reducing solution connected to the NO chemiluminescence detector and is 
shown in Figure 3.1. After the appropriate reducing solution was added to the purging 
vial (D x H: 20mm x 70mm), the solution was purged by nitrogen via a fritted disk (Pore 
Diameter: 25-50 µm) at the bottom of the vial. When using the reducing solution 
described in Method 3, a purging vial with a water jacket was used in order to keep the 
reducing solution at a constant temperature of 50 °C. All other reducing solutions were 
used in the purging vial shown in the figure at room temperature. Aqueous samples from 
the experiments were obtaining using a gas-tight syringe (Hamilton Company, Reno, 
NV) and then injected into 10 ml of the reducing solution. The NO released from the 
sample was carried with the nitrogen purge to the detector, where it reacted with ozone to 
60 
Sample 
Injection 
Reducing 
Reagent 
NO 
Ice Trap 
Vacuum 
Chemiluminescence 
Analyzer for NO 
G 
Ozone 
__.. ==::=::~ Generator 
Signal 
Recorder 
Figure 3.1 Experimental set-up of using the chemiluminescence analyzer to measure 
nitrosated L-cysteine that has been broken off the surface of L-cysteine 
modified PET. 
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give a signal. The volume of each sample varied between 20 and200 µ1 depending on 
the detection limits. The output signal from the detector was sent to an integrator that 
calculated the area under each sample peak. The areas were compared to the standards 
for quantification. 
3.3 Results 
3.3.1 Fluorescence Microscopy Analysis ofL-Cysteine Modified PET Samples 
Figure 3.2 shows the scans taken of the surface of the following samples that were 
labeled with the fluorescent probe 5-IAF: 1) blank PET, 2) ethylenediamine attached to 
PET, 3) ethylenediamine and glutaraldehyde attached to PET, 4) ethylenediamine, 
glutaraldehyde, and L-cysteine attached to PET, and 5) ethylenediamine, glutaraldehyde, 
and glycine attached to PET. A lighter scan is indicative of the more fluorescence on the 
sample. Thus, the scans that are darker shades (black) show very little to no fluorescence 
on the samples. 
The first scan shows the surface of a blank sample of PET'. The scan shows some 
minor scattered fluorescence on the sample; the sample is essentially non-fluorescent. 
There were no thiol groups on the blank surface to react with the fluorescent probe; 
therefore, it is believed that the minor scattered fluorescence is due to autofluorescence 
from the PET sample. 
The second scan shows the sample with ethylenediamine attached to the surface. 
The scan is very bright and highly fluorescent. 5-IAF can also react with primary amines 
in the absence ofthiol groups. The bright fluorescence shows a high concentration of 
ethylenediamine completely covering the surface of PET. 
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Scan 1. Blank PET 
Scan 3. PET+ Ethylenediamine + 
Glutaraldehyde 
Scan 5. PET + Ethylenediamine + 
Glutaraldehyde + Glycine 
Scan 2. PET + Ethylenediamine 
Scan 4. PET+ Ethylenediamine + 
Glutaraldehyde + L-cysteine 
Figure 3.2 Fluorescence microscopy analysis of modified PET samples using 5-IAF. 
Scans are shown at 80x magnification. 
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The third scan shows the sample with ethylenediamine attached to the surface of 
PET and then glutaraldehyde attached to the terminal amine group of ethylenediamine. 
Similar to the first scan of blank PET, there is only minor scattered fluorescence on the 
sample. Since the fluorescent probe does not react with aldehyde groups that are present 
on the surface after the addition of glutaraldehyde, fluorescence was not expected. It is 
also important to point out that there appears to be complete coverage of glutaraldehyde 
on the surface, because any exposed amine groups would react with the fluorescent probe 
and result in bright fluorescence on the surface. 
The fourth scan shows the sample of PET with both linker groups 
{ ethylenediamine and glutaraldehyde) and L-cysteine attached to the surface of PET. 
This scan shows bright fluorescence on the -surface; however, the fluorescence is not as 
bright and as widespread on the surface as seen in the second scan with just 
ethylenediamine on the surface. It is believed that this is due to one or a combination of 
the following reasons: i) 5-IAF is more reactive with amine groups that with thiol groups 
and/or ii) there is not complete coverage ofL-cysteine on the surface, due to possible 
crosslinking of the glutaraldehyde groups. Also seen in this scan is a series of striations 
on the surface of the sample. These striations were first noticed in an image sent by 
DuPont of the surface analysis from a scanning electron microscope, shown in Figure 3.3. 
It is believed that these striations are a result of fabrication of the PET films and that the 
crosslinkers and the L-cysteine react with the surface of PET along these striations. 
The fifth scan shows the sample of PET with both linker groups and glycine 
attached to the surface of PET. This sample was used as a control group to test the 
selectivity of the fluorescent probe. Glycine does not contain any thiol or primary amine 
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Figure 3.3 Film surface characteristics of Melinex S polyethylene terephthalate (PET) 
provided by DuPont Teijin Films™. One fringe displacement - 0.273 µm. 
65 
groups that would react with the fluorescent probe. As shown in the scan, only minor 
scattered fluorescence is shown on the surface of the sample due to autofluorescence. 
3.3.2 XPS analysis ofL-Cysteine Modified PET Samples 
Table 3.1 shows the results of XPS analysis ofL-cysteine-modified PET surfaces. 
The rows labeled "measured" in the table shows the atomic percent of each element 
measured by XPS. The rows labeled ''theoretical" in the table shows the atomic percent 
of each element determined by assuming there is complete coverage of each group 
attached to the PET surface and exactly a one-to-one binding between the PET surface, 
each linker group, and L-cysteine. For example, the monomer that makes up PET 
contains 10 carbon atoms and 4 oxygen atoms; therefore, assuming that XPS measures · 
one monomer on the surface of PET and that there is no surface contamination, there 
would be 71.43 atom% of carbon and 28.57 atom% of oxygen on the surface. Assuming 
next that one ethylenediamine molecule binds to one PET monomer on the surface and 
that one glutaraldehyde molecule binds to one ethylenediamine molecule, there would be 
15 carbon atoms, 4 oxygen atoms, and 2 nitrogen atoms, resulting in 71.43 atom% of 
carbon, 19.05 atom% of oxygen and 9.52 atom% of nitrogen on the surface. The same 
reasoning would apply to the addition ofL-cysteine to the surface of PET via 
ethylenediamine and glutaraldehyde. When interpreting the data from XPS analysis, it is 
important to remember that the analysis is only of the surface of the sample and not the 
bulk and that measured values may not match theoretical values due to changes occurring 
at the surface for numerous reasons, including oxidation, contamination, etching, 
measurement of partial monomers, etc. 
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. TABLE 3.1 
Atom% of Elements on Blank PET Sample and Modified PET Samples 
(Comparison of Theoretical with Measured by XPS) 
Sample 
Description Blank PET PET+ED+GA PET + ED + GA+ Crs 
C's 74.01 ± 0.32 72.21 ± 0.52 74.21 ± 1.17 (Measured) 
C's 71.43 71.43 66.67 (Theoretical) 
O's 25.99± 0.31 23.25 ± 0.08 · 20.57 ± 0.99 (Measured) 
O's 18.52 (Theoretical) 28.57 19.05 
N's 0 4.54± 0.44 4.70± 0.36 (Measured) 
N's 0 9.52 11.11 (Theoretical) 
S's 0 0. 0.52± 0.18 (Measured) 
S's 0 0 3.70 (Theoretical) 
Abbreviations. PET= Polyethylene Terephthalate, ED= Ethylenediamine, GA= Glutaraldehyde,.Cys = L-Cysteine, 
C = Carbon, 0 = Oxygen, N = Nitrogen, S = Sulfur 
Note. Values shown are mean values± standard deviation (n=2). 
For the blank PET sample, the measured atomic percent of carbon is more than 
the theoretical value and the measured atomic percent of oxygen is less. This could 
possibly be due to contamination at the PET surface or the XPS sampling includes partial 
monomers, in addition to entire monomers, such that the theoretical reasoning involving 
complete monomers is different than that actually measured. 
When interpreting the data for the PET sample with ethylenediamine and 
glutaraldehyde attached, the amount of nitrogen is a good indicator of the amount of 
ethylenediamine attached to the surface since ethylenediamine is the only component that 
contains nitrogen. The measured value is approximately one half of the theoretical value, 
approximately 4.5 atom%, suggesting incomplete coverage of ethylenediamine on the 
PET surface. Also for this sample, the measured oxygen content is more than the 
theoretical value, which could also be due to less than a one-to-one binding of 
ethylenediamine to the PET surface. For example, if there was a 3:1 :1 ratio of 
PET:ethylenediamine:glutaraldehyde, then this would result in theoretical atom% of 
71.43, 24.49, and 4.08 for carbon, oxygen, and nitrogen on the surface, respectively, 
which matches the measured values closer than assuming a 1: 1: 1 ratio of 
PET:ethylenediamine:glutaraldehyde. In addition to incomplete coverage of 
ethylenediamine on the PET surface, there could also be some crosslinking of the 
glutaraldehyde residues that would also result in lower atom% of nitrogen and a higher 
atom% of oxygen on the surface. Studies have shown the polymerization of 
glutaraldehyde can occur quickly in aqueous solutions under alkaline pH conditions to 
yield an unsaturated product shown next in Equation 3.4 (Monsan et al., 1975; Richards 
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and Knowles, 1968). However, glutaraldehyde polymeric moieties can also exist in 
aqueous solutions as low as pH 5 (Richards and Knowles, 1968). 
0 0 
II II 
0 0 0 H-C H-C 0 
II II 
H_;C-(CH2) 3 -C-H ~ 
II _cl I 11 
H-C-(CH2) 3 -?"t_ C -(CH2) 2 -?3=n C -(CHz)2 - C-H 
H H 
Eq. 3.4 
When interpreting the data for the PET sample with both linker groups and L-
cysteine attached, the amount of sulfur is a good indicator of the amount of L-cysteine 
attached to the surface, since L-cysteine is the only group that contains sulfur. The 
measured amount of sulfur is less than the theoretical value by approximately 86%, 
suggesting incomplete coverage ofL-cysteine on the surface of the modified polymer. It 
is probable that this was due to the incomplete coverage of ethylenediamine on the 
surface and/or glutaraldehyde ctosslinking on the surface that resulted in fewer sites 
available for L-cysteine attachment. The interpretation of the XPS results at this point of 
the analysis becomes very difficult due to the many possible combinations of the groups 
on the surface. However, the incomplete coverage of L-cysteine on the surface could also 
be due to other problems such as steric hindrance of the linker groups or L-cysteine, 
reactivity problems, or equilibrium issues. 
XPS was also used to ensure that L.,-cysteine was completely removed from the 
surface of a L-cysteine modified PET sample after one hour of nitrosation in an acidic 
nitrite solution. XPS showed that there was no detectable sulfur on the surface after one 
hour in the acidic nitrite solution (Table 3.2). When comparing the L-cysteine modified 
sample to the sample of a blank PET submitted to the same experimental conditions, 
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TABLE 3.2 
Atom% of Elements on a Modified PET Sample and a Blank PET Sample Placed in an Acidic Nitrite 
Solution for One Hour, Compared to a Modified PET Sample Not Placed in an Acidic Solution 
Sample 
Description 
C's 
O's 
N's 
S's 
Modified PET 
in Acidic Nitrite 
Solution 
71.84 
23.31 
4.85 
0 
Blank PET 
in Acidic Nitrite 
Solution 
73.79 
26.21 
0 
0 
Modified PET 
not in Acidic 
Nitrite Solution 
73.38 
21.26 
4.96 
0.40 
Abbreviations. PET= Polyethylene Terephthalate, C = Carbon, 0 = Oxygen, N = Nitrogen, S = Sulfur 
there were still levels of nitrogen detected on the surface that indicates ethylenediamine 
was still present on the surface. Therefore, an imine bond (RHC=NHR') was broken, 
since ethylenediamine was still detected on the surface but L-cysteine was not. However, 
it is difficult to determine from the results if it was the imine bond between 
ethylenediamine and glutaraldehyde or the imine bond between glutaraldehyde and L-
cysteine. It is believed that the terminal imine bond between glutaraldehyde and L-
cysteine was broken since it is not as stable as the imine bond between ethylenediamine 
and glutaraldehyde, especially if glutaraldehyde crosslinking is present. 
3.3.3 Chemiluminescence Analysis ofL-Cysteine Modified PET Samples 
Method 1 · 
The first test used to validate this m~thod involved measuring the response from a 
10 µM N02- solution, a 10 µM CySNO solution, and a solution of 5 µM N02- and 5 µM 
CySNO in both reducing solutions. Figure 3.4 shows the responses from the solutions in 
both reducing solutions. For the responses in reducing solution A, the signal from all 
three standard solutions should be the same, since this reducing solution converts N02-
and CySNO to NO to be measured. As shown, there is no significant difference between 
the responses from all three standard solutions in reducing solution A. For reducing 
solution B, the signal from the 10 µM N02- solution should be the same as that from the 
reducing solution A, since this reducing solution also converts N02- to NO to be 
measured. However, the signal from reducing solution B is suppressed slightly. The 
suppression of the NO signal from nitrite shows that some of the nitrite may be reacting 
with the L-cysteine in the reducing solution. For reducing solution B, the signal from the 
10 µM CySNO solution should be completely suppressed, since this reducing solution 
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Figure 3.4 Signal from the NO chemiluminescence analyzer for nitrite, CySNO, and an 
equimolar mixture of the two in both reducing solutions, one with free iodine 
(A) and one with L-cysteine (B). Values shown are mean values± standard 
deviation (n=3). 
72 
suppresses the release of NO from CySNO. However, a small signal was detected. It 
appears that reducing solution B is only able to suppress the signal from a CySNO 
solution by approximately 90%. For the solution of 5 µM nitrite and 5 µM CySNO the 
response from reducing solution B should be only 50% of the response from reducing 
solution A, due to suppression of the CySNO in reducing solution B. As shown, the 
signal is only suppressed by 46%. The slight discrepancy may be due to reducing 
solution B not being able to completely suppress the signal from CySNO as shown for 
the 10 µM CySNO solution. 
As an additional test to validate this method, 2.5, 5 and 10 µM L-cysteine 
solutions were nitrosated using 5 µM nitrite solutions. The samples were measured and 
the results are reported in Table 3.3. For reducing solution A, the measured 
concentrations for all of the solutions should be 5 µM since this was the starting 
concentration of nitrite added to each solution and reducing solution A converts both 
N02- and CySNO to NO to be measured. As shown, the mean values range from 4.72 to 
5.50 µM. For reducing solution B, the measured concentration for each solution should 
be equal to the amount of excess nitrite, assuming that all ·of the L-cysteine was 
nitrosated, since the NO contribution from CySNO is suppressed in reducing solution B. 
An excess nitrite concentration of2.5 µMis expected for the first solution listed in the 
table and 2.28 µM was measured in this reducing solution. Some of the excess nitrite 
may have reacted with the L-cysteine in the reducing solution before it could be 
converted to NO and measured. For the second and third test solutions, there should not 
be any excess nitrite due to it all reacting with the L-cysteine in the solution; however, a 
concentration of 0.35 µM and 0. 79 µM was measured, respectively'. There may have 
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+>, 
[L-Cysteine] in 
Solution 
(µM) 
2.50 
5.00 
10.00 
TABLE3.3 
Chemiluminescence Analysis of No2 • and CySNO in Solution Following Nitrosation 
(CySNO is calculated by the difference from the responses in two reducing solutions) 
[N02·] in Measured [N02·] and Measured [N02-] in Calculated 
Solution [CySNO] in Reducing Reducing Solution B [CySNO] 
.(µM) Solution A (µM) (µM) (A-B) (µM) 
5.00 4.72± 0.02 2.28 ± 0.01 2.44 ± 0.03 
5.00 5.39 ± 0.15 0.35 ± 0.03 5.04 ± 0.18 
5.00 .· 5.50 ± 0.07 0.79 ± 0.03. 4.71 ± 0.10 
Note. Values shown are mean values± standard deviation (n=3). 
Percent Error in 
Measurement 
-2.40 ± 1.20 
0.80 ± 3~60 
-5.80 ± 2.00 
been some release of NO from the CySNO in this solution that caused the measured 
concentration to be higher than expected. As described earlier, not the entire signal from 
CySNO is suppressed in this reducing solution and the release of NO from CySNO 
contributes to the measured concentration in this reducing solution. The measured 
CySNO is the difference between the two reducing solution values. The percent error 
between the measured and expected CySNO for this method ranged from 0.8% to 5.8% 
and the standard deviation between samples were shown to be low (Table 3.3). 
When using this method to measure the amount of L-cysteine on the surface of a 
modified sample of PET, the average measured surface concentration was 5.8 ± 1.7 
nmols/cm2 (n=3). This measured concentration was calculated by assuming that reducing 
solution B suppresses approximately 90% of the signal from CySNO. 
Method 2 
The results from the experiment using ammonium sulfamate and sulfanilamide to 
react with N02~ in solution in order to suppress the NO signal from N02-in the reducing 
solution showed that both scavengers completely suppressed any detectable signal from 
all of the nitrite solutions tested (5, 10, and 100 µM: n=3). These results show that 
. .. . 
ammonium sulfamate or sulfanilamide are both good candidates to suppress the NO 
signal from excess nitrite in solution such that the contribution of CySNO in solution is 
only detected. 
Sulfanilamide was used in solutions of free L-cysteine nitrosated using either a 
-1 :2 or 2:1 molar ratio ofL-cysteine:nitrite in a 0.5M HCl solution. Table 3.4 shows the 
results for measuring the CySNO in solution. For the lower concentration of CySNO in 
solution, the percent etror in the measurement ranged from 14% for the 1 :2 ratio ofL-
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TABLE 3.4 
Chemiluminescence Analysis of CySNO in Solution with Sulfanilamide 
(Using the reducing solution of potassium iodide in acetic acid saturated with iodine) 
[L-Cysteine] [NO;] Measured [CySNO] in 
in Solution in Solution Reducing Solution A Percent Error in 
(µM) (µM) (µM) Measurement 
1.00 1.00 0.71 ± 0.05 -29.00 ± 5.00 
1.00 2.00 0.86± 0.03 -14.00 ± 3.00 
10.00 10.00 8.43 ± 0.31 -15.70 ± 3.10 
10.00 20.00 8.64± 0.22 -13.60 ± 2.20 
Note. Values shown are mean values± standard deviation (n=3). 
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cysteine to nitrite to 29% for the 1: 1 ratio of L-cysteine to nitrite (n=3). For the higher 
concentration of CySNO in solution, the percent error in the measurement ranged from 
13 .6% for the 1 :2 ratio of L-cysteine to nitrite to 15. 7% for the 1: 1 ratio of L-cysteine to 
nitrite (n=3). Due to the high percent error for this method, it appears that sulfanilamide 
may affect the measurement of CySNO when using the reducing solution. CySNO is not 
very stable in solution; therefore, some NO may be released from CySNO and converted 
back to nitrite that can then be scavenged by sulfanilamide. This would result in a 
measurement lower than expected, which is seen in the results. This method has been 
successful when used to measure BSANO in solution, which is larger and more stable 
than CySNO in solution (unpublished results). 
When using this method to measure the amount of L-cysteine on the surface of a 
modified sample of PET, the average measured surface concentration was 4.1 ± 2.1 
nmols/cm2 (n=3). This compares to 5.8 nmols/cm2 measured by method 1. The 
measured concentration from this method may be lower than the actual concentration due 
to the instability of CySNO in the solution containing sulfanilamide, as shown in the 
analysis of nitrosated free L-cysteine in solution. 
Method 3 
To validate this method, solutions of free L-cysteine of the following 
concentrations: 1, 5, 10, and 20 µm were nitrosated using either a 1:1 or a 2:1 molar ratio 
of nitrite:L-cysteine. The CySNO concentration in each solution was measured directly 
by using the reducing solution containing copper chloride with L-cysteine. The results 
are shown in Figure 3.5. The response from each of the CySNO solutions was 
proportional to its concentration. The signal for the 5 µM CySNO solution was 
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Figure 3.5 Signal from the NO chemiluminescence analyzer for CySNO in the reducing 
solution of copper chloride supplemented with L-cysteine at pH 7.4 and 50°C. 
Values shown are mean values± standard deviation (n=3). 
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approximately 5 times that of the signal from the 1 µM CySNO solution. The signal 
from the 10 µM and 20 µM CySNO solutions was approximately 2 and 4 times that of 
the signal from the 5 µM CySNO solution. The proportional responses were seen for 
both the 2: 1 and 1: 1 nitrite to L-cysteine solutions. The response from the 2: 1 solution 
was slightly higher at each concentration compared to the 1: 1 solution. This may be due 
to the reducing solution not being able to completely suppress all of the excess acidic 
nitrite in the 2: 1 solutions. As seen in the figure, there was a low signal detected for a 40 
µM acidic nitrite solution, approximately equal to the signal from the 1 µM CySNO 
solution. 
When using this method to measure the amount of L-cysteine on the surface of a 
modified sample of PET, the average measured surface concentration was 6.5 ± 1.3 
nmols/cm2 (n=3). This compares to 5.8 nmols/cm2 measured by method 1 and4.l 
nmols/cm2 measured by method 2. The measured concentration from this method may be 
higher than the actual concentration ifthe signal from the excess acidic nitrite in the 
solution is not completely suppressed by the reducing solution. 
For all of the chemiluminescence methods, the detection limit for N02-was as 
low as 5 pmol per injection, which corresponds to 0.1 µM if a 50 µ1 sample was injected. 
Each time samples were analyzed at a significant time following the previous calibration, 
a corresponding calibration curve was established in order to minimize any inter-assay 
error. 
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3 .4 Discussion 
. Several methods were presented that can be used for the surface characterization 
of a modified PET surface, including the detection of L-cysteine attached to the surface. 
Currently, there are limited methods available to characterize such a surface, as described 
in this chapter, and even those methods discussed still have limitations to overcome 
before the surface can be completely characterized. 
Using fluorescence microscopy to characterize a modified surface has many 
advantages, including visualization of the surface and being able to probe specific areas 
and/or molecules on a the surface. Unfortunately, there are also problems with using 
· fluorescence microscopy to characterize a modified surface, including fading, 
autofluorescence, and selectivity. Fading of the fluorescent dye can be avoided by taking 
steps in the preparation and use of the dye to avoid all possible light sources that can 
cause the fluorescence intensity to fade. Autofluorescence was not a problem for this 
study. As shown in the scans of the blank PET samples, there was only a slight amount 
of autofluorescence, and small amourits can be removed by adjusting the gain setting of 
the laser of the microscope. There are many fluorescent probes available for detecting 
. thiols; however, as shown in the scans of the PET samples with the ethylenediamine only 
attached, the fluorescence probe also reacted with the amine group and was not specific 
for thiols only. This was not a problem for this study, because it was shown that the 
glutaraldehyde attached to the ethylenediamine did not react with the fluorescent probe 
and blocked any reaction between ethylenediamine and the probe. Still, the problem of 
selectivity must be considered when using other fluorescent probes with other modified 
samples in order to ensure that only the target molecule is being probed. Probably the 
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greatest limitation of this method is that under the current procedure it is difficult to 
quantify the amount of fluorescence on the surface of a modified sample and relate it to 
the molar concentration ofL-cysteine on the surface. Recently, some studies have shown 
that it may be possible to quantify the surface density of a fluorescent label with the 
optical microscope (Hanley and Harris, 2001; Model and Healy, 2000); however, a good 
standard sample with a known L-cysteine surface concentration is needed to relate it to 
the surface density of the fluorescent label. We will continue to explore the possibility to 
quantify the amount of fluorescence on the modified PET sample and to relate it to the 
. concentration of L-cysteine on the surface. 
· The elemental analysis of a surface by XPS is a good tool for surface 
characterization. The measured atom% of elements on the surface could be compared to 
the theoretical atom% of elements on the surface in order to indicate if there is one-to-one 
binding. Also, certain elements in some of the groups attached to the surface of PET 
could be used as markers to indicate the amount of surface coverage. After the addition 
of ethylenediamine and glutaraldehyde to the surface of PET, nitrogen was used as a 
marker to indicate the amount of ethylenediamine attached to the surface, since 
ethylenediamine is the only component that contains nitrogen. After L-cysteine was 
attached to the surface of PET, sulfur was used as a marker to indicate the amount ofL-
cysteine attached to the surface, since L-cysteine is the only component to contain sulfur. 
It is difficult to determine the proportion of each group on the modified surface (i.e. one-
to-one binding) due to incomplete coverage and/or crosslinking of some groups that 
affect the atom% measurements on the surface. As with fluorescence microscopy, the 
problem with this type of analysis is that it does not give surface concentrations of 
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molecules on the surface, instead it gives surface percentages of atoms on the surface. 
However, if a reliable standard sample with known surface concentrations could be 
developed, then the surface percentages given by XPS analysis could be transformed to 
surface concentrations. In the future, if a sample could be accurately measured by means 
of another method, XPS may be favorable to use for the analysis of the unknown samples 
due to its high sensitivity and accuracy. Due to the high cost of XPS, it may not be 
readily available to every laboratory and another less costly measurement method with 
slightly lower accuracy may be more favorable. 
Several chemiluminescence-based methods were also presented, which can be 
used for the detection of immobilized L-cysteine on a PET surface. The 
chemiluminescence-based methods used to measure L-cysteine utilized a variety of 
reducing solutions to measure either CySNO and/or excess nitrite in solution. Three 
methods using different types of reducing solutions were described in this chapter. The 
accuracy in the measurement ofL-cysteine varied depending on the reducing solution 
used in the various methods. When validating each method by using known standard 
solutions ofL-cysteine, some methods did better than others, however all the methods 
had problems. Even though the first method had low percent errors in the measurement 
of the standard solutions, there are some problems to consider. The reducing solution of 
potassium iodide in glacial acetic acid containing L-cysteine did not seem to be stable 
and was not able to completely suppress the release of NO from CySNO. Also, since two 
measurements must be made in order to determine the concentration of CySNO, there is 
the possibility of introducing twice the amount of experimental error into the 
measurement. The major problem with the second method that used nitrite scavengers, 
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ammonium sulfamate and sulfanilamide, was that the scavengers also interfered with the 
measurement of CySNO. The main problem with the third method was the instability of 
the reducing solution. The pH of the reducing solution must be maintained near 7 in 
order to suppress any signal from the excess nitrite in the solution. Due to this instability, 
only a few samples of the highly acidic solutions could be analyzed at a time before the 
pH of the reducing solution would decrease. If the samples were neutralized prior to 
analysis in the reducing solution, the release rates in the reducing solution were too slow 
to quantify. All three of the measurement methods did result in a measured surface 
concentration of L-cysteine in the same order of magnitude and only varied by less than 
1.8 nmol/cm2 standard deviations. Therefore, it is believed that the actual surface 
concentration of L-cysteine on the surface of a modified PET sample is within the range 
of 4.1 to 6.5 nmols/cm2• The chemiluminescence-based methods must continue to be 
improved by using various types of reducing solutions, nitrite scavengers, experimental 
settings, (temperature, pH, etc.) and/or more sensitive analyzers, etc. in order to improve 
the accuracy of the method. 
The chemiluminescence assay is the only method we have found to be able to 
quantitatively measure the concentration of L-cysteine attached to the surface of a 
modified PET sample. However, this method could be easily adapted to measure any 
thiol group immobilized on any type of solid surface, provided that the thiol group could 
be removed from the surface into the surrounding solution for measurement. This 
method was also shown to have low detection limits: 5 pmol N02- or CySNO can easily 
be measured at the lower detection limit. This method also has excellent selectivity for 
thiols. Unlike the fluorescent probe that also reacted with amines or XPS that does not 
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detect L-cysteine, but rather the sulfur atom in L-cysteine, the chemiluminescence 
method only measures the thiols that can be nitrosated with N02-. 
The major disadvantage to the chemiluminescence method is that the L-cysteine 
is broken off of the PET sample during the nitrosation process, rendering the sample 
unusable for additional studies. Therefore, samples can only be characterized after use. 
Since it would be advantageous to be able to modify a sample, characterize it, and then 
use it, we are continuing to investigate other methods that could be developed to 
characterize surfaces modified with L-cysteine, without damaging the modified surface. 
The methods described in this chapter to characterize the surface of the L-cysteine 
modified polymer were used in the optimization process of the polymer modification 
process (Chapter 4). The methods were used to characterize not only L-cysteine 
modified polymers, but two other modified polymers containing L-cysteine moieties, 2-
iminothiolane and a cysteine polypeptide chain. The characterization methods were used 
with the optimization methods to determine the modification process that resulted in the 
most thiol groups on the surface of the modified sample. 
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CHAPTER4 
OPTIMIZATION OF THE POLYMER MODIFICATION PROCESS 
4.1 Introduction 
One hypothesis was that the addition of more L-cysteine sites or different L-
cysteine-containing moieties on the polymer will increase the NO-release rate per unit 
area and lead to a greater inhibition of platelet deposition on the modified polymer. 
Therefore, the polymer modification process was optimized in order to increase the 
number of L-cysteine sites or different L-cysteine-containing moieties on the polymer. 
The following moieties were used in the optimization of the polymer modification 
process: 1) L-cysteine, 2) a L-cysteine containing moiety, 2-Iminothiolane, and 3) a 
polypeptide containing multiple cysteine residues .. Each moiety was attached to PET by 
using linker groups. Optimization of each moiety was performed by using factorial 
designs that varied the reaction times and molar concentrations of each group involved in 
the modification process. The optimal design was determined by measuring the relative 
amount of the thiol groups on the surface by techniques described in Chapter 3. 
In a classical type of scientific experiment, it is customary to hold most of the 
variable factors constant and to allow only one or two to vary in each experiment. A 
series of experiments in which only one factor is varied at a time would be both lengthy 
and costly, and might still be unsatisfactory because of systematic changes in the general 
background conditions. An alternative approach is to try to investigate variations in 
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several factors simultaneously. This is the idea of a factorial experiment in which the set 
of experiments is made large enough to include all possible combinations oflevels of the 
. different factors. There are many important advantages in using this type of 
experimentation as compared with the standard classical method (Bailey, 1995): 
• One can obtain a broad picture of the effect of each factor in the different 
conditions furnished by variations in the other factors. 
• The use of a wide range of factor combinations provides a more reliable basis 
for making practical recommendations that will be valid in variable 
circumstances. 
• If all the factors happen to act independently of each other, one can obtain as 
much information about each from a single experiment as one would if the 
whole experiment were devoted to only one factor. 
• If the factors are not independent of one another, one can automatically collect 
a great deal of information about the nature of the interaction. 
There are potential problems with trying to include too many factors in one 
experiment. Although, theoretically, the inclusion of a large number leads to greater 
efficiency, there is often considerable difficulty in handlmg and interpreting very 
complex results (Bailey, 1995). 
A design in which there are several factors (n factors), each at two levels, is called 
a 2n factorial design. Levels may be two quantitative levels, such as two concentrations, 
or two qualitative alternatives. In some cases, one level is simply the absence of the 
factor and the other its presence. So, for the case of optimizing the process of attaching 
L-cysteine to the surface of the polymer, a 2n factorial design including six factors 
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(concentration and reaction time for each of the three reaction steps) would result in 26 or 
64 experiments. It is also possible to have designs with more than two levels for several 
factors, as long as all of the factors have the same number oflevels. Higher-level designs 
may give more information, but they are more complicated due to the difficulty in 
handling and interpreting very complex results. 
Using a complete factorial design with two levels to optimize the process of 
· attaching L-cysteine to the surface of PET would result in many experiments that would 
be very time-consuming and costly to perform. Therefore, a fractional factorial design 
that consisted of only a fraction of the total number of runs was used. When the fraction 
of runs is selected appropriately, the effects of factors and even some interactions can be 
estimated with fewer runs (Frank and Todeschini, 1994). The assumption is that the 
effect of the majority of interactions is negligible (Frank and Todeschini, 1994). 
A commonly used fractional factorial design is the Plackett-Burman design. The 
I 
term "Plackett and Burman design" has its origin in a paper written by R. L. Plackett and 
J.P. Burman in 1946 (Plackett and Burman, 1946). It is generally used to indicate certain 
two-level fractional factorial designs which allow efficient estimation of the main effects 
of an factors being explored, assuming that all interactions between factors can be 
ignored. The model is of the form: 
Eq. 4.1 
where Y is the response,~ is a constant and A 1 to An are the coefficients of the response 
values. The design analyzes the input data and presents rank ordering of the variable 
with magnitude of effect, and designates signs to the effects to indicate whether an 
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increase in a factor is positive or not. The effect of each variable is determined by the 
following expression: 
(Ef~ ) _ LR(+)-LR(-) 1ect i - ri Eq.4.2 
' 
where R(+) is a ( +) or high level response, R(-) is a (-) or low level response, and n is the 
total number of factors. The main effects are interpreted to mean that the net effect of 
increasing the factor level, averaged over all other factor levels, from low to high is to 
increase or decrease the response, depending on the magnitude and direction of the main 
effect value of the factor. The magnitude of the main effect can be related to its 
significance in the optimization study. The greater the magnitude, the more influence it 
has on the optimization process. The sign of the main effect is related to the direction the · 
level should be increased or decreased to influence the optimization process. 
4.2 Materials and Methods 
4.2.1 Reagents 
Glacial acetic acid, potassium iodide, and sodium nitrite were purchased from 
Fisher Scientific (Fairlawn, NJ). Phosphate buffered saline (PBS, pH 7.4) was obtained 
from Life Technologies (Gaithersburg, MD). Polyethylene terephthalate (PET) 
(thickness= 0.2 mm) was supplied by DuPont (Hopewell, VA). Oregon Green® 488 
carboxylic acid, succinimidyl ester *5-isomer* and 5-Iodoacetamidofluorescein (5-IAF) 
was purchased from Molecular Probes (Eugene, OR). Potassium Phosphate, monobasic 
was purchased from EM Science (Gibbstown, NJ). The L-cysteine polypeptide (Cys-
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Gly-Cys-Gly-Cys) was purchased from the Molecular Biology Resource Facility 
(Norman, OK). Ethylenediamine, glutaraldehyde (GA), glycine, 2-iminothiolane 
hydrochloride, iodine, L-cysteine, Trizma® base (tris[hydroxymethyl]aminomethane), 
and all the other reagents were purchased from Sigma Chemical Co. (St. Louis, MO). All 
water used was of HPLC-grade quality and was deoxygenated by bubbling nitrogen in 
the water prior to use. 
4.2.2 Modification of PET Samples 
Other than the factors shown in the factorial designs, all other reaction conditions 
were similar to those used previously in the modification process (see Section 3.2.2) and 
were held constant for all samples. These constants include the following: 
• . All steps were performed in a glove box under a N2 atmosphere. 
• Oxygen was removed from all solutions by bubbling N2 through the solutions. 
• All steps involving thiol groups were kept covered to prevent damaging light 
from the sample. 
• Each run in the Plackett-Burman factorial design or in the complete factorial 
designs was performed in triplicate in order to measure standard deviations. 
• PET samples were soaked in 100% acetone for 24 hours prior to the 
modification procedures in order to remove any impurities from the surface of 
the sample. The samples were then allowed to dry completely for 24 hours. 
• During the reaction step with ethylenediamine, samples were placed in a 
reciprocating water bath set ata temperature of 40°C and 130 cycles. 
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• During the reaction step with glutaraldehyde, samples were placed on a hand 
motion shaker to be well shaken at room temperature, while N2 was bubbled 
through each solution containing a sample. 
• During the reaction steps with the thiol groups, samples were placed on a hand 
motion shaker to be well shaken at room temperature. 
• All samples were thoroughly rinsed with deoxygenated water after each 
reaction step. 
• All chemiluminescence and fluorescence analyses were performed within 24 
hours after completion of the sample modification process. The time of XPS 
analysis varied depending on the turnaround time of the XPS facility. The 
extended period of time for XPS did not affect the analysis because, unlike the 
other two measurement methods that can only measure thiols in their reduced 
form, XPS can detect thiols on the.surface in either their reduced or oxidized 
form, by measuring sulfur, which is only found in the thiol group on the 
surface. 
4.2.3 Optimization ofL-Cysteine onto PET Surface 
The reaction scheme used to attach L-cysteine to the surface of PET included the 
reactions shown in Figure 4.1 along with the constants described in the previous section 
(Section 4.2.2). For the optimization of the process of attaching L-cysteine onto the 
surface of PET, Table 4.1 shows a 2-level, 6-factor, and 12-run Plackett-Burman factorial 
design that was generated by using the Excel design macro DOE KISS 97. This 
statistical program prepares Plackett-Burman factorial designs at different combinations 
of levels and factors by using the model shown in Equation 4.1. The six factors in the 
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Figure 4.1 Reaction schemes ofimmobilizing L-cysteine onto the surface of polyethylene 
terephthalate (PET) by first adding an amine group by the use of 
ethylenediamine and then using glutaraldehyde as a crosslinker. 
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TABLE4.l 
Plackett-Burman Factorial Design for Optimizing the Process of Attaching L-Cysteine to 
the Surface of PET 
Factors 
Run Number A B C D E F 
1 1 -1 1 -1 -1 -1 
2 1 1 -1 1 -1 -1 
3 -1 1 1 -1 1 -1 
4 1 -1 1 1 -1 1 
5 1 1 -1 1 1 -1 
6 1 1 1 -1 1 1 
7 -1 1 1 1 -1 1 
8 ' -1 -1 1 1 1 -1 
9 .,.1 -1 -1 l 1 l 
10 l -1 -1 -1 1 1 
11 -1 1 -1 -1 -1 1 
12 -1 -1 -1 -1 -1 -1 
Parameter Levels 
Code Factor -1 (Low) +1 (High) 
A ·· Ethylenediamine 8 hrs 3 days Reaction Time 
B Ethylenediamine 30 vol% 70 vol% Concentration 
C Glutaraldehyde 15 min 4hrs Reaction Time · 
D Glutaraldehyde 0.2 vol% 5vo1% Concentration 
E L..:Cysteine 1 hr 4 days Reaction Time 
F L-Cysteine 0.0002 wt% 2wt% Concentration 
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design make up each of the reaction steps to attach L-cysteine to PET, including: 1) 
ethylenediamine reaction time, 2) ethylenediamine concentration, 3) glutaraldehyde 
reaction time, 4) glutaraldehyde concentration, 5) L-cysteine reaction time, and 6) L-
cysteine concentration. The high ( +) and low (-) levels of each factor were determined by 
setting the levels for the attachment ofL-cysteine to PET used in the previous reaction 
scheme shown in Figure 2.6 as median values. Extreme levels were chosen in order to 
clearly determine the effect of each factor on the process. 
After the first week of the optimization studies, it was discovered that there were 
problems with some of the selected level values. One problem was the initial L-cysteine 
concentration set at 20 wt%. Although the solubility ofL-cysteine in water is high (150 
mg/ml), it was very difficult to completely dissolve the solid at the 20 wt% level. Once 
the L-cysteine was completely dissolved into solution, after a few hours solid crystals 
would begin to appear on the surface of the PET sample. Therefore, the new high level 
was set at 2 wt%. Other problems were with the ethylenediamine reaction time and 
concentration. It was discovered that at the initial high level ethyl~nediamine 
concentration of 90 vol% and the initial high level reaction. time of 4 days, the highly 
basic solution disintegrated the PET sample. A separate study was performed to test the 
effect of various ethylenediamine concentrations on the PET sample. PET samples (1 cm 
x 3 cm) were placed into the following ethylenediamine concentrations for 24 hours and 
then analyzed using fluorescence microscopy: 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 
100 vol%. During the 24-hour reaction time, the samples were placed in a reciprocating 
water bath at a temperature of 40°C and 130 cycles. The time of 24 hours was selected 
due the following reasons: 1) this was the time period set for the mean level and it 
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seemed to be successful, 2) at 8 hours there was little sign that ethylenediamine had 
reacted with PET, and 3) at 3 days most concentrations of ethylenediamine had done 
some damage to the surface of PET. An amine-specific fluorescent probe, Oregon 
Green® 488 carboxylic acid, succinimidyl ester *5-isomer*, was used to analyze the 
surface coverage of ethylenediamine on PET. After the samples reacted with the 
ethylenediamine, they were rinsed well, and then placed in a 27.5 µM Oregon Green® 
488 solution in 50 mM potassium phosphate buffer (pH - 9) and shaken for one hour to 
allow the fluorescent probe to react with the amine groups on the PET surface. The 
samples were rinsed with water and kept in the dark until analysis, which directly 
followed. The surface of each sample was examined by using an argon laser-scanning · 
microscope (Leica TCS SP2, Exton, PA) in confocal mode with a 10.0 x 40.0 oil 
immersion objective lens. The filter set was set at 488 nm excitation and 515 nm 
emission. After reviewing the results from this study (shown later in the chapter), the 
low, and high levels for the ethylenediamine concentration were set at 30 vol% and 70 
vol%, respectively, and the low and high levels for the ethylenediamine reaction time 
were set at 8 hours and 3 days, respectively. 
To measure the amount ofL-cysteine attached to the surface of each PET sample 
of the optimization studies, the fluorescence microscopy and chemiluminescence 
measurement methods described in Sections 3.2.3 and 3.2.6, respectively, were utilized. 
XPS was not used at this point due to the high analysis cost. Three 1 cm x 1 cm pieces 
were cut from each 1 cm x 3 cm PET sample in the optimization study, in order to use a 1 
cm x 1 cm piece of each sample in each measurement method. All samples were kept in 
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the glove box under a N2 atmosphere and covered to prevent exposure to damaging light 
until ready for analysis. 
Chemiluminescence Method 1, described in Section 3.2.6, was used to measure 
the amount of L-cysteine on the samples. This method was selected because it was 
shown to accurately measure L-cysteine in solution (Chapter 3) and it has been the most 
used method in past research to measure the amount ofL-cysteine attached to PET. To 
break off and nitrosate L-cysteine on each sample, each sample was placed in an amber 
vial containing 1 ml of a 0.5 M HCl solution initially containing 40 µM N02-. A higher 
concentration of N02 - was used in the nitrosation of PET-Cys in order to ensure that there 
would be an excess of N02- for complete nitrosation; The vials were sealed and 
nitrosation was a.1,lowed to proceed for 1 hour, afterwhich the amount of nitrosated L-
cysteine in the solution surrounding the each sample was measured by using the same 
protocol described in Section 3.2.6. 
To qualitative assess the amount of L-cysteine on the PET samples by using 
fluorescence microscopy, the fluorescent probe 5-IAF was used in a method similar to 
that described in Section 3.2.3. Each sample and a blank PET sample (control) were 
placed into an amber vial with 4 ml of 133 µM 5-IAF solution in a 50 µM phosphate 
buffer (pH - 8). The vials were sealed and shaken for two hours. The samples were 
rinsed with water and kept in the dark until analysis. The surface of each sample was 
. . 
examined by using an argon laser-scanning microscope (Leica TCS SP2, Exton~ PA) in 
confocal mode with a 10.0 x 40.0 oil immersion objective lens. The filter set was set at 
488 nm excitation and 515 nm emission. The gain for the argon laser was set so that the 
mean intensity from the blank PET sample was zero. The mean intensity of each sample 
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was measured keeping the gain setting constant. The mean intensities could then be 
compared and contrasted among the samples. 
The advantage of using a Plackett-Burman fractional factorial design is that it 
allows one to investigate the effect of many factors on a process without having to 
perform excessive experiments. The results from the initial design can show which 
factors are the most important and can lead to a more specialized design. Using the 
results from the first design, the ethylenediamine reaction time and concentration were 
set constant at 24 hours and 40 vol%, respectively, and the glutaraldehyde reaction time 
was set constant at 15 minutes. A 2-level, 3-factor, and 8-run complete factorial design 
varying the other factors of glutaraldehyde concentration and L-cysteine reaction time 
. and concentration was used to further optimize the modification process of adding L-
. cysteine to PET and is shown in Table 4.2. For this design, only the Chemiluminescence 
Method 1, described previously, was used to measure the amount of L-cysteine on the 
surface of the samples. After optimizing the process to attach L-cysteine to PET, a 
· sample was prepared and analyzed by using the XPS measurement method in order to 
compare the XPS results with those from the optimized process using 2-iminothiolane 
and cysteine polypeptide. 
4.2.4 Optimization of2-Iminothiolane onto PET Surface 
2-Iminothiolane has been used in research to introduce thiol groups in proteins 
and to attach thiol groups to surfaces (Phaneuf et al., 1997; Weber et al., 2000). 2-
Irninothiolane is a thiolating agent for primary amines. It was selected to be attached to 
the surface of PET for the following reasons: 
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TABLE4.2 
Full Factorial Design for Optimizing the Process of Attaching L-Cysteine to the Surface of PET by 
Varying Glutaraldehyde Concentration and L-Cysteine Reaction Time and Concentration 
Factors 
Run Number 
Glutaraldehyde L-Cysteine L-Cysteine 
Concentration Reaction Time Concentration 
1 0.02 vol% 1 hour 0.0002wt% 
2 0.02 vol% 1 hour 2wt% 
3 0.02 vol% 4 days 0.0002 wt% 
4 0.02 vol% 4days 2wt% 
5 0.2 vol% 1 hour 0.0002 wt% 
6 0.2 vol% 1 hour 2wt% 
7 0.2 vol% 4 days 0.0002 wt% 
8 0.2 vol% 4days 2wt% 
• It can be attached directly to the amine group of ethylenediamine on the 
polymer, thus removing the extra linkage of glutaraldehyde and resulting in a 
shorter chain length extending from the polymer. Therefore, the effect of 
chain length can be investigated by comparing the shorter chain length of this 
system to the longer chain length of the L-cysteine residue system. This was 
done by comparing which system produced the most thiol groups on the 
surface and which system prevented platelet attachment the best (Chapter 5). 
Also, by not using the glutaraldehyde linkage, this is one less step in the 
optimization of the modification process. 
• It remains in a stable ring formation at low pH values, which at pH 7 - 10 the 
ring opens and reacts by amidine bond to present the free thiol. This makes 2-
Iminothiolane easier to store in solution than free L-cysteine because it cannot 
form disulfide linkages while in its ring form. 
• It has a small molecular weight of 137.6, which is similar to that ofL-cysteine 
of 121.1. As a result, the transnitrosation properties of2-iminothiolane may 
also be similar to those ofL-cysteine. 
The reaction scheme to attach 2-iminothiolane to the surface of PET is shown in Figure 
4.2. 
To optimize the modification process of attaching 2-iminothiolane to the surface 
of PET, a 3-level, 2-factor, and 9-run complete factorial design was used, as shown in 
Table 4.3. Since the optimal ethylenediamine concentration and reaction time were 
determined from the optimization of attaching L-cysteine to the surface of PET, 40 vol% 
and 24 hours were used, respectively. The 2-iminothiolane concentration and reaction 
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Figure 4.2 Reaction schemes of immobilizing 2-iminothiolane onto the surface of 
polyethylene terephthalate (PET) by first adding an amine group by the use of 
ethylenediamine. 
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TABLE4.3 
Full Factorial Design for Optimizing the Process of Attaching 
2-Iminothiolane to the Surface of PET 
Factors 
2-Iminothiolane 2-Iminothiolane 
Run Number 
Reaction Time Concentration 
1 1 hour 16.5 nM 
2 1 hour 16.5 µM 
3 1 hour 1.65 mM 
4 24 hours 16.5 nM 
5 24 hours 16.5 µM 
6 24 hours 1.65 mM 
7 4 days 16.5nM 
8 4days 16.5 µM 
9 4days 1.65 mM 
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time factors were the only factors varied; therefore, a 3-level design was used in order to 
get more information about the effect of the factors on the optimization process. For the 
2-iminothiolane reaction time, past studies had varied the reaction time from 15 minutes 
to 24 hours (Weber et al., 2000). Therefore, reaction times of 1 hour, 24 hours, and 4 
days were selected in order to measure the effect of within the range of past studies (1 
hour and 24 hours) and to go beyond the range (4 days). 2-Iminothiolane concentrations 
for the optimization study were chosen to be similar to the ones used in the optimization 
study with L-cysteine. The L-cysteine molar concentrations used in the optimization 
study varied from 16.5 nM to 0.165 mM. The 2-iminothiolane molar concentrations were 
varied from 16.5 nM to 1.65 mM. A higher concentration of2-iminothiolane was used 
since it dissolves easier in water than L-cysteine and this concentration is still within the 
solubility limit for 2-iminothiolane (100 mg/ml). The pH of the 2-iminothiolane 
solutions prepared in deoxygenated water (pH - 4) was adjusted to 7.5 by using sodium 
hydroxide solutions, just prior to its reaction with ethylenediamine on the polymer 
surface. 
To measure the amount of 2-iminothiolane attached to the surface of each PET 
sample of the optimization studies, the XPS and Chemiluminescence Method 1 
measurement methods described in Sections 3.2.4 and 3.2.6 were utilized, respectively. 
The results from the L-cysteine optimization studies (see Results section) show that it 
was difficult to use fluorescence microscopy to quantify the amount ofthiol group on the 
surface of the sample, so it was not used in further optimization studies. Three 1 cm x 1 
cm pieces were cut from each 1 cm x 3 cm PET sample in the optimization study, in 
order to use a 1 cm x 1 cm piece of each sample in each measurement method. All 
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samples were kept in the glove box under a N2 atmosphere :;ind covered to prevent 
exposure to damaging light until ready for analysis. Since XPS analysis is costly, the 
modified samples from the optimization study were first analyzed by the 
chemiluminescence method. Chemiluminescence Method 1 was used to measure the 
amount of 2-iminothiolane on the surface of the modified PET samples. The 
experimental procedures used were the same as those described above to measure the 
amount of L-cysteine. The results of the analysis (see Results section) revealed very little 
or no free thiol groups attached to the surface of the 2-iminothiolane-modified PET 
samples. After reviewing other studies that used 2-iminothiolane to introduce free thiol 
groups to surfaces, some changes were made to the experimental design (Weber et al., 
2000). First, the pH of the 2-iminothiolane solution may not have been high enough to 
open the ring in order for it to react by amidine bond to expose the free thiol group. 
Therefore, the pH of the 2-iminothiolane solutions was raised to 9 to ensure more open 
rings and exposed free thiol groups. In order to control the pH of the solution better, the 
2-iminothiolane solutions were prepared in 0.001 M Trizma® base buffer and the pH was 
adjusted by using sodium hydroxide solutions. The next important change to the 
optimization design involved the concentration of the 2-iminothiolane solutions. Other 
studies used higher concentrations to attach 2-iminothiolane onto surfaces; therefore, the 
concentrations in the factorial design were proportionally increased to 50 nM, 50 µM, 
and 50 mM (Weber et al., 2000). The last change involved the reaction time for 2-
iminothiolane. Since there were not any significant changes in the amount of 2-
iminothiolane attached to the surface after 24 hours or 4 days shown in the previous 
optimization study or other studies shown in literature{Weber et al., 2000), the high level 
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reaction time was decreased from 4 days to 3 days in order to decrease the amount of 
time to complete the optimization study. The improved factorial design used to optimize 
the process of attaching 2-iminothiolane to the surface of PET is shown in Table 4.4. 
Modified samples from the new factorial design were then analyzed by using the 
Chemiluminescence Method 1 and by XPS. Samples, 1 cm x 1 cm samples cut from the 
original 3 cm x 3 cm modified samples, were sent to the XPS facilities at the Chemistry 
Department at Lehigh University (Bethlehem, PA) to be analyzed. The analysis reveals 
the atomic percent of sulfur on each sample that can be used to compare the amount of 
thiol group on each sample, since 2-iminothiolane is the only group on the surface that 
contains sulfur. 
4.2.5 Optimization of Cysteine Polypeptide onto PET Surface 
A cysteine polypeptide was chosen to be attached to the surface of PET in order 
to add a greater number of thiol groups to the surface in long, linear chains. Initially, the 
goal was to attach as many cysteine residues as possible in various chain lengths. After 
consulting many peptide synthesis facilities, both commercial and academic, it was 
discovered that L-cysteine residues can become vary unstable in long, linear chains. 
Many cysteine residues within one polypeptide are susceptible to oxidation leading to the 
formation of disulfide linkages. Excessive disulfide linking can lead to an extensive 
crosslinking of chains either within themselves or with other chains that can eventually 
result in the peptide precipitating out of solution. Therefore, there is a limitation to the 
number of cysteine residues that can be added to one peptide, and it is better to put 
"spacer" residues between the cysteine residues in order to prevent disulfide linkages. 
However, there may still be crosslinking between separate chains. A polypeptide with 
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TABLE4.4 
Improved Factorial Design for Optimizing the Process of 
Attaching 2-Iminothiolane to the Surface of PET 
Factors 
2-Iminothiolane 2-Iminothiolane 
Run Number 
Reaction Time Concentration 
1 1 hour 50nM 
2 1 hour 50µM 
3 1 hour 50mM 
4 24 hours 50nM 
5 24 hours 50µM 
6 24 hours 50mM 
7 3 days 50nM 
8 3 days 50µM 
9 3 days 50mM 
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the sequence of Cys-Gly-Cys-Gly-Cys was selected and the Molecular Biology Resource 
Facility at the University of Oklahoma Health Sciences Center (Oklahoma City, OK) 
synthesized and purified the peptide. The polypeptide was made under acidic conditions 
and in a reducing solution in order to keep the cysteine residues from becoming oxidized. 
The polypeptide was lyophilized and sealed under argon prior to shipping. The peptide 
was kept on ice during shipping and stored in a -86°C freezer until ready for use in order 
to keep it stable. Three cysteine residues were selected because this is believed to be the 
maximum number of cysteine residues that can be added to a single polypeptide without 
causing significant disulfide linkages within the polypeptide chain (Jackson, 2002). 
Glycine was chosen to be the spacer residue because it is a very small and unreactive 
molecule that has also been used in past studies as a control group that can be attached to 
the surface of PET in the same method as L-cysteine. The reaction scheme for attaching 
the cysteine polypeptide to PET is similar to that shown in Figure 4.1 for attaching L-
cysteine to PET, the only difference is that the single L-cysteine residue is replaced with 
the cysteine polypeptide. Due to the high cost and the limited amount of cysteine 
polypeptide that can be synthesized at a time, smaller PET samples of 1 cm x 2 cm and 
therefore smaller volumes of solutions were used in the optimization studies. 
A 3-level, 2-factor, 9-run complete factorial design was used to optimize the 
process of attaching the cysteine polypeptide to the surface of PET. The optimal reaction 
times and concentrations for ethylenediamine (24 hours and 40 vol%, respectively) and 
glutaraldehyde (15 minutes and 0.02 vol%, respectively) determined from the 
optimization of attaching L-cysteine to the surface of PET were used in this design and 
only the polypeptide concentration and reaction time were varied, as shown in Table 4.5. 
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TABLE4.5 
Full Factorial Design for Optimizing the Process of Attaching 
Cysteine Polypeptide to the Surface of PET 
Factors 
Run Number 
Cysteine Polypeptide Cysteine Polypeptide 
Reaction Time Concentration 
1 1 hour 14.5 nM 
2 1 hour 14.5 µM 
3 lhour 14.5mM 
4 24 hours 14.5 nM 
5 24 hours 14.5 µM 
6 24 hours .14.5 mM 
7 3 days 14.5 nM 
8 3 days 14.5 µM 
9 3 days 14.5mM 
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The cysteine polypeptide concentration levels and reaction time levels selected are 
similar to those seen in the factorial design of optimizing the process to attach 2-
iminothiolane to PET. The cysteine polypeptide solutions were prepared in 
deoxygenated water and the pH adjusted to 7 by adding sodium hydroxide solution. The 
modified samples were analyzed via the XPS and Chemiluminescence Method 1, using 
the same procedures as previously described in Sections 3.2.4 and 3.2.6, respectively. 
Two 1 cm x 1 cm pieces were cut from each l cm x 2 cm PET sample in the optimization 
study in order to use a 1 cm x 1 cm piece of each sample in each measurement method. 
All samples were kept in the glove box under a N2 atmosphere and covered to prevent 
exposure to damaging light until ready for analysis. 
4.3 Results 
4.3.1 Optimization ofL-Cysteine onto PET Surface 
Analysis of PET Samples in Ethylenediamine Solutions 
PET samples were reacted with the following concentrations of ethylenediamine 
for 24 hours: 0, 10, 20, 30, 40, 50, 60, 70, 80, 90, and 100 vol%; At the 70 vol% 
concentration and all higher concentrations, the PET samples were completely dissolved 
by the ethylenediamine solution. The ethylenediamine on all ofthe remaining samples 
was reacted with the fluorescent probe Oregon Green® 488 and was analyzed by using 
fluorescent microscopy. Figure 4.3 shows the scans of each PET sample that was reacted 
with the different concentrations of ethylenediamine. A lighter scan is indicative of the 
more fluorescence on the sample. Thus, the scans that are darker shades (black) show 
very little to no fluorescence on the samples. 
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30% Ethylenediamine 40% Ethylenediamine 
50% Ethylenediamine 60% Ethylenediamine 
Figure 4.3 Fluorescence microscopy analysis of PET samples in various concentrations of 
ethylenediamine solutions. The gain setting was constant for all scans. Scans 
are shown at 400x magnification. 
108 
In order to compare the amount of fluorescence on all of the samples, the gain 
setting on the argon laser-scanning microscope was set constant for the analysis of each 
sample. There was no detectable fluorescence on the samples that were in the 0, 10, and 
20 vol% ethylenediamine solutions (not shown in Figure 4.3). Thus, the concentrations 
were not high enough for the PET samples to undergo aminolysis. The scan of the PET 
sample that was in the 30 vol% ethylenediamine solution begins to show slight 
fluorescence on the surface. Although the fluorescence is slight indicating only a small 
amount of surface coverage of ethylenediamine, coverage does seem to be evenly 
distributed on the surface. The scans taken of the samples in the 40, 50, and 60 vol% 
ethylenediamine solutions show bright fluorescence evenly covering the surface. This 
indicates that at these concentrations, the surface ofthe samples undergo complete 
aminolysis. However, there are significant differences in the appearance of the physical 
properties of these samples that are better seen in Figure 4.4. 
For the analysis of the physical characteristics of the surface of the samples 
shown in Figure 4.4, the gain setting on the argon laser-scanning microscope was 
adj~sted for each sample, in order to acquire the best quality image of the surface. 
Therefore, the contrast of the fluorescence in the scans is not indicative of the amount of 
ethylenediamine on the samples, as shown previously in: Figure 4.3. The scan for the 
sample in the 30 vol% solution shows a relatively smooth surface compared to the scans 
of the surfaces of the samples that were in the higher concentration solutions. Starting 
with the scan of the sample in the 40 vol% solution, there appears to be parallel striations 
on the surface. These striations were also seen in the fluorescence microscopy analysis 
of the samples used in each step of the process of attaching L-cysteine to the surface in 
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30% Ethylenediamine 40% Ethylenediamine 50% Ethylenediamine 
60% Ethylenediamine 60% Ethylenediamine 60% Ethylenediamine 
Figure 4.4 Fluorescence microscopy analysis of the effects of various concentrations of ethylenediamine on the physical properties of 
the surface of PET. The gain setting varied for each scan. Scans are shown at 400x magnification. 
Chapter 3. It is believed that these striations are due to the fabrication process of the PET 
films, since they were also seen in the scanning electron microscope analysis performed 
by DuPont (shown in Figure 3.3). It appears that ethylenediamine reacts with the surface 
of PET along these striations. The thin black lines also seen in the scan of the sample in 
the 40 vol% solution are believed to be very small cracks in the surface where the 
ethylenediamine begin to break down the surface. 
These cracks become wider in the scans of the samples in the 50 and 60 vol% 
solutions. The sample in the 60 vol% solution begins to break apart even further, with 
large gaps on the surface. There are three scans of the sample that was in the 60 vol%. 
solution that were taken at different areas on the sample. At some points on the sample 
there is extensive surface damage, where the sample is beginning to break apart, similar 
to those samples that were in the higher concentration solutions. After reviewing the 
surface analysis of the samples in the various concentrations of ethylenediamine, a 
concentration of 40 vol% was selected for the remainder of the optimization studies. 
This concentration was chosen because it shows good surface coverage of 
ethylenediamine with minimal damage to the surface. The 50 vol% solution is believed 
to lead to even more coverage of ethylenediamine on the surface, but at the expense of 
extensive surface damage. Even though the physical properties of PET are not directly 
investigated in this research, it still must be considered for future applications of the 
design. 
Analysis of Plackett-Burman Factorial Design 
The results of the chemiluminescence and fluorescence analyses of the Plackett-
Burmanfactorial design for L-cysteine are shown in Figures 4.5 and 4.6, respectively. 
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Figure 4.5 L-cysteine surface concentrations on the PET samples from the Plackett-
Burman factorial design for optimizing the process of attaching L-cysteine to 
the surface of PET, a~ determined by chemiluminescence analysis. Data 
shown are mean values ± standard deviation (n=3). 
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Figure 4.6 Mean intensity of fluorescence on the PET samples from the Plackett-Burman 
factorial design for optimizing the process of attaching L-cysteine to the 
surface of PET, as determined by chemiluminescence analysis. Data shown 
are mean values± standard deviation (n=3). 
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There are no results for the analyses of the samples from ruhs 2, 5, and 6 since the 
samples were destroyed due to the high reaction time and concentration of the 
ethylenediamine step. This was also shown in the results from the study investigating the 
effects of different concentrations of ethylenediamine on the surface of PET, described 
, above; therefore the same effects were expected in the Plackett-Burman factorial design. 
The high levels were chosen in order to measure the effect when paired with a lower 
level, such as a high reaction time with a low concentration. For the remaining samples 
of the other runs, the results from the chemiluminescence anaJysis show that runs 10 and 
11 produced samples with the most L-cysteine attached to the surface with 9.5 and 11.5 
nmol/cm2, respectively. Conversely, samples from runs 9 and 12 had the least amount of 
L-cysteine attached to the surface with 0.6 and 0.8 nmol/cm2, respectively. This was 
expected from run 12 since all the factors for this run are set at the low levels. By using · 
the other extremes the following conclusions can be made: 1) the samples with more L-
cysteine attached to the surface had low levels for glutaraldehyde reaction time and 
concentration and a high level for L-cysteine concentration, and 2) the samples with less 
L-cysteine attached to the surface had low levels for ethylenediamine reaction time and 
concentration and a high level for glutaraldehyde concentration. These conclusions are 
all based on the assumption that there is no interaction between any of the factors; 
however, there may be interactions and the outcomes may be due to more of a 
combination of factors. 
The results from the fluorescence analysis are inconclusive. Although some 
trends in the results seem to mimic those seen for the chemiluminescence analysis 
( especially for runs 10 and 11 ), there is too much variance in the method to be able to 
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compare the samples quantitatively. Some problems with the method include the 
following: 
• Stability of the fluorescent probe: the fluorescence from the samples fades 
quickly and it is difficult to compare the amount of fading from each sample 
prior to analysis. 
• Consistency in intensity measurements: due to time constraints, even though 
all of the samples were modified and analyzed within a certain time period, 
samples were analyzed on different days. The intensity of the laser on the 
scanning microscope decreases slightly after each use and may affect the 
intensity reading for samples analyzed on different days. 
• Detection limits: some of the samples with less L-cysteine attached to the 
surface had very low intensities that were difficult to detect; therefore, it was 
difficult to compare the samples with the low intensities. 
Due to the problems with the fluorescence microscopy analysis, it was not a 
useful measurement method compared to the amount of analysis time and cost and 
· therefore was not used in the remaining optimization studies. Therefore, XPS was used 
in the remaining optimization studies as another measurement method to compare 
samples. 
Table 4.6 shows the main effects of each of the six factors on the optimization 
process, determined by using Equation 4.2 and the results from the chemiluminescence 
analysis. Due to the inconclusive results from the fluorescence microscopy analysis, the 
main effects were not calculated based on the results ofthis method. The main effects 
are interpreted to mean that the net effect of increasing the factor level, averaged over all 
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TABLE4.6 
The Effect of the Factors in the Plackett-Burman Factorial Design for Optimizing the 
Process of Attaching L-Cysteine to the Surface of PET (Based on Mean L-Cysteine 
Concentrations Determined by Chemiluminescence Analysis) 
Factor Main Effect 
Ethylenediamine Reaction Time (A) -1.0 
Ethylenediamine Concentration (B) -0.8 
Glutaraldehyde Reaction Time (C) -3.4 
Glutaraldehyde Concentration (D) -5.0 
L-Cysteine Reaction Time (E) -3.0 
L-Cysteine Concentration (F) +8.1 
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other factor levels from low to high, is to increase or decrease the response, depending on 
the magnitude and direction of the main effect value of the factor. The magnitude of the 
main effect can be related to its significance in the optimization study. The greater the 
magnitude, the more influence it has on the optimization process. The sign of the main 
effect is related to the direction the level should be increased or decreased to influence 
the optimization process. 
Taking all of this into consideration when interpreting the results shown in Table 
4.6 for the main effects determined from the chemiluminescence analysis, the L-cysteine 
concentration has the most influence in the optimization study. It is also shown that the . 
L-cysteine concentration has a positive effect, which means that the high level L-cysteine 
concentration results in more L-cysteine attached to the surface of the PET sample than 
the low level L-cysteine concentration. These findings are intuitive and were expected 
for the optimization process. 
Another factor that is shown to have a large effect on the optimization process is 
the glutaraldehyde concentration. This factor has a negative effect, which means that the 
low level glutaraldehyde concentration results in more L-cysteine attached to the surface 
of the PET sample than the high level glutaraldehyde concentration. It is believed that 
this is due to the tendency of glutaraldehyde to crosslink at higher concentrations, 
resulting in few sites for L-cysteine to react. This topic was also discussed in the 
previous chapter during the results from the XPS analysis of the process to attach L-
cysteine to the surface of PET. 
The factors that seem to have the least effect on the optimization process are the 
ethylenediamine reaction time and concentration. Unless the high levels or low levels of 
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each were used simultaneously, the limits of the factors were close enough not to have a 
significant effect on the optimization process. Therefore, considering the results from the 
fluorescence microscopy study of the effects of various concentrations of 
ethylenediamine on the surface of PET along with the results from the Plackett-Burman 
factorial design, the ethylenediamine reaction time and concentration levels were set 
constant at 24 hours and 40 vol%, respectively. In order to use a complete factorial 
design to further investigate changes and combinations within some of the more 
significant factors, without having to perform excessive experiments, one more factor 
needed to be held constant in order to vary the remaining three. The glutaraldehyde 
reaction time was selected to be held constant at 15 minutes. The reaction time was 
chosen because, it is believed that the glutaraldehyde concentration has a more significant 
effect on the optimization process, and that the L-cysteine reaction time and 
concentration may produce significant effects in combination with changes to the 
glutaraldehyde concentration. 
Analysis of Complete Factorial Design 
The results of the chemiluminescence analysis of the samples from the 2-level, 3-
factor, and 8-run complete factorial design are shown in Figure 4.7. Runs 4 and 8 
produced samples with the most L-cysteine attached to the surface with 6.1 and 6.6 
nmol/cm2, respectively. However, runs 2 and 6 also produced samples with a significant 
amount ofL-cysteine on the surface relative to the samples from the remaining runs, with 
4.6 nmol/cm2 on each sample. Conversely, samples from runs 5 and 7 had the least 
amount ofL-cysteine attached to the surface with 0.4 and 0.5 nmol/cm2, respectively. As 
a result of this factorial design, the most L-cysteine measured on the modified surface 
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Figure 4.7 L-cysteine surface concentrations on the PET samples from the 2-level, 3-
factor, and 8-run full factorial design for optimizing the process of attaching 
L-cysteine to the surface of PET, as determined by chemiluminescence 
analysis. Data shown are mean values ± standard deviation (n=3). 
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was 6.6 nmol/cm2. This is significantly lower that the samples with the most L-cysteine 
measured on the surface from the Plackett-Burman factorial design, which was in the 9.5 
- 11.5 nmol/cm2 range. This is believed to be due to ·changes made to the 
ethylenediamine step of the modification process. For the runs in the Plackett-Burman 
factorial design that produced samples with high surface concentrations ofL-cysteine, the 
samples were submitted to either high ethylenediamine concentrations or long 
ethylenediamine reaction times. Therefore, these factors in combination with the other 
optimal conditions for the runs resulted in samples with high L-cysteine surface 
concentrations. However, as discussed earlier, these high level ethylenediamine factors 
can begin to cause damage to the surface of the PET sample. So, by setting the factors 
for ethylenediamine to prevent surface damage to the sample, L-cysteine surface 
coverage may have been sacrificed. 
The main effects calculated for the three factors that were varied for this complete 
factorial design are: 1)-0.7 for the glutaraldehyde concentration, 2) +2.4 for the L-
cysteine reaction time, and 3) + 12.4 for the L-cysteine concentration. Comparing the 
magnitudes of the main effects, the L-cysteine concentration has the most influence on 
the optimization process. The effect is also positive revealing that the higher level 
concentration causes an increase in the surface coverage ofL-cysteine on the sample. 
The lower magnitude of the other two factors shows that they are not as significant as the 
L-cysteine concentration, however their sign reveals some important information. The 
negative effect of the glutaraldehyde concentration shows that the lower level 
concentration results in an increase in the surface coverage of L-cysteine on the sample, 
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and the positive effect of the L-cysteine reaction time shows just the opposite, an increase 
in the reaction time increases the surface coverage. 
Analysis of the Optimal Design 
After reviewing the results from both the Plackett-Burman factorial design and 
the complete factorial design, the following optimal factors were selected for attaching L-
cysteine to the surface of PET by using the reactions shown in Figure 4.1 along with the 
constants described in Section 4.2.2: 
• Ethylenediamine Reaction Time: 24 hours 
• Ethylenediamine Concentration: 40 vol% 
• Glutaraldehyde Reaction Time: 15 minutes 
• Glutaraldehyde Concentration: 0.02 vol% 
• L-Cysteine Reaction Time: 12 hours 
• L-Cysteine Concentration: 2 wt% 
For the L-cysteine reaction time, the results of the factorial designs showed that 
longer reaction times lead to greater L-cysteine surface coverage on the sample; therefore 
a reaction time greater than 1 hour was needed, but from past experience and other 
studies, there does not appear to be a significant difference in surface coverage after a 
reaction time of 12 hours (Duan and Lewis, 2002). Therefore, a L-cysteine reaction time 
of 12 hours was chosen instead of the 4 day time period in order to decrease the time it 
takes to modify samples. Any small increase in surface coverage after a reaction time of 
12 hours would not be significant enough to justify the extended time. 
Table 4. 7 shows the results of the XPS analysis of each step of the process of 
attaching L-cysteine to the surface of PET, using the optimal factors. The atom% of each 
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-N N 
Sample 
Description 
C's 
(Measured) 
C's 
(Theoretical) 
O's 
(Measured) 
O's 
(Theoretical) 
N's 
(Measured) 
N's 
(Theoretical) 
S's 
(Measured) 
S's 
(Theoretical) 
TABLE4.7 
Atom% of Elements on Optimized L-Cysteine Modified PET Samples 
(Comparison of Theoretical with Measured by XPS) 
Blank PET PET+ED PET+ED+GA PET+ ED+ GA+ Cys 
73.79 72.03 72.58 75.04 
71.43 66.67 71.43 66.67 
26.21 24.29 23.19 19.86 
28.57 20.00 19.05 18.52 
0 3.68 4.23 4.45 
0 13.33 9.52 11.11 
0 0 0 0.65 
0 0 0 3.70 
Abbreviations. PET = Polyethylene Terephthalate, ED = Ethylenediamine, GA= Glutaraldehyde, Cys = L-Cysteine, C = Carbon, 
0 = Oxygen, N = Nitrogen, S = Sulfur 
element measured on the surface of the optimized samples was compared to the 
theoretical atom% of each element on the surface, assuming a one-to-one binding of each 
groups as previously described in Chapter 3. The analysis of the blank sample of PET 
shows the atomic% of carbon and oxygen similar to the theoretical amounts. The 
analysis of the sample with ethylenediamine shows a lower nitrogen content than 
expected when compared to the theoretical amounts (approximately 28% of the 
theoretical atom%). This is believed to be due to incomplete surface coverage of 
ethylenediamine. Since there are not any nitrogen atoms on blank PET, all the nitrogen 
contribution is due to the addition of ethylenediamine on the surface: This results in 
more open sites on the PET sample, which would also lead to an increase in the oxygen 
and carbon content on the surface, also shown in the table. The incomplete surface 
coverage of ethylenediamine must be considered when analyzing the remaining samples 
with glutaraldehyde attached and L-cysteine attached. The low L-cysteine content on the 
surface may also be attributed to fewer available reaction sites due to possible 
crosslinking of the glutaraldehyde residues on the surface as described in Chapter 3. 
When comparing the XPS results of the optimized polymer with those from the 
previous modification process described in Chapter 3, the following two conclusions can 
be made: 1) there was less surface coverage of ethylenediamine when comparing the 
nitrogen content after the addition of ethylenediamine to the polymer surface, and 2) 
there was more surface coverage ofL-cysteine when comparing the sulfur content after 
the addition ofL-cysteine to the polymer surface. The reason that there was less surface· 
coverage of ethylenediamine on the optimized L-cysteine modified polymer sample 
compared to the L-cysteine modified polymer samples described previously in Chapter 3 
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is believed to be due to the lower concentration of ethylenediamine used to modify the 
samples in the optimized modification process. The fluorescent studies analyzing the 
effect of ethylenediamine on the physical surface properties of the polymer (Section 4.3.1 
Analysis of PET Samples in Ethylenediamine Solutions) showed that the 
concentration that was previously used to modify the polymer samples, described in 
Chapter 3, (50 vol%) was degrading the surface of the polymer. Therefore, the 
concentration of ethylenediamine was lowered ( 40 vol%) for use in the optimization 
studies in order to prevent surface damage. The reason there was more surface coverage 
ofL-cysteine on the optimized L-cysteine modified polYI]ler compared to the L-cysteine 
modified polymer described previously in Chapter 3 is believed to simply be due to the 
fact that the modification process was now optimized. 
4.3.2 Optimization of2-Iminothiolane onto PET Surface 
Figure 4.8 shows the results from the chemiluminescence analysis of the initial 
complete factorial design used to optimize the process of attaching 2-iminothiolane to the 
surface of PET. The results show very little to no 2-iminothiolane attached to the surface 
of the samples, due to problems already discussed earlier in the chapter. One conclusion 
that may be made about the results is that the one hour reaction time for 2-iminothiolane 
is not long enough for it to react with the ethylenediamine on the surface. Runs 1, 2, and 
3 produced samples that did not have any detectable 2-iminothiolane on their surfaces 
and these were the only runs that had the one hour 2-iminothiolane reaction time. 
Figure 4.9 shows the results from the improved complete factorial design. For 
this design, there were detectable amounts of2-iminothiolane on the surface of all the 
samples. There were three runs in the design, runs 6, 8, and 9, which produced samples 
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Figure 4.8 2-Iminothiolane surface concentrations on the PET samples from the initial 3-
level, 2-factor, and 9-run full factorial design for optimizing the process of 
attaching 2-iminothiolane to the surface of PET, as determined by 
chemiluminescence analysis. Data shown are mean values± standard 
deviation (n=3). 
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Figure 4.9 2-Iminothiolane surface concentrations on the PET samples from the improved 
3-level, 2-factor, and 9-run full factorial design for optimizing the process of 
attaching 2-iminothiolane to the surface of PET, as determined by 
chemiluminescence analysis. Data shown are mean values± standard 
deviation (n=3). 
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with the most 2-iminothiolane on the surface with 3.9, 4.1, and 4.7 nmol/cm2 on each, 
respectively. Samples from the first three runs, 1, 2, and 3, had the least amount of2-
iminothiolane on their surfaces. This was also seen in the results for the initial complete 
factorial design, and was expected due to the low 2-iminothiolane reaction time. For the 
runs with the longer reaction times, it appears that the higher the concentration of 2-
iminothiolane used in the run, the higher the concentration of2-iminothiolane measured 
on the surface. However, the reaction times may also play an important role, as seen for 
run 8, where the mid level concentration with the high level reaction time resulted in a 
high surface concentration of 2-iminothiolane. 
The results from the XPS analysis of the samples from the improved factorial 
design are shown in Table 4.8. Even though this analysis method does not give a direct 
measurement for the surface concentration of2-iminothiolane, some conclusions can be 
made by comparing the amount of sulfur on the surface of each sample. 2-iminothiolane 
is the only group on the surface that contains sulfur; therefore, the amount of2-
iminothiolane on the surface of each sample can be compared by examining the amount 
of sulfur on each surface. Also, the amount of nitrogen on the surface of each sample is a 
good indicator of the amount of ethylenediamine on the surface; however, 2-
iminothiolane also contains nitrogen and contributes to the total atom% of nitrogen on the 
surface. The amount of nitrogen on the samples all fall within the range of3.51-4.95 
atom%, which is considerably lower than the theoretical atom% of nitrogen of 14.285%. 
The samples with the least amount of sulfur on their surfaces included those from runs l, 
4, and 7 which had the low level 2-iminothiolane concentration and run 2, which had the 
mid level concentration, but had the low level 2-iminothiolane reaction time. The sample 
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Run# 
TABLE4.8 
Atom% of Elements on 2-hninothiolane Modified PET Samples 
(Comparison of Theoretical with Measured by XPS) 
C's O's N's 
Theoretical 66.67 14.285 14.285 
1 75.12 20.97 3.76 
2 76.41 19.37 4.04 
3 73.60 20.40 4.91 
4 77.48 18.87 3.51 
5 76.13 18.87 4.44 
6 75.54 19.29 3.98 
7 74.64 20.24 4.95 
8 76.90 18.59 4.09 
9 75.27 19.82 3.61 
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S's 
4.76 
0.14 
0.18 
1.10 
0.14 
0.56 
1.19 
0.16 
0.42 
1.29 
from run 3 with the low level 2-iminothiolane reaction time had a relatively high amount 
of sulfur on the surface. This could be do the high level 2-iminothiolane concentration in 
this run and/or this sample had a high atom% of nitrogen on its surface compared to the 
other samples, indicating it had more ethylenediamine on the surface promoting more 
reaction sites for the 2-iminothiolane. The sample from run 7 also had a high atom% of 
nitrogen on its surface, however it had a low atom% of sulfur on its surface. This is 
believed to be due to the low level 2-iminothiolane concentration in this run. The 
samples with the greatest amount of sulfur on their surfaces are those from runs 3, 6, and 
9, which all included the high level 2-iminothiolane concentration in their runs. 
When comparing the XPS analysis of the samples from the optimization study 
with the theoretical values, there are significant differences. All samples had higher 
carbon and oxygen content compared to the theoretical values. Also, all the samples had 
lower nitrogen and sulfur content compared to the theoretical values. The lower atom% 
of nitrogen is indicative of a 3:1 ratio of PET:ethylenediamine, as seen from the XPS 
studies in Chapter 3. An incomplete coverage of ethylenediamine on the surface 
resulting in more open PET sites would also lead to higher carbon and oxygen contents 
on the surface, also seen in the XPS results. However, it is important to remember that 
the theoretical values are based on a clean surface with one-to-one binding of each 
molecule with perfect detection of the entire surface. It is very unlikely that all of these 
conditions are met in order to match measurements with the theoretical values. 
Based on the results from the chemiluminescence and XPS analysis of the 
samples from the complete factorial designs, the following optimal fac;tors were selected 
129 
for the process of attaching 2-iminothiolane to the surface of PET by using the reactions 
shown in Figure 4.2 along with the constants described in Section 4.2.2: 
• 2-Iminothiolane Reaction Time: 24 hours 
• 2-Iminothiolane Concentration: 50 mM 
Since the results from the chemiluminescence and XPS analyses show that there 
is not a significant difference between the 24 hour and 3 day reactions times, the 24 hour 
reaction time was selected in order to decrease the amount of time to modify samples. 
4.3.3 Optimization of Cysteine Polypeptide onto PET Surface 
Figure 4.10 show the results from the chemiluminescence analysis of the 
complete factorial design for the optimization of the process of attaching the cysteine 
polypeptide to the surface of PET. There was not any detectable cysteine polypeptide on 
the surfaces of the samples from runs 1 -4. Runs 1 - 3 all had the low level cysteine 
polypeptide reaction time, which indicates that the reaction time was not long enough for 
the cysteine polypeptide to react with the glutaraldehyde on the surface. Run 4 had the 
mid level reaction time, but the low level cysteine polypeptide concentration, indicating 
that at this low concentration, a longer reaction time was required. The dependence on 
reaction time is further shown in run 7 with the low level cysteine polypeptide 
concentration but the high level reaction, which had detectable cysteine polypeptide on 
its surface. Runs 6 and 9 produced samples with the greatest amount of cysteine 
polypeptide on their surfaces, with 2.60 and 2.52 nmols/cm2, respectively. Both runs had 
the high level cysteine polypeptide concentration. The only difference between the runs 
was that run 6 had the mid level cysteine polypeptide reaction time and run 9 had the 
high level reaction time. There does not appear to be a significant difference in the 
130 
"""' N 
E 
(.) 
---
VJ 
0 
E 
i:: 
'-' 
i:: 
.s 
...... 
<'3 
.Cl 
i:: 
<l) 
(.) 
i:: 
0 
u 
<l) 
(.) 
~ 
~ 
;:l 
Cl) 
<l) 
"O 
8 
7 
6 
5 
4 
3 
·-g_ 2 -+-~~~~~~~~~~~~~~~~~~4~ 
<l) 
~ 
0 p.. 
<l) 
i:: 
] O +-~~--...~~~-.-~~~-.--~~-,----'-------'-'--,---"-'--'---,---'~-'-...,.---'-...:!:....l~~.L...:.c..-L-1 
VJ 
(] Run #1 Run #2 Run #3 Run #4 Run #5 Run #6 Run #7 Run #8 Run #9 
Figure 4.10 Cysteine polypeptide surface concentrations on the PET samples from the 
improved 3-level, 2-factor, and 9-run full factorial design for optimizing the 
process of attaching the cysteine polypeptide to the surface of PET, as 
determined by chemiluminescence analysis. Data shown are mean values ± 
standard deviation (n=3). 
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amount of cysteine polypeptide on the surface of samples submitted to either a mid or 
high level reaction time, as long as the cysteine polypeptide concentration is mid to high 
level. 
The results from the XPS analysis of the samples from the full factorial design are 
shown in Table 4.9. As before, sulfur is used as an indicator of the amount of cysteine 
polypeptide on the surface of each sample since the cysteine polypeptide is the only 
group on the surface that contains the sulfur atom. The results of the XPS analysis of the 
samples from runs 1 -4 are the same as those from the chemiluminescence analysis, 
there was no detectable amount of sulfur on the samples, which can be interpreted as no 
detectable amount of cysteine polypeptide ~m the samples. The atomic% of nitrogen on 
the samples from runs 1 - 4 are all in the same range as the other samples from the other 
runs; therefore, there were available reactions sites on the surface for cysteine 
polypeptide, but the reaction time was not long enough. Another similarity with the 
results from the chemiluminescence analysis was that the samples from runs 6 and 9 had 
the highest atomic% of sulfur on their surfaces, signifying that these runs produced 
samples with the highest surface concentration of cysteine polypeptide. 
Similar to the previous optimization studies, the actual measured values from the 
XPS analysis do not match the theoretical values shown in the table for a modified 
surface with one-to-one binding of each species. The trends in the measured values are 
also similar to those seen previously. All the samples had higher carbon content and 
most had higher oxygen content compared to the theoretical values. Also, all the samples 
had lower nitrogen and sulfur content compared to the theoretical values. Therefore, the 
conclusions made earlier that there is incomplete coverage of ethylenediamine and 
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TABLE4.9 
Atom% of Elements on Cysteine Polypeptide Modified PET Samples 
(Comparison of Theoretical with Measured by XPS) 
Run# C's O's N's S's 
Theoretical 59.58 19.15 14.89 6.38 
1 77.74 17.78 4.48 0 
2 77.57 18.31 4.12 0 
3 76.84 19.30 3.86 0 
4 76.37 20.04 3.58 0 
5 77.57 17.49 4.76 0.18 
6 75.49 19.11 4.31 1.10 
7 74.97 20.28 4.42 0.32 
8 76.34 18.57 4.61 0.48 
9 75.02 19.01 4.97 1.00 
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possible glutaraldehyde crosslinking can also be made for these sample; however, it is 
important to remember that the theoretical values represent the perfect conditions and 
may never be reached. 
Based on the results from the chemiluminescence and XPS analysis of the 
samples from the full factorial designs, the following optimal factors were selected for 
the process of attaching cysteine polypeptide to the surface of PET by using the reactions 
shown in Figure 4.1, the only difference is that the single L-cysteine residue is replaced 
with the cysteine polypeptide, along with the constants described in Section 4.2.2: 
• Cysteine Polypeptide Reaction Time: 24 hours 
• Cysteine Polypeptide Concentration: 14.5 mM 
Since the results from the chemiluminescence and XPS analyses show that there 
is not a significant difference between the 24 hour and 3 day reactions times, the 24 hour 
reaction time was selected in order to decrease the amount of time to modify samples. 
4.4 Discussion 
The Plackett-Burman factorial design was shown to be a useful tool in the 
optimization of the process to modify the surface of PET. Several factors were 
investigated at one time without having to perform an excessive number of experiments. 
Even though this factorial design did not directly result in the optimal process, it did 
narrow the range of factors to be further investigated. This was done by determining the 
effect of each factor on the process. By finding the factors that had the most effect on the 
process, a full factorial design was used to further study the effect of different levels on 
the process and among each other. This strategy was used for the optimization of the 
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process of attaching L-cysteine to the surface of PET. From the initial Plackett-Burman 
design it was discovered immediately that the ethylenediamine and L-cysteine 
concentrations were important. Samples disintegrated after being in the high level 
ethylenediamine concentration, and it was difficult to prepare the high level L-cysteine 
concentration because L-cysteine would not completely dissolve in solution and some 
solid crystals would begin to form on the surface of the PET sample. These discoveries 
led to additional studies to investigate the best concentration ranges to use for the 
ethylenediamine and L-cysteine factors in the factorial design. With the new findings, 
changes were made to the initial Plackett-Burman factorial design and from the improved 
design it was discovered that the negative effects of the glutaraldehyde concentration and 
L-cysteine reaction time and the positive effect of the L-cysteine concentration were the 
most significant factors in the process and were investigated further in a complete 
factorial design. Finally, the optimal conditions for the process of attaching L-cysteine to 
the surface of PET were determined after reviewing the results from all of the 
optimization studies. 
Another important discovery made during the optimization of L-cysteine was that 
even though fluorescence microscopy was a good qualitative method to investigate the 
physical properties of a surface, it failed as a method to quantitatively measure the 
amount ofL-cysteine on the surface of the samples. This problem was due to several 
reasons discussed earlier, the most important related to the stability of the fluorescent 
probe and the difficulty in accurately quantifying the amount of fluorescence on each 
sample. However, with improved measurement techniques, it is believed that in the 
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future this method will be an important analysis tool for investigating surfaces, since it 
could reveal important data both visually and quantitatively. 
XPS was chosen as a better method to analyze the samples from the optimization 
studies. Currently this is a very expensive analysis method and the data from the analysis 
can be difficult to interpret since the method only measures the atom% of elements on a 
surface and not molar surface concentrations. Another problem is that the current XPS 
method does not reveal the type of bonding occurring or the form of the molecule on the 
surface. Therefore, it is difficult to determine if the thiol groups attached to the surface 
are in their oxidized or reduced forms, since XPS does not detect thiols, but only the 
sulfur atom in the thiol group. More detailed XPS analysis techniques can be used to 
determine the type of bonding and the form of groups on surfaces, but the analysis cost is 
even higher and the method is not always accurate. XPS is still a valuable method for 
determining if a specific atom is on a surface, making it one of the most popular methods 
for characterizing a surface. 
The optimization study using 2-iminothiolane was simplified by using the results 
from the optimization study with L-cysteine (i.e. using the optimal ethylenediamine 
conditions). A complete factorial design was used to investigate the factors of 2-
iminothiolane reaction time and concentration. The first optimization study was 
unsuccessful due to problems with the 2-iminothiolane solutions. It was discovered that 
· the pH of the solution was not high enough to break the ring formation in 2-
iminothiolane, allowing the ring to react via an amidine bond to ethylenediamine on the 
polymer surface and to expose the free thiol group. Changes were made to the 
experimental design and the complete factorial design was repeated. The samples were 
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analyzed by both chemiluminescence and XPS methods to determine the optimal 
conditions for the process of attaching 2-iminothiolane to the surface of PET. 
The optimization study using cysteine polypeptide was also simplified by using 
the results from the optimization study with L-cysteine. The optimal factors for the 
ethylenediamine and glutaraldehyde steps, determined earlier, were used and the cysteine 
polypeptide reaction time and concentration factors were varied in a complete factorial 
design. The samples were analyzed by both chemiluminescence and XPS methods to 
determine the optimal conditions for the process of attaching cysteine polypeptide to the 
surface of PET . 
. When comparing the surface concentrations of thiol groups from each of the 
optimized processes determined from the chemiluminescence analysis method, the 
amount of thiol groups on the surface increased in order with the following groups: 
cysteine polypeptide < 2-iminothiolane < L-cysteine. When considering the solution 
concentration of each thiol group used in the optimization studies, the 2-iminothiolane 
concentration was higher than that ofL-cysteine and the cysteine polypeptide, showing 
that the higher thiol solution concentration does not always result in a higher thiol surface 
· · conceritration. The high level concentration factors for each were set due to specific 
reasons based on either past studies or availability, as described previously. For example, 
in the optimization of L-cysteine, when the low level L-cysteine concentration was used 
(16.5 µM), in some cases the resulting thiol concentration on the surface of the samples 
was higher than that in the other optimization studies using the high level thiol 
concentrations of 50 mM for 2-iminothiolane and 14.5 mM for the cysteine polypeptide 
in the- optimization process. 
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Other possible explanations for the lower surface concentrations of cysteine 
polypeptide and 2-iminothiolane on the samples include: 
• The surface concentration of cysteine polypeptide on the samples may be low 
due to disulfide linkages between the cysteine residues on the peptide chain. 
The chemiluminescence method only measures thiols in their reduced form 
because they must first be nitrosated prior to measurement; therefore, the 
. surface concentration of cysteine polypeptide may be higher than that 
measured by the chemiluminescence method. 
• The surface concentration of 2-iminothiolane on the samples may be low due 
to problems with breaking the ring formation of the molecule so it can react 
with ethylenediamine on the surface. Also, 2-iminothiolane may return to its 
ring formation under the acidic conditions used during the nitrosation process 
of the chemiluminescence method, leaving it unable to be detected by the 
chemiluminescence method. 
When comparing the surface concentrations ofthiol groups from each of the 
optimized processes determined from the XPS analysis method, by comparing the atom% 
of sulfur on the surface, the results varied differently than those from the 
chemiluminescence analysis. The optimized 2-iminothiolane and cysteine polypeptide 
samples both had a higher atom% of sulfur on their surfaces compared to the optimized 
L-cysteine sample; however, the theoretical values indicate that they should have a higher 
atom% of sulfur on their surfaces compared to the L-cysteine sample, 4. 76 and 6.38 
atom% compared to 3.70 atom%, respectively. Compared to the theoretical atom% of 
sulfur, the optimized 2-iminothiolane sample did have approximately 1.5 times as much 
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sulfur on its surface compared to the optimized L-cysteine and cysteine polypeptide 
samples. This inconsistency in the analysis of the 2-iminothiolane optimized sample 
between the two analysis methods may be due to what is actually measured by each 
method. The chemiluminescence method only measures thiols in their reduced state, 
since the thiols must be nitrosated prior to measurement in the reducing solutions. XPS 
does not measure thiols directly; instead it measures the atomic percentage of sulfur on 
the surface, regardless of the thiol oxidation state or the possibility of disulfide bonding. 
Therefore, there may be more 2-iminothiolane on the surface of the optimized polymer 
compared to L-cysteine or the cysteine polypeptide, but, as shown by the 
chemiluminescence analysis, only a fraction is in its reduced state. The thiol group must 
be in its reduced state in order for it to become nitrosated by transnitrosation and to 
release NO into the surrounding area to prevent platelet attachment to the modified 
surface. 
Once the processes to modify the polymer with the three thiol groups (L-cysteine, · 
2-iminothiolane, and cysteine polypeptide) were optimized, the next step was to use the 
optimized polymers in experiments with platelets. Studying the optimized polymers with 
platelets tested the hypothesis that the addition of more L-cysteine sites or different L-
cysteine-containing moieties on the polymer will increase the NO-release rate per unit 
area and lead to a greater inhibition of platelet deposition on the modified polymer. The 
studies were performed to test if the optimized polymers prevented platelet attachment to 
the surface better than the L-cysteine modified polymers used in past research (Section 
2.5.3) and which group attached to the surface of the polymer prevented platelet 
attachment the best under the experimental conditions. 
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CHAPTERS 
UTILIZATION OF THE OPTIMIZED POLYMERS IN AN IN VITRO SYSTEM 
WITH PLATELETS 
5 .1 Introduction 
The hypothesis was that the optimized polymers will significantly decrease 
platelet attachment to the polymer surface compared to control samples. This study is the 
first step in the process to investigate the utilization of the optimized polymers and the 
mechanisms by which they function. The main purpose of this study is to investigate 
how well the optimized polymers prevent platelet attachment to their surfaces under · 
controlled conditions. Once it is determined how well these optimized polymers prevent 
platelet attachment to their surfaces, further studies may be performed to investigate the 
exact mechanisms and components involved. As described previously, the modified 
polymer inhibits platelet attachment by utilizing naturally occurring nitrosothiols in the 
plasma that can transfer nitric oxide (NO) to the attached thiol on the modified polymer. 
It has also been shown that there are other plasma components, such as metal ions that 
promote the release of NO from nitrosothiols (Singh et al., 1996). Therefore, 
nitrosothiols must be present with the platelets in order for the modified polymer to 
inhibit platelet attachment. 
Slit flow chambers are commonly used in research to study the interactions 
between a surface and a flowing solution or suspension (Azeredo et al., 2003; Chotard-
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Ghodsnia et al., 2002; Ruel et al., 1995; van Kooten et al., 1992). A specific type of slit-
flow chamber is a parallel plate flow chamber. In a parallel flow chamber, a solution or 
suspension flows through a thin slit between two parallel plates. The surface under 
investigation may be either the surface of the plate itself or a thin film placed between the 
two plates. The parallel plate flow chamber design used for this study is similar to the 
one used in past studies and is shown in Figure 5 .1 (Duan and Lewis, 2002; Ramamurthi 
and Lewis, 1998). 
Several established techniques can be used to measure the amount of platelet 
deposition on surfaces. Some of the more commontechniques include: 1) scanning 
electron microscopy (SEM)(Dadsetan et al., 2001; de Brito Alves et al., 2003), 2) 
fluorescent microscopy (Adams .and Feuerstein~ 1980; Baker et al., 1997), and 3) 
radiolabeling (Datz, 1986; Desai and Thakur, 1986). Each technique may also have 
several different ways of operation. All of these techniques are well established and each 
has been shown to adequately measure platelets on surfaces. For this study, fluorescent 
microscopy and radio labeling were selected to measure the amount of platelet deposition 
on the modified polymers. The SEM technique was not selected due to its high cost. 
Similar to SEM, fluorescent microscopy can also visually show platelet deposition on the 
surface, but at a much lower cost. 
Several fluorescent probes can be used to label platelets in order to view the 
platelets with a fluorescence microscope. The ideal method involves a label that is 
detectable with a high level of sensitivity, is stable over the lifespan of the platelet, and 
does not alter the normal functional and survival characteristics of the cells. 5-
Chloromethylfluorescein diacetate (CMFDA) is one probe that is used to label platelets. 
141 
(a) 
Modified/ Pol:j ~b~0.2mm 
Perfusate in ~--------------' =ate out 
(b) IE-----70mm-~~------?t 
0 0 0 0 0 
w= 10mm 
d=3mrn 
0 
Screw socket 
Figure 5.1 Parallel plate flow chamber used to test platelet deposition on the optimized 
polymers. (a) Side view. (b) Top view. Figure from Duan, 2001. 
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CMFDA freely passes through cell membranes, and is a colorless, nonfluorescent 
compound that contains a reactive chloromethyl group. Once inside of a cell, the 
chloromethyl group reacts with intracellular thiols, transforming the probe into a cell-
associated dye-thiol adduct. After cytosolic esterases cleave off the acetate groups of 
CMFDA, a brightly fluorescent product is generated. This particular probe would not be 
a good selection for this study because any excess probe in the platelet suspension that 
may come into contact with the modified polymer may also react with the free thiol 
groups on the surface of the modified polymers. The probe may also react with any 
exposed amine groups on the surface of the modified polymers, as seen earlier with the 
reaction of 5-IAF with ethylenediamine. Another type of probe is an antibody specific 
probe for platelet surface receptors that is labeled with a fluorochrome. This probe is 
very specific to platelets, and several types of fluorochromes are available. 
Unfortunately, this label is very expensive and requires large amounts of the probe to 
ensure complete labeling of the platelets. The most common probe used to label platelets 
is quinacrine dihydrochloride, or better known by its common name, mepacrine. 
Mepacrine accumulates rapidly and selectively into platelet dense granules. This probe 
was selected due to its wide use in platelet applications and its low cost. 
The two most common radiolabels used to label platelets are chromium-51 (Cr-
51) and indium-111 (In-111 ). Because of different physical and chemical natures of 
chromium and indium, the radionuclides are known to bind to different intracellular 
components. A large proportion of C_r-51 is known to bind to the nucleotides, and a small 
proportion ofradioactivity remains in the membranes (Cunningham and Siegel, 1982). In 
contrast, In-111 complexes appear to bind to other cytoplasmic components with least 
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radioactivity on the membranes {Thakur et al., 1976). In-111 is superior over Cr-51 in 
labeling platelets for use in vivo, because the gamma emissions of Cr-51 are too low to 
allow external imaging; However, Cr-51 is suitable for labeling platelets to be used in 
experiments in vitro. Cr-51 also has some advantages over In-111 including a longer life 
span and unlike Cr-51, there is a small spontaneous release ofln-111 from labeled 
platelets. Therefore, Cr-51 was selected to be used to radiolabel the platelets in the study 
with the modified polymers. 
For this study, the following four solutions were used in the perfusion 
experiments with the optimized polymers: 
• Solution A: A labeled platelet suspension in buffer solution 
• Solution B: A labeled platelet suspension in a buffer solution containing 7 
µM nitrosated bovine serum albumin (BSANO). This is the typical 
concentration ofnitrosated albumin in human blood) (Stamler et al., 1992a). 
Bovine serum albumin (BSA) was used instead of human serum albumin 
(HSA) because BSA is less costly and has been shown to have identical 
transnitrosation properties as that ofHSA (Scorza et al., 1997). 
• Solution C: A labeled platelet suspension in a plasma solution 
• Solution D: A labeled platelet suspension in whole blood solution 
Each of the solutions described above will be used in order to study the effect of 
different constituents and possible mechanisms the modified polymers may be utilizing to 
inhibit platelet deposition. Solution A will be used to measure the effect of platelet 
deposition on the modified polymer in the absence of nitrosothiols. It is believed that the 
modified polymers prevent platelet deposition by the transfer of NO from nitrosothiols in 
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the plasma to the thiol group on the modified polymer and then the NO is released from 
the polymer into the surroundings to prevent platelet deposition. Therefore, if no 
nitrosothiols are available, then the modified polymers should not be able to inhibit 
platelet deposition and platelet deposition should be similar to that on the control sample. 
Solution B is used to investigate if nitrosated albumin is the primary plasma constituent 
needed to freely transfer NO to the thiol group on the modified polymers to prevent 
platelet deposition. Even though nitrosated albumin makes up the largest quantity of 
nitrosothiols in plasma, it is believed that there are other constituents in the plasma that 
are needed for the transfer of NO between nitrosothiols and for the release of NO from 
nitrosothiols, such as metal chelators like Cu+. Therefore, the amount of platelet 
inhibition by using solution B can be compared to the amount by using solutions C or D 
that contain all of the plasma constituents. Finally, solutions C and D can be used to 
compare the difference in platelet deposition on the modified polymers without and with 
the presence of red blood cells, respectively. Hemoglobin found in red blood cells in 
whole blood has been shown to react readily with NO in solution and take part in 
transnitrosation between circulating. nitrosothiols (Winterbourn, 1990). Therefore, by 
comparing the results of platelet inhibition on modified polymers by using solutions C 
and D, the effects of hemoglobin on the transnitrosation, NO release, and platelet 
deposition process can be assessed. 
5.2 Materials and Methods 
5.2.1 Reagents 
Sodium nitrite was purchased from Fisher Scientific (Fairlawn, NJ). Phosphate 
buffered saline (PBS, pH 7.4) was obtained from Life Technologies (Gaithersburg, MD). 
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Polyethylene terephthalate (PET) (thickness = 0.2 mm) was supplied by DuPont 
(Hopewell, VA). Bovine serum albumin (BSA), citrate-dextrose solution (ACD), 
ethylenediamine, glutaraldehyde (GA), glycine, HEPES, 2-iminothiolane hydrochloride, 
iodine, L-cysteine, quinacrine dihydrochloride (mepacrine ), Trizma® base 
(tris[hydroxymethyl]aminomethane), Tyrode's salts, and all the other reagents were 
purchased from Sigma Chemical Co. (St. Louis, MO). The L-cysteine polypeptide (Cys-
Gly-Cys-Gly-Cys) and the glycine polypeptide (Gly-Gly-Gly-Gly-Gly) were purchased 
from the Molecular Biology Resource Facility (Norman, OK). Chromium-51 was 
purchased from Amersham Biosciences (Arlington Heights, IL). All water used was of 
HPLC-grade quality and was deoxygenated by bubbling nitrogen in the water prior to 
use. 
5.2.2 Preparation of Platelets for Use in Perfusion Studies 
Platelet Isolation 
Human platelets are among the most widely studied cells in the body. A vast 
number of investigators are presently isolating and successfully using platelets in studies; 
however, the methods used in these studies vary radically. Some important points in the 
methods that vary among the studies and that were considered for the platelet preparation 
for this study are listed below. 
• Many drugs are known to interfere with platelet function and therefore, it is 
crucial to ensure that potential blood donors have not ingested such drugs 
during the previous 14 days. These drugs include antiplatelet drugs, such as 
aspirin, and other non-steroidal anti-inflammatory drugs and antihistamines. 
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• Several anticoagulants are available. The choice of anticoagulant depends on 
what aspect of platelet function is to be examined. Heparin has been widely 
used as an anticoagulant; however, some heparin preparations cause platelet 
aggregation and it prevents platelets from aggregating in an irreversible 
manner. Inhibition of coagulation by chelating divalent cations, such as 
ethylenediarninetetraacetic acid (EDTA), has also been widely used, but is not 
ideal as it both affects cell surface adhesive receptors and may deplete 
intracellular calcium stores. Any of the three citric acid based anticoagulants 
can be used without effecting normal platelet function, which includes sodium 
citrate, citrate-citric acid-dextrose (CCD), and acid-citric acid-dextrose 
(ACD). ACD was selected to be used in the platelet isolation procedures. 
• There are many different types of buffers used to wash and store platelets. 
Ideally, the buffer mimics the properties of the natural medium for platelets, 
plasma, including a balance of salts and the addition of important proteins. 
Some of the more common types of buffers used with platelets are l)Tyrode's 
balance salt solution, 2) Eagle's minimal essential medium, and 3) buffered 
saline glucose citrate (BSGC). All seem to work equally well in preserving 
the function of plates in solution for washing and storing purposes. Tyrode's 
balance salt solution was chosen to be used in the platelet studies. 
• The aggregation of platelets in solution is pH dependent. The recovery of 
platelets is higher if the pH of the solution is slightly acidic. This is due to a 
decrease in platelet adhesiveness and aggregation. Repeated centrifugation 
releases ADP from the red blood cells, increasing platelet adhesiveness. 
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Acidification affects the electrostatic forces at the platelet's surface, inhibiting 
the effect of ADP. Acidity also reduces the metabolism of ATP to ADP 
(Flatow and Freireich, 1966). Studies have shown that platelet aggregation 
caused by centrifugation occurs at a pH above 6.3 (Aster and Jandl, 1964). 
Therefore, ACD was added to each platelet solution that was centrifuged in a 
quantity sufficient to keep the pH below 6.3. The amount of ACD added 
depended on the type of platelet solution and the volume of the solution. 
• The type and number of platelets isolated are dependent on the centrifugation 
method used in the process. Ideal centrifugation conditions for the production 
of platelet rich plasma (PRP) are 1750 to 2700 g-min (Woods et al., 1976). At 
higher forces, too many platelets are lost, whereas lower forces result in 
excessive red blood cell contamination. The duration of centrifugation can 
affect the age of the platelets recovered. With.longer centrifugation times, the 
younger platelets, which are more adhesive than older ones, tend to sediment 
out of the PRP (McBride, 1968). Optimal conditions for production of the 
platelet pellet are 10,000 to 20,000 g-min (Mathias and Welch, 1984) and 
were used during platelet isolation procedures. 
• The type and amount of agitation affects platelet aggregation properties. A 
study between a tumbler and a horizontal type agitator showed that the 
tumbler agitator did more damage to the platelets than the horizontal tumbler 
under the same experimental conditions. Also, excessive agitation (> one 
hour) can damage platelets (Bannai et al., 1985). A horizontal tumbler was 
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used for the platelet labeling procedures and agitation times did not exceed 
one hour. 
• Platelet aggregation and deaggregation are temperature dependent. The rate 
of aggregation is less at 20°C (- room temperature) than at 37°C 
(-physiological temperature), and ADP doe not cause aggregation at 0°C 
except when high concentrations of the nucleotide are used. Thus, platelet 
solutions were prepared and stored at lower temperatures (- 4°C) and then the 
temperature was raised to 37°C for use in use in the platelet studies. 
The methods used to obtain and isolate the platelets used in this study were 
approved by the Institutional Review Board for Human Research at Oklahoma State 
University, Stillwater, OK. Blood was solicited from healthy individuals 18 years old or 
older. Informed consent was obtained from all donors. The protocol used to isolate 
platelets and prepare them for the perfusion studies with the optimized polymers is shown 
in the steps below: 
1. Human blood was drawn from paid research donors by trained medical 
technicians at the Student Health Center at Oklahoma State University by 
venipuncture in volumes not exceeding 30 ml per drawing. Blood volume 
from two donors was used for each experiment in order to isolate a sufficient 
number of platelets. Blood samples from individual donors were kept 
separate in order to avoid any adverse effects, such as complement activation. 
Blood was not drawn from a single subject any more than twice a week. The 
initial 2-3 ml of blood was discarded to prevent the blood from clotting, since 
the initial small volume of blood is rich in clotting factors. The rest of the 
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blood sample was drawn into six 5 ml tubes, ea~h containing an anticoagulant 
(1 part of 0.105 M of trisodium citrate per 9 parts of whole blood). The 
samples were stored on ice in a sealed container for transport back to the 
laboratory. Platelet preparation took place within 30 minutes of obtaining the 
blood samples. 
2. Once back at the laboratory, samples were divided equally by volume into six 
15 ml centrifuge tubes (-9 ml per tube). Once again, blood samples from 
individual donors were kept separate. The blood samples were centrifuged at 
200x g for 10 minutes to separate the red blood cells from the platelet rich 
plasma (PRP). The heavier red blood cells migrated to the bottom of the 
centrifuged tubes leaving the lighter PRP on top. 
3. The PRP was removed from each tube, combined, and divided equally by 
volume between two 15 ml centrifuge tubes (-8-13 ml), ensuring that samples 
from individual donors were kept separate. The tubes containing the red 
blood cells were stored at 4 °C until ready for use in the perfusion studies. 
The anticoagulant ACD was added to each tube containing the PRP (1:10 v/v) 
in order to prevent platelet aggregation during centrifugation. The samples 
were centrifuged at 500x g for 15 minutes to separate the platelets from the 
plasma solution. The platelets migrated to the bottom of the centrifuge tube 
and formed a pellet in the platelet poor plasma (PPP) solution. 
4. The PPP solution was carefully removed from each tube, in order to avoid 
disturbing the platelet pellet. The PPP was placed in a centrifuge tube and 
stored at 4 °C until ready for use in the perfusion studies. The platelet pellet 
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was gently resuspended in -10 ml of a sterile-filtered HEPES-buffered 
Tyrode's solution (8.0 g NaCl, 2.38 g HEPES, 1.0 g D-glucose, 1.0 g 
NaHC03, 0.2 g KCl, 0.2 g CaCl, 0.1 g MgCl, 0.05 g NaH2P04•H20 in 1.0 L 
HPLC-grade water, pH 7.4). At first, ACD was added to each at a 1:10 v/v 
ratio, but after the next centrifugation step, the platelets aggregated in 
solution. It was determined that the pH of the platelet solution was too high 
for centrifugation (pH 6.2). Therefore, ACD was added to Tyrode's buffer at 
a 1.25:10 v/v ratio in order to lower the pH to 6.0. This ratio of ACD was 
added to Tyrode's buffer during all wash steps and storage of the platelets, in 
order to prevent aggregation. 
Platelet Counting 
Once the platelets were isolated, they were counted by using phase microscopy. 
A 1% ammonium oxalate solution was prepared in HPLC-grade water and sterile filtered. 
To a 1.5 ml microcentrifuge tube, 50 µL of the platelet suspension was added to 950 µL 
of 1 % ammonium oxalate and mixed thoroughly. The ammonium oxalate stimulated the 
lysis of any remaining red blood cells in the platelet suspension that could possibly 
interfere with the platelet count. Approximately 20 µL of the suspension was added to 
one side of a haemocytometer and allowed to settle for 15 minutes to ensure even 
distribution of the platelets on the counting surface. The haemocytometer was examined 
under a phase microscope ( 400x magnification), and a 5 x 5 grid was used to count the 
platelets. Platelets were counted from five blocks in the grid (the four comers and the 
middle) and an average platelet count was determined by taking the average of the counts 
from the five blocks. Each block also had its own 4 x 4 grid to aid in the counting of the 
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platelets. Figure 5.2 shows an example of the platelets spread over one of the 5 x 5 
counting grids. The smaller spheres that make up the majority of the cells shown in the 
image are the platelets, and the few larger spheres seen sporadically in the image are red 
blood cells. As shown in Figure 5.2, some of the platelets were already forming 
aggregates on the surface of the haemocytometer after only five minutes due to platelet 
activation. The modified polymers should decrease the number of platelets or prevent 
platelets from becoming activated and attaching to the modified surface. The volume 
within one grid was 104 ml ( determined by manufacturer). Therefore, the platelet 
concentration was calculated by taking the average platelet count within one grid divided 
by the volume for that grid. The concentration of the original 10 ml platelet suspension 
was determined by correcting for the dilution of the sample in the ammonium oxalate 
solution. After counting the platelets in each solution, the platelets from each donor were 
mixed and then equally divided by volume between two tubes, prior to labeling. 
Platelet Labeling 
Platelets were labeled with either the fluorescent label mepacrine or the radiolabel 
Cr-51, prior to their use in the perfusion studies. The labeling process took place after the 
isolation and· counting procedures. The steps, used to label the platelets with either 
mepacrine or Cr-51, are described below. 
1. The platelet suspensions were centrifuged at 500x g for 15 minutes and the 
Tyrode's buffer solution gently removed so to not disturb the platelet pellet. 
• To label the platelets with the fluorescent probe, the platelets were 
resuspended in 10 ml of a 10 µM mepacrine solution prepared in Tyrode's 
buffer with ACD. 
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Figure 5.2 An example of one of the 5 x 5 grids (outlined by the triple lines) on the 
haemocytometer used to count platelets by phase microscopy. Sample at 400x 
magnification. 
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• To label the platelets with the radiolabel, the platelets were resuspended 
with Cr-51 (100 µCi per 15 x 109platelets) in Tyrode's buffer with ACD. 
The volume of Cr-51 added to the platelet solution was determined by the 
following expression, based on the specific activity of the Cr-51 solution. 
Vol. of Cr-51 added (µL) = VC (lOO µCi) 
S.A. (15 x 109 platelets) Eq. 5.1 
. where, 
V = the volume of the platelet suspension (ml) 
C = the concentration of the platelet solution (platelets/ml) 
S.A. = the specific activity of Cr-51 (µCi/ml) 
The specific activity of Cr-51 was calculated according to the following: 
S.A. (µCi/ml) = N0 (µCi/ml) x exp (- 0·693 x T) 
T112 
where, 
Eq. 5.2 
N0 = initial specific activity of Cr-51 (supplied by manufacturer) 
T = the time since the determination ofN0 (days) 
T112 = the half-life of Cr-51 (26.6 days) 
2. Each centrifuge tube was attached to a horizontal rotating plate and was gently 
rotated at the lowest setting for 30 minutes. 
3. The platelet suspensions were centrifuged at 500x g for 15 minutes and the 
mepacrine or Cr-51 solution gently removed. 
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4. To remove any excess label that did not react whh the platelets, the platelets 
were washed by resuspending them in 10 ml of Tyrode's buffer with ACD. 
The suspensions were centrifuged at 500x g for 15 minutes and the wash 
solution gently removed. This wash step was r'epeated to ensure complete 
removal of any excess label. 
All steps of the fluorescent labeling procedure were done in the dark with all 
solutions and samples covered in order to avoid damaging light. The fluorescently 
labeled samples were stored and transported in a black sample box until ready for 
analysis. 
All personnel involved in the handling of the radioisotope received training and 
certification by the Radiological Safety Officer (RSO) at Oklahoma State University, 
Stillwater, OK. All steps of the radiolabeling procedure were performed in a designated 
work area behind lead shielding at least 1/8 in thick, to shield from harmful gamma 
radiation from Ci-51. A Geiger counter was also used to survey the area where the 
radiolabel was used and stored. The radiolabeled samples were stored and transported in 
a lead-lined sample box until ready for analysis. All dry and liquid waste from the 
radiolabeling procedures was disposed ofby the guidelines set forth by the RSO. 
5.2.3 Preparation of Optimized Polymers and Control Samples 
Fresh samples of the modified polymers were prepared prior to each perfusion: 
experiment and used within 12 hours after modification. Samples modified by each of 
the groups described in Chapter 4 were used in the perfusion studies, including L-
cysteine, 2-iminothiolane, and the cysteine polypeptide. The modified samples were 
prepared by using the optimized conditions determined in Chapter 4. All samples were 
155 
stored under a N2 atmosphere until ready for use in the perfusion studies. An extra 
sample was prepared in each batch of modified polymers used in the perfusion studies in 
order to measure the average thiol surface.concentration on the samples, assuming that 
samples from the same batch will have approximately the same thiol surface 
concentration. The thiol concentration on the surface of the samples was measured by 
using the Chemiluminescence Method 1 (see Section 3.2.6). 
Control samples for the perfusion experiments included glycine-modified samples 
and glycine polypeptide-modified samples. The glycine-modified sample was a control 
sample in past studies (Duan, 2001) and was selected as a control sample for this study 
for the following reasons: 1) glycine (MW= 75.1) is similar in size to L-cysteine (MW= 
121.1) and 2-iminothiolane (MW= 137.6), 2)the method for attaching glycine to the 
surface of PET is similar to that for attaching the other groups in the modification 
. process, and 3) it does not contain a thiol group; therefore, it does not react with NO or 
participate in transnitrosation reactions. To prepare the glycine-modified samples, the 
same procedures that were used to prepare the optimized L-cysteine modified samples 
were used, except that glycine was substituted for L-cysteine in the last step. The 
glycine-modified control samples were prepared in parallel with each of the other 
modified samples that were used in the perfusion studies. 
In order to test the .effect on platelets of the size of the molecule attached to the 
surface of PET, such 3:s the cysteine polypeptide, a glycine polypeptide modified sample 
was used as a control sample. The glycine polypeptide is a linear peptide containing five 
glycine residues. It is attached to the surface of PET in a method similar for attaching the 
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cysteine-polypeptide to the surface of PET, except that the glycine polypeptide was 
substituted for the cysteine polypeptide in the last step. 
5.2.4 Parallel Plate Perfusion Studies 
As mentioned previously, there were four types of solutions that were used in the 
perfusion studies, 1) Tyrode's buffer solution, 2) 7 µM BSANO solution, 3) 50 vol% 
plasma solution, and~) 50 vol% whole blood solution. The Tyrode's buffer solution 
used in the perfusion studies was the same as that used in the platelet preparation 
procedures .. The BSANO solution was prepared -12 hours prior to its use in the 
perfusion studies. To prepare the BSANO solution: 10 ml of20 µM BSA in a 0.5 M · 
HCL solution, initially containing 40 µM N02-, was shaken for 12 hours to completely 
nitrosate all of the BSA. An excess ofN02- was used in order to ensure complete 
nitrosation of the BSA in the solution. Studies have shown an understoichiometric 
concentration of free thiols in BSA (0.53 ± 0.02-SH/molecule) due to mixed disulfides 
(DeMaster et al., 1995; Stubauer et al., 1999). Other studies have shown that with excess 
nitrite, BSA is nitrosated to yield a stoichiometry of 0.85 ± 0.07 mol S-NO/mol BSA 
(Scharfstein et al., 1994). Therefore, even though steps were taken to keep BSA in its 
reduced form (N2 atmosphere, no light, deoxygenated solutions, etc.) the actual 
concentration ofBSANO may be lower than expected. Just prior to its use in the 
perfusion studies, the BSANO solution was neutralized by using NaOH solutions and 
diluted to its final concentration of7 µM by using Tyrode's buffer. The plasma solution 
used in the perfusion studies was 50 vol% of the plasma saved from the platelet isolation 
procedure in Tyrode's buffer. The whole blood solution was prepared by mixing equal 
volumes ofplasma and red blood cell suspension saved from the platelet isolation 
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procedures and preparing a 50 vol% solution in Tyrode's buffer. The plasma and whole 
blood suspension used for each perfusion study was isolated from only one of the two 
donors, ensuring that samples from individual donors were kept separate. Since the 
whole blood and plasma solutions contain the large red blood cells and/or large proteins, 
each were diluted with Tyrode's buffer in order to flow through the parallel plate flow 
chamber (described below) easier, allowing more platelets to make contact with the 
surface of the modified polymers. ACD was not added to any of the solutions used in the 
perfusion studies, so that it would not interfere with the natural platelet activation 
mechanisms. Each solution contained approximately the same number of platelets, and 
the solutions were heated to physiological temperature (37 °C) just prior to use in the 
perfusion studies. Not adding ACD to the solutions and heating the solutions to 
physiological temperature were done in order to mimic physiological conditions as 
closely as possible during the perfusion studies. 
As shown previously in Figure 5.1 a parallel plate flow chamber was used to test 
platelet adhesion under flow conditions on the optimized samples described in Chapter 4. 
The flow chamber consists of two sections, the bottom plate and the top plate. The 
bottom, thicker plate contains a very thin flow slit (0.20 ± 0.01 mm deep, 10 mm wide, 
and 70 mm long) with a perfusate inlet and outlet, which are inclined at a 45° angle and 
have a diameter of 3 mm. The top plate is used to cover the bottom plate, to form a seal 
between the two plates so that the perfusate only flows through the thin slit. The two 
plates were sealed by using two C-clamps connected to each end of the parallel plate 
chamber. Pharmed® tubing (i.d. = 3mm) is connected to the perfusate inlet and outlet via 
polypropylene luer fittings. Pharmed® tubing is specially designed to be used in 
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biological applications due to its inert properties. A variable flow syringe pump (Model 
74900-10, Cole Parmer, Vernon Hills, IL) was used to perfuse the platelet suspension 
through the chamber. Just prior to performing each perfusion study, a sample modified 
with one of the groups described in Chapter 4 along with a glycine-modified control 
sample, both approximately 1 cm x 3 cm, were wetted with buffer and attached end~to-
end to the top plate of the perfusion chamber. The samples were position in such a way 
that once the top plate was sealed to the bottom plate, the samples covered the area of the 
thin slit and the solutions flowed over the bottom surface of each sample. The samples 
were slightly wider (- 1.2 cm) than the width of the thin slit (1.0 cm), to ensure that the 
samples would not fall into the slit if the samples came unattached from the top plate. 
There was approximately 0.5 cm gap between the end of each sample and the inlet or 
outlet ports of the slit. To investigate if there were any entrance or exit flow effects on 
the placement of samples within the perfusion chamber or if the order of the samples in 
the perfusion chamber had an impact on the reaction of platelets with the surfaces, two 
glycine-modified control samples were placed end-to-end in the perfusion chamber and 
tested under the same conditions in the procedures described above for the perfusion 
studies. The order of the samples in the perfusion chamber was also varied among the 
runs, in order to ensure that the placement of the samples in the chamber did not affect 
platelet interaction with the surface of the modified polymer. Fresh polymer samples 
were used with each of the four test solutions. Thus, a total of eight samples (one 
optimized and one control for each of the four test solutions) were tested for each 
perfusion study. In order to perform statistical analyses, each perfusion study was also 
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performed in triplicate, each on a separate day. The procedures for each perfusion 
experiment were as follows: 
• Perfused with 5 ml ofTyrode's buffer for 5 min at a flow rate of 1.0 ml/min in 
order to rinse the sample and to remove any contaminants from the system. 
• Perfused with 10 ml of one of the test solutions containing platelets labeled 
with either Iilepacrine or Cr-51 for 10 min at a flow rate of 1.0 ml/min. 
• Perfused with 10 ml ofTyrode's buffer for 10 min at a flow rate of 1.0 ml/min 
to remove any platelets that are not attached to the surface of the sample. 
For a specific flow rate, the dimensions of the flow channel determine the shear 
rate. A flow rate of 1.0 ml/min was used in this study, which corresponds to a wall shear 
rate (y) of250 s-1 (laminar flow) according to the following equation: (Sakariassen et al., 
1989) 
( -1) 3 Q 
y s = 2 60wb 2 Eq. 5.3 
where, 
Q = volumetric flow rate (ml/min) 
w = slit width ( cm) 
b = half-thickness of the flow slit (cm) 
This flow rate was selected in order to produce a wall shear rate that was within the 
physiological range. 
In order to investigate if the size of the molecule attached to the surface of PET 
had an effect on platelet attachment, a glycine polypeptide modified sample was tested in 
the perfusion chamber along with a glycine-modified control sample, both 1 cm x 3 cm. 
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Each perfusion experiment was carried out as described above, using each of the four test 
solutions. The perfusion studies using the glycine polypeptide modified samples were 
also performed in triplicate. 
5.2.5 Surface Analysis of the Modified Polymer Samples 
The surfaces of the modified polymer samples used in the perfusion studies with 
the fluorescently labeled platelet solutions were analyzed by using an argon laser-
scanning microscope (Leica TCS SP2, Exton, PA) in confocal mode with a 10.0 x 40.0 
oil immersion objective lens. The filters were set at 436 nm for the excitation and 525 
· nm for the emission. Due to the weak signal of the fluorescent label, viewing was 
improved by using a mercury lamp. The surface coverage of platelets on samples was 
compared by counting the number of individual platelets on the surface of each sample 
within a certain surface area. The modified polymer samples used in the perfusion 
studies with the radiolabeled platelet solutions were analyzed by measuring the amount of 
radioactivity, measured in counts, on each sample with a COBRA-II autogamma counter 
(Packard Instrument Company, Meriden, CT). 
The counts of each sample, either the number of fluorescently labeled platelets or 
amount ofradioactivity, were compared as a percentage of the glycine-modified control 
sample paired with each during the perfusion studies. Both the analysis of the 
fluorescently labeled platelets and the analysis of the radiolabeled platelets were 
normalized based on the number of platelets in the test solution prior to perfusion over 
the sample. 
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5.3 Results 
5.3.1 Preparation of Optimized Polymers and Control Samples 
The analysis of the modified samples taken from each batch of the modified 
polymers prepared for the perfusion studies showed that the concentration of the thiol 
groups on the surface of each sample were similar to the measured values of the 
optimized samples from Chapter 4. The average thiol surface concentrations were 5.9 ± 
0.5 nmols/cm2, 4.3 ± 0.7 nmols/cm2, and 2.3 ± 0.4 nmols/cm2 for the L-cysteine, 2-
iminothiolane, and cysteine polypeptide modified samples, respectively. 
5.3.2 Parallel Plate Perfusion Studies 
Analysis of Fluorescently Labeled Platelets 
In order to compare the amount of platelet attachment on the modified samples 
used in the perfusion studies, the number of platelets within a given area on each sample 
was to be counted and compared. Unfortunately, the number of platelets on each sample 
could not be determined due to several problems, including: 1) aggregates on the surfaces 
made it difficult to determine the number of individual platelets, 2) the weak signal of the 
fluorescent probe made it difficult to identify some platelets, 3) the thickness of the 
platelet layers resulted in many different planes of focus, making it difficult to identify all 
of the individual platelets, and 4) because the thin polymer film was semi-transparent, it 
was difficult to distinguish if the platelets were only in layers on one side of the polymer 
or if some platelets were able to contact the surface of the polymer that was attached to 
the top plate and there was a fluorescent signal from these platelets passing through the 
sample. 
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Due to the difficulty of trying to perform a quantitative analysis with the samples 
containing the fluorescently labeled platelets, a more qualitative analysis was attempted 
to get some useful information from the samples. Each modified sample that was used in 
the perfusion study was compared side-by-side to its corresponding control sample from 
the study. It is still difficult to draw direct conclusions from this qualitative analysis; 
however, it may be possible to find trends in the data that can be useful when interpreting 
the data from other analysis techniques, such as the radiolabeled platelets. An important 
point to remember when comparing the images from the fluorescent analysis is that 
unlike previous studies from Chapters 3 and 4, the contrast of the fluorescence is not 
related to the coverage of platelets on the surface. The gain on the scanning laser 
microscope was adjusted in order to acquire the best possible image; therefore, some 
images may be brighter or darker than others. The images can only be compared by 
examining the number of platelets on each image. 
Figures 5.3 to 5.6 show the images of the L-cysteine modified samples after their 
use in the perfusion studies with Tyrode's buffer, BSANO, plasma, and whole blood, 
respectively. In Figure 5.3, the scan of the L-cysteine modified sample was mistakenly 
taken at 800x magnification; therefore, the scan of the glycine modified sample was 
increased to 800x magnification in order to compare the two samples. All other scans of 
the samples were at 400x magnification. There were no significant differences in the 
amount of scatter of the platelets on the surfaces shown in Figures 5.3, 5.4, and 5.6 that 
were used in the perfusion studies with platelets in the Tyrode's buffer solution, the 
BSANO solution, and the whole blood solution, respectively. For the samples shown in 
Figure 5.5, there appears to be slightly fewer platelets attached to the surface of the L-
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(a) L-Cysteine Modified PET 
(b) Glycine Modified PET 
Figure 5.3 Scans of the fluorescently labeled platelets on the surface of (a) L-cysteine 
modified PET and (b) glycine modified PET. Both samples were used in the 
perfusion study with platelets in a Tyrode's buffer solution. Scans are shown 
at 800x magnification. 
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(a) L-Cysteine Modified PET 
(b) Glycine Modified PET 
Figure 5.4 Scans of the fluorescently labeled platelets on the surface of (a) L-cysteine 
modified PET and (b) glycine modified PET. Both samples were used in the 
perfusion study with platelets in a 7 µM BSANO solution. Scans are shown at 
400x magnification. 
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(a) L-Cysteine Modified PET 
(b) Glycine Modified PET 
Figure 5.5 Scans of the fluorescently labeled platelets on the surface of (a) L-cysteine 
modified PET and (b) glycine modified PET. Both samples were used in the 
perfusion study with platelets in a plasma solution. Scans are shown at 400x 
magnification. 
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(a) L-Cysteine Modified PET 
(b) Glycine Modified PET 
Figure 5.6 Scans of the fluorescently labeled platelets on the surface of (a) L-cysteine 
modified PET and (b) glycine modified PET. Both samples were used in the 
perfusion study with platelets in a whole blood solution. Scans are shown at 
400x magnification. 
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cysteine modified polymer sample compared to the glycine modified polymer control 
sample. These samples were used in the perfusion studies with platelets in the plasma 
solution. It appears that the L-cysteine modified samples may be inhibiting some platelet 
attachment to their surfaces when perfused with platelets in a plasma solution. However, 
due to problems with the accuracy of this method, further analysis must be done in order 
to verify this conclusion. 
Figures 5.7 to 5.10 show the images of the 2-iminothiolane modified samples 
after their use in the perfusion studies with Tyrode's buffer, BSANO, plasma, and whole 
blood, respectively. There was no significant difference in the amount of scatter of the 
platelets on the surfaces between the samples shown in any of the figures. This was also 
the case for the cysteine polypeptide modified samples and the glycine polypeptide 
modified samples (data not shown). Due to the problems of this analysis method, it did 
not reveal very much useful information about the perfusion studies. 
Analysis of Radiolabeled Platelets 
Two glycine modified PET samples were used in the perfusion chamber with each 
test solution in order to investigate if the order of the sample in the chamber has an affect 
on platelet attachment. After measuring the radioactivity of the radiolabeled platelets 
attached to each sample, there was no significant difference of platelet attachment 
between each set of glycine modified samples. 
The results from the perfusion studies using radiolabeled platelets in each of the 
four test solutions are shown in Figure 5.11. As shown, there was a great deal of 
variability in the results that can be attributed to a combination of factors including, 1) 
variance in the surface concentration of the thiol group on each modified polymer, 2) 
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(a) 2-Iminothiolane Modified PET 
(b) Glycine Modified PET 
Figure 5.7 Scans of the fluorescently labeled platelets on the surface of (a) 2-
iminothiolane modified PET and (b) glycine modified PET. Both samples 
were used in the perfusion study with platelets in a Tyrode's buffer solution. 
Scans are shown at 400x magnification. 
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(a) 2-Iminothiolane Modified PET 
(b) Glycine Modified PET 
Figure 5.8 Scans of the fluorescently labeled platelets on the surface of (a) 2-
iminothiolane modified PET and (b) glycine modified PET. Both samples 
were used in the perfusion study with platelets in a 7 µM BSANO solution. 
Scans are shown at 400x magnification. 
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(a) 2-Iminothiolane Modified PET 
(b) Glycine Modified PET 
Figure 5.9 Scans of the fluorescently labeled platelets on the surface of (a) 2-
iminothiolane modified PET and (b) glycine modified PET. Both samples 
were used in the perfusion study with platelets in a plasma solution. Scans are 
shown at 400x magnification. 
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(a) 2-Iminothiolane Modified PET 
(b) Glycine Modified PET 
Figure 5.10 Scans of the fluorescently labeled platelets on the surface of (a) 2-
iminothiolane modified PET and (b) glycine modified PET. Both samples 
were used in the perfusion study with platelets in a whole blood solution. 
Scans are shown at 400x magnification. 
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Figure 5 .11 The amount of platelet attachment on the surface of each modified sample as a percent of each control sample (glycine). 
The amount of platelet attachment was determined by measuring the radioactivity of the radio labeled platelets attached to 
each sample. Values shown are mean values ± standard deviation (n=3). 
variance in the experimental conditions, and 3) variance in the method used to measure 
the radiolabel on the samples. As shown previously, there can be a lot of variance 
between the thiol surface concentrations between samples with the same modification 
process. Less thiol content on the surface would lead to less NO release to inhibit platelet 
attachment. The perfusion experiments were performed three times for each type of 
modified polymer sample, in order to measure the variance in the experimental 
procedure. One of the major problems with biological in vitro experiments is the amount 
of variables involved that cannot be controlled or sometimes even known. For example, 
even though donors go through a stringent screening process, there still may exist 
significant differences between donors, such as differences in platelet function, 
differences in diets that may affect the type and amount of proteins and small molecules 
in their blood, and even differences in stress levels that can lead to the release of 
hormones or other factors into the blood that may affect platelet function. There was 
little variability in the method used to measure the amount of radiolabel on each sample. 
Standard solutions ofCr-51 were used to calibrate the gamma counter prior to measuring 
any of the samples and there was less than a I 0% difference in the measurements. 
Some conclusions about the perfusion experiment can be made by comparing the 
mean values of platelet attachment to the surface of each sample. Only the polymers 
modified with the three groups used in the optimization studies from Chapter 4 will be 
discussed first, saving the discussion of the glycine polypeptide modified polymer for 
later. When comparing the samples that were perfused with platelets in the Tyrode's 
buffer solution, there were no significant differences in platelet attachment between any 
of the samples. This was expected, since there is not any NO available in the solution to 
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be transferred to the surface of the modified polymers and released in order to prevent 
platelet attachment. 
When comparing the samples that were perfused with platelets in the BSANO 
solution, there were decreases in platelet attachment to the surface of the modified 
samples. Platelet attachment was decreased by approximately 26%, 27%, and 42% for 
the samples modified with L-cysteine, 2-iminothiolane, and cysteine polypeptide, 
respectively. When these results are compared to the previous ones for the samples 
perfused with the platelets in Tyrode's buffer solution, it appears that the BSANO does 
affect platelet attachment to the surface of the modified polymers. It is believed that this 
is due to the transfer of NO from the BSANOto the surface of the modified polymers to 
be used to inhibit platelet attachment. 
The most significant decreases in platelet attachment to the modified polymers 
were seen when comparing the samples that were perfused with platelets in the plasma 
solution. Platelet attachment was decreased by approximately 65%, 37%, and 47% for 
the samples modified with L-cysteine, 2-iminothiolane, and cysteine polypeptide, 
respectively. These results indicate that there may be factors other than just BSANO that 
are involved in the mechanisms used by the modified polymers to prevent platelet 
attachment. 
When comparing the samples that were perfused with platelets in the whole 
blood solution, there were decreases in the amount of platelets attached to the surface of 
the modified samples. Platelet attachment was decreased by approximately 53%, 32%, 
and 49% for the samples modified with L-cysteine, 2-iminothiolane, and cysteine 
polypeptide, respectively. Platelet attachment to the modified surfaces was prevented 
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more when compared to the samples perfused with either the buffer solution or the 
BSANO solution, but less when compared to the samples perfused with the plasma 
solution for the L-cysteine and 2-iminothiolane modified samples. It is difficult to 
determine from these results if the hemoglobin in the whole blood had any effect on the 
mechanisms used by the modified polymers to prevent platelet attachment. It is believed 
that platelet attachment was higher than expected for this group, due to the higher 
viscosity of the solution may have trapped more platelets onto the surface. After the 
samples that had been perfused with the whole blood solutions were rinsed, some of the 
red blood cell suspension remained on the surface. All samples were rinsed with the . 
same volume of buffer for the same amount of time in order to ensure that approximately 
the same number of platelets would be rinsed from the surface of each sample. However, 
since the whole blood solution was more viscous than the other solutions, the rinse 
conditions were not adequate enough to completely remove all of the red blood cell 
suspension, which was visually identified on the surface of the samples. Platelets could 
have been trapped among the red blood cells remaining on the surface, resulting in higher 
platelet counts for these samples. The differences between the plasma and the whole 
blood solutions are important to study because if the modified polymers are used in vivo, 
then they will be exposed to whole blood and not just plasma. 
When comparing which optimized polymer prevents platelet attachment the best, 
the L-cysteine modified polymer did best when used in the plasma and whole blood 
solutions. From Chapter 4, the L-cysteine modified polymer was shown to have the most 
thiol groups attached to its surface. The hypothesis was that the addition of more L-
cysteine sites or different L-cysteine-containing moieties on the polymer will increase the 
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NO-release rate per unit area and lead to a greater inhibition of platelet deposition on the 
modified polymer. Therefore, it is believed that the L-cysteine modified polymer was 
able to prevent platelet attachment the best because it contained the most thiol groups on 
its surface. The cysteine polypeptide modified polymer did the best in the BSANO 
solution, but did not do as well as the L-cysteine modified polymer in the plasma and 
whole blood solutions, especially in the plasma solution. The 2-iminothiolane modified 
polymer did the worst of the three modified polymers in all three solutions; however, 
there were still significant decreases in platelet attachment to the modified material in 
each of the three solutions, when compared to the control sample. 
It appears that chain length (size) of the group attached to the surface does not 
have a significant effect on platelet inhibition. The cysteine polypeptide modified 
polymer in one case inhibited platelets better than a polymer modified with a smaller 
group (2-iminothiolane) and in another case did not inhibit platelets as well as a polymer 
modified with a smaller group (L-cysteine). However, 2-iminothiolane may have not 
prevented platelet attachment as well, due to other undetermined factors not related to its 
size. When comparing platelet attachment on the glycine polypeptide arid the glycine 
modified samples, there was no significant difference between the two samples in any of 
the test solutions, also showing that chain length may not be a factor. 
5.4 Discussion 
This study was the first step in the process to investigate the utilization of the 
optimized polymers and the mechanisms by which they function. The main purpose was 
to investigate how well the optimized polymers prevent platelet attachment to their 
surfaces under controlled conditions. To do this, a parallel plate flow chamber was 
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utilized in order to measure platelet attachment on the modified polymers compared to a 
control sample, under flow conditions. 
Four specific solutions were selected to be used in the perfusion studies in order 
to test for specific factors. The solution of platelets in the Tyrode's buffer served as a 
control solution that could be compared to the other test solutions. As expected, there 
were not any significant differences in platelet attachment on the modified polymers 
compared to the control polymers. The second solution of platelets in 7 µM BSANO was 
used to investigate if nitrosated albumin is the primary plasma constituent needed to 
freely transfer NO to the thiol group on the modified polymers to prevent platelet 
deposition. The results indicated a decrease in platelet attachment on the modified 
polymers, suggesting that the polymers are functioning by the proposed mechanisms. 
The third solution of platelets in plasma was used to determine ifBSANO is the only 
factor from plasma that is required in the mechanisms by which the modified polymers 
prevent platelet attachment, or if other factors found in plasma are needed. As shown by 
the enhanced decrease in platelet attachment on the modified polymers, it appears that 
there are.other factors in plasma that are important and that this phenomenon should be 
further investigated in order to utilize these factors to further decrease and eventually 
prevent platelet attachment on the modified polymers. Finally, the fourth solution of 
platelets in whole blood was used to study the effect of hemoglobin as a possible carrier 
of NO to the modified polymer in order to further inhibit platelet attachment. 
Unfortunately, no conclusions could be made from this study due to platelet attachment 
was actually higher than that seen previously with the plasma solution. It is possible that 
the more viscous whole blood solution (more than twice as viscous as plasma) causes 
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more platelets to attach to the surface under flow conditions. As discussed previously, 
during the perfusion studies it was noticeable that the whole blood solutions were more 
difficult to rinse from the samples than the other solutions. 
The three modified polymers that were optimized, as discussed in Chapter 4 were 
each used in the perfusion studies in order to compare which modification could best 
inhibit platelet attachment to its surface. Other factors, such as the type of group on the 
surface, the size of the group on the surface, and the thiol concentration on the surface 
were also studied to measure their possible effects on platelet attachment. Overall, 
platelet attachment was inhibited by the polymer modified by one of the three groups in 
the following order from least to greatest: 2-iminothiolane, cysteine polypeptide, and L-
cysteine. L-cysteine is the smallest of the three groups that were attached to the surface 
and it also consistently had the highest thiol surface concentration. Cysteine polypeptide 
contained three cysteine residues per peptide chain and was the largest of the three 
groups. This modified polymer consistently had the lowest thiol surface concentration. 
2-Iminothiolane was slightly larger than L-cysteine and was attached by only one linker 
group instead of two that were used with L-cysteine and cysteine polypeptide. This 
group consistently had a thiol surface concentration between that of the other two groups. 
The size alone of the group on the modified polymer does not seem to be significant, as 
shown from the results of the perfusion studies using glycine polypeptide modified 
samples. There was no significant difference in platelet attachment of the glycine 
modified sample compared to the control sample in any of the perfusion studies. At this 
point, it is still inconclusive if it is the type of group attached to the polymer or if it is the 
thiol concentration on the surface of the polymer that affects platelet attachment more. 
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This is due to the finding that although both L-cysteine and 2-iminothiolane modified 
polymers have higher thiol surface concentrations compared to cysteine polypeptide 
modified polymer, cysteine polypeptide modified polymer inhibited platelets better than 
the 2-iminothiolane modified polymer. 
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CHAPTER6 
CONCLUSIONS AND FUTURE WORK 
The purpose of this research was to improve the haemocompatibility ofblood-
contacting biomaterials by modifying the surface of the material in such a way that it 
utilizes naturally occurring compounds and mechanisms in the body. The major driving 
force for this research was the need for more biocompatible materials that can be used in 
blood-contacting applications. According to the American Heart Association, such 
applications have drastically increased in the United States alone from 1979 to 2000 
(Association, 2003). 
Previous research demonstrated the ability to modify the surface of a biomaterial 
in such a way that it utilizes naturally occurring components and mechanisms that are 
readily available and that will not expire (Duan and Lewis, 2002). One of the naturally 
occurring components utilized by this design is endogenous NO bound to serum albumin 
in human plasma (Stamler et al., 1992a). By attaching L-cysteine to the surface of a 
biomaterial one of the naturally occurring mechanisms used by this design is the transfer 
of NO from the nitrosated serum albumin to the L-cysteine through transnitrosation 
(Meyer et al., 1994; Scharfstein et al., 1994). The nitrosated L-cysteine is very unstable 
and due to the presence of naturally present metal ions in blood (Beloso and Williams, 
1997; Singh et al., 1996), NO is released from the surface and available to inhibit platelet 
attachment. The initial findings from the past studies laid the groundwork for this present 
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research. First, the concentration of NO needed to prevent platelets from attaching to a 
surface was determined (Ramamurthi and Lewis, 1998). Next, a design to attach L-
cysteine to the surface of a polymer was developed and steps were taken to characterize 
the modified surface (Duan, 2001). Lastly, the modified material was tested in vitro with 
platelets in both at both stagnant and flow conditions (Duan, 200 I). The research 
described in this thesis continued the work and attempted to solve any open problems 
from the past studies. 
The objectives for this project included: 
• Surface characterization of the modified material in order to depict changes to 
the surface and to accurately measure these changes. 
• Optimization of the process to modify the biomaterial in order to maximize its 
effectiveness. 
• Utilization of the modified material in a system with platelets in order to 
measure the effectiveness of the material to prevent platelet attachment. 
There were some problems when attempting to characterize the surface of the 
modified material in the past research studies. There were not any methods readily 
available that could measure L-cysteine attached to a surface at low concentrations ( < I 0 
nmols/cm2), and the chemiluminescence method developed by past studies showed some 
inconsistencies. It was also desired to have alternative methods to validate the 
chemiluminescence method. In Chapter 3, several measurement methods were 
investigated to measure thiol groups on surfaces including fluorescence microscopy, x-
ray photoelectron spectroscopy (XPS), and several chemiluminescence-based assays to 
measure thiols on surfaces and solutions. The advantage of fluorescence microscopy was 
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the ability to visualize the surface coverage of the thiol group. Some disadvantages with 
fluorescence microscopy included the lack of specificity of the fluorescence probe and 
the analysis was more qualitative and did not directly produce surface molar 
concentrations. The advantage of XPS was that it was a highly precise and detailed 
analysis of only the surface of the material. The disadvantage of XPS was that it only 
measured the atomic percentages on the surface, which made it difficult to determine a 
molar surface concentration. The chemiluminescence-based assays were the most 
successful in measuring surface molar concentrations ofthiols. The advantage of the 
chemiluminescence-based method was that it could accurately measure (within 1 % error} 
molar concentrations of any thiol-containing compound with a detection limit in the pmol 
range. The major disadvantage to this method was that the thiol group had to be broken 
off of the surface and into solution prior to measurement, therefore leaving the sample 
unable to be reused. 
In past research studies, L-cysteine modified polymer was tested in vitro with 
platelets in both stagnant and flow conditions in order to measure the amount of platelet 
attachment to the surface. Although the studies showed a significant reduction in platelet 
attachment to the modified material, the modified materials were unable to completely 
inhibit platelet attachment to the surface. It was hypothesized that the addition of more 
L-cysteine sites or different L-cysteine-containing moieties on the polymer will increase 
the NO-release rate per unit area and will increase the inhibition of platelet deposition. In 
Chapter 4, the optimization of the polymer modification process was performed in order 
to maximize the amount ofthiol groups on the surface of the modified polymer. The 
following groups were used in the modification process: 1. L-cysteine residues, 2. a L-
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cysteine containing moiety, 2-Iminothiolane, and 3. a polypeptide containing multiple 
cysteine residues, Cys-Gly-Cys-Gly-Cys. Multiple factorial designs were used for the 
optimization of the modification process, along with the measurement techniques from 
Chapter 3. Not only did this research show that each of the three groups could be 
successfully attached to PET,'but it also determined the optimal conditions to attach the 
groups. The chemiluminescence and XPS methods were the most successful in 
comparing the modified samples. The fluorescent microscopy method is a useful 
analysis method when there are significant differences between samples, but is 
inconclusive when attempting to use it to compare samples with small difference, as 
some samples from the optimization study. When comparing the surface concentrations 
of thiol groups from each of the optimized processes determined from the 
chemiluminescence analysis method, the amount ofthiol groups on the surface increased 
in order with the following groups: cysteine polypeptide < 2-iminothiolane < L-cysteine. 
In past studies, only the L-cysteine modified polymer was tested in a perfusion 
chamber with platelet solutions, and the only platelet solutions that were studied were 
platelets in a buffer solution and platelets in a plasma solution. The studies performed in 
Chapter 5 were the first step in the process to investigate the utilization of the optimized 
polymers and the mechanisms by which they function. The main purpose was to 
investigate how well the optimized polymers prevent platelet attachment to their surfaces 
under controlled conditions. To do this, a parallel plate flow chamber was utilized in 
order to measure platelet attachment on the modified polymers compared to a control 
sample, under flow conditions. Four solutions containing either fluorescently labeled or 
radiolabled platelets were used in the perfusion studies, 1) Tyrode's buffer solution, 2) 7 
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µM BSANO solution, 3) 50 vol% plasma solution, and 4) 50 vol% whole blood solution. 
It was difficult to quantify the number of platelets on the surface of the modified samples 
by using the fluorescently-labeled platelets; therefore, the Cr-51 labeled platelets were 
used to quantify the number of platelets on the modified samples by measuring the 
amount of radioactivity of the labeled platelets on the surface of each modified sample. 
The platelet perfusion studies show that components in the plasma are important in the 
mechanisms used by the modified polymers to prevent platelet attachment. Also shown 
was that the modified polymers inhibited platelets less in the whole blood solution 
compared to the plasma solution. Overall, platelet attachment was inhibited by the 
polymer modified by one of the three groups in the following order from least to greatest: 
2-iminothiolane, cysteine polypeptide, and L-cysteine. The longer chain length of the 
glycine polypeptide modified sample did not show any significant effects on plate 
attachment. 
In order to improve the modified polymers ability to further decrease and 
eventually prevent platelet attachment to their surfaces, future work must still be 
performed in this research area, including: 
• Continue to develop more accurate methods to measure the thiol surface 
concentrations on the modified samples, without destroying the samples. 
• Continue to attach other thiol groups to the polymers to investigate the effect 
on platelet attachment. 
• Study the kinetics of the reactions taking place at the surface of the polymer 
and in the surrounding solution. First, all of the species involved in the 
mechanisms would need to be determined, measured, and modeled. Next, all 
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of the reactions taking place at the surface and in the surrounding solution 
would need to be determined. Finally, equilibrium rate constants for the 
transnitrosation reactions and the rate constants for the release of NO from 
thiol groups would need to be determined. 
• Study the effects of storage on the modified polymers. For all of the studies in 
this research, samples were used within 24 hours after they were modified. 
Studies should be performed to determine the "shelf-life" of these modified 
materials and the best conditions for storage. 
• Study the reusability of the modified polymers. For the studies in this 
research, the modified polymers were only used once. Studies should be 
performed to investig~te if the modified polymers are still effective after 
repeated use. 
• Study the long-term properties of the modified polymers. Modified polymers 
that were used in this research were only used for short-time periods. Studies 
should be performed to measure how long the modified polymers continue to 
significantly prevent platelet attachment to the surface. 
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